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Abstract 
 
Biomedical models of addiction are becoming increasingly prevalent in public discourse about 
cigarette smoking, however there is some concern that smoking is becoming overly 
medicalised. Neuroscience research has revealed that nicotine use is associated with long-
lasting changes in the brain, and these findings are being presented in the media and in 
advertising campaigns for smoking cessation pharmacotherapies. The “brain disease model of 
addiction”, which posits that chronic drug use leads to long-term changes in brain networks 
that make it very difficult to quit, is increasingly being applied to tobacco dependence. This is 
controversial in the tobacco control field, where population-based strategies have been 
successful in reducing the prevalence of smoking. Proponents of a biomedical model of tobacco 
dependence believe that it will lead to increased treatment seeking, more efficacious 
treatments, and a reduction in stigma. Critics of a biomedical model of nicotine addiction have 
expressed concerns that it will reduce individual responsibility for smoking, increase stigma, 
and undermine individuals’ beliefs in their ability to quit. While these competing views on the 
impacts of biomedical models of addiction have been debated in the academic literature, it is 
unknown to what extent members of the public endorse a biomedical model of tobacco 
dependence, and have incorporated it into their everyday understandings of smoking.  
 
This research examined the influence of biomedical discourses of smoking on lay beliefs of 
Australian smokers and non-smokers about tobacco dependence and its treatment. It also 
explored daily smokers’ attitudes to the labelling of nicotine addiction as a “brain disease.” A 
mixed methods approach was used to ascertain the extent to which biomedical understandings 
of smoking have been incorporated into lay discourse on smoking and quitting; how Australian 
smokers understand nicotine addiction and the role of the brain; and how endorsement of the 
brain disease model of addiction may be related to smokers’ attitudes towards smoking 
cessation and preferences for quitting methods.  
 
The thesis is comprised of three studies. Firstly, a secondary analysis of data from interviews 
with 55 members of the general public, including never smokers, ex-smokers and current 
smokers. The data was analysed to ascertain public attitudes on the best methods for quitting 
smoking. Results revealed that while cessation medications were frequently described as a 
helpful means to quit, the role of willpower, choice, and motivation were seen as central. 
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Medications were often described as a “second line of defence”, or as aids to be used alongside 
counselling or behavioural strategies.  
 
A second qualitative study involved in-depth interviews with 29 daily smokers about their 
views on smoking cessation and their understanding of the role of the brain in smoking. The 
results revealed positive attitudes to quitting without assistance. Cessation medications were 
not perceived as magic bullets, and willpower and personal responsibility were emphasised. 
While many smokers were aware that smoking affected their brain, few agreed it was a brain 
disease. Participants expressed concerns that biomedical understandings of smoking could 
increase the stigma of smoking, diminish personal responsibility for cessation, and deter 
smokers from seeking treatment.  
 
These qualitative results informed the design of a quantitative survey completed by 1538 
Australian smokers. This survey examined endorsement of neurobiological explanations of 
smoking, and their relationship to self-efficacy and treatment preferences. Approximately one 
third of participants agreed that smoking was a brain disease and more than half agreed that 
smoking changes the chemistry of the brain. Endorsement of the brain disease label, and 
agreement that smoking changes the chemistry of the brain, were associated with greater 
intention to use cessation medications. However the effect sizes were small, suggesting that 
beliefs about smoking and the brain may have modest real world impact. Contrary to the claim 
that promotion of brain-based explanations of smoking will increase feelings of fatalism, this 
survey shows that agreement with the claim that smoking is a brain disease was associated with 
higher self-efficacy.  
 
A medical, or chronic disease, model that emphasises the role of neurochemistry in tobacco 
dependence, while becoming more dominant in academic discourse, was not accepted by most 
Australian smokers. Concerns about negative consequences of describing smoking in this way, 
and wariness about the motives behind public health anti-smoking campaigns, were reasons 
behind this rejection. Consistent with existing literature on lay understandings of health and 
illness, alternatives discourses that describe it as a matter of willpower, choice, and a habit, 
remain strongly rooted in public dialogue about smoking. This means that smokers are unlikely 
to see the terminology of smoking as a “brain disease” positively. However, smokers were 
interested in information about the effects of smoking on the brain, and further research should 
investigate constructive ways of presenting this information in health promotion material and 
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clinical interactions. Biomedical explanations of smoking should acknowledge the agency of 
individuals and the complexity of addiction to cigarettes in order to be believable and 
acceptable to smokers.  
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Chapter 1. Introduction 
The prevalence of daily smoking in Australia has declined substantially in recent decades from 
35% in 1980 to 12.8% in 2013 (Australian Institute of Health and Welfare, 2014). However, 
smoking remains a major public health problem that is the largest avoidable contributor to the 
burden of death and disease in the country (Begg et al., 2007). The reduction in the prevalence 
of smoking has occurred alongside, and been influenced by, a significant cultural shift in public 
understandings of smoking. 
1. Changing public portrayals of smoking 
Prior to the recognition of the health risks of smoking and the addictiveness of nicotine, 
smoking was commonly portrayed as a personal choice and a bad habit. Quitting was often 
described as a simple matter of exercising one’s willpower (White, Oliffe, & Bottorff, 2013). 
More recent conceptualisations of smoking frame it as “nicotine addiction”: a chronic health 
condition that entails a loss of control over smoking that requires treatment by health 
professionals (Fiore et al., 2008). 
 
This is part of a more general shift towards the biomedicalisation of addiction (Campbell, 2007; 
Midanik, 2006). A key driver of the biomedicalisation of smoking has been the growth in 
neuroscientific research on addiction. Findings from neuroscience research have demonstrated 
differences in the neurochemistry and neuroanatomy of addicted individuals, which are 
theorised to account for addicted persons’ impaired control over their drug use. This has led to 
the claim that addiction is a “chronic, relapsing brain disease” (National Institute on Drug 
Abuse, 2007). 
 
Proponents of this “brain disease model of addiction” (BDMA) hope that it will lead to the 
development of novel pharmacotherapies for treatment and a reduction in the stigma associated 
with drug addiction (Volkow & Koob, 2015). Because nicotine addiction is often excluded 
from discussions about the BDMA, the social implications of this discourse for nicotine 
addiction have not been adequately explored. This is problematic as public portrayals of 
smoking increasingly refer to the role that the brain plays in tobacco dependence, and describe 
new brain-based therapies for smoking, such as transcranial magnetic stimulation, that are 
being developed (Rose et al., 2011). 
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 Public perceptions of smoking and quitting 
Lay understandings of smoking have the potential to influence the behaviour and cessation 
strategies of smokers. It is therefore important to investigate the extent to which members of 
the public, including smokers, see smoking as a medical problem in need of treatment. In the 
tobacco control field, there has been some debate about the benefits of the biomedicalisation 
of smoking. In Australia, the use of pharmacotherapy for smoking cessation is increasing and 
healthcare practitioners are encouraged to identify smokers and provide them with 
pharmacological assistance to quit (Zwar et al., 2014). While an increase in treatment seeking 
is generally seen as a positive development (Aveyard & Raw, 2012; Britton, 2009; Zwar et al., 
2014), some have speculated that emphasising the biological basis of addiction and medical 
treatment for tobacco dependence may make smokers think that quitting smoking is harder than 
it actually is (Chapman, 2011; Zhu, Lee, Zhuang, Gamst, & Wolfson, 2012). There is concern 
that this could reduce self-efficacy, which is central to successful quit attempts (DiClemente, 
Prochaska, & Gibertini, 1985; Schnoll et al., 2011). Others hypothesise that the availability of 
medical treatments for smoking cessation may lead to a belief that there are “magic bullets” to 
treat tobacco dependence, which is especially concerning for young people at risk of tobacco 
dependence (Dingel, Karkazis, & Koenig, 2011). There is little empirical evidence with which 
to test these competing claims about the social impact of biomedicalised views of smoking.  
 Overview of the thesis 
The original aim of this thesis was to explore whether smokers endorse the idea that smoking 
is a brain disease, and the potential of beliefs about smoking and the brain to influence smoking 
behaviours and treatment choices. As the literature review progressed, and data collection 
began, it became clear that a wider point of view was necessary in order to examine this 
question. Firstly, the brain disease model of addiction was one example of a more general shift 
towards the medicalisation of smoking. This was a contentious matter in the tobacco control 
field, with topical debates about the efficacy and cost-effectiveness of quit attempts using 
pharmacotherapy and support from health professionals, compared to that of unassisted 
quitting; and theorised potential adverse consequences that could arise from promoting a 
medical model of smoking cessation. Also, it was impossible to examine ideas and beliefs 
around the brain disease model of addiction without reference to alternative models of smoking 
that were held by the Australian public. Thus, the aim of the thesis shifted to an exploration of 
the extent to which biomedical understandings of tobacco dependence have been incorporated 
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into public understandings of smoking and attitudes towards smoking cessation in Australia. 
The brain disease model became one aspect of this analysis.  
 
In order to more fully explain the context of the study, Chapter 2 outlines the debates 
surrounding the biomedicalisation of cigarette smoking. This chapter includes a brief outline 
on the theory of medicalisation, a discussion on the extent to which smoking has become 
medicalised, and a critical review of debates in tobacco control about the benefits of a medical 
approach to smoking cessation. The BDMA, as an influential medical model of addiction, is 
presented, and its implications for tobacco control discussed.  
 
Chapter 3 investigates the extent to which medical understandings of smoking are present in 
public discourse on tobacco dependence and smoking cessation. The chapter first explains the 
importance of investigating lay understandings in public health research. It then presents the 
limited empirical research on lay conceptualisations of addiction and smoking, including the 
role that biology is perceived to play in smoking behaviour. Examples of advertisements and 
health promotion materials from Australia are provided to illustrate how the Australian public 
is being exposed to a biomedical discourse on smoking and smoking cessation.  
 
Chapter 4 describes the methods that were used in this project. It explains the mixed methods 
approach that was employed and the rationale and design of the research project. Three separate 
studies were conducted as part of the thesis:   
 
Study 1 – A secondary analysis of data from interviews with 55 members of the 
Australian public (including never smokers, ex-smokers and current smokers) on their 
views about addiction and its treatment. The analysis reported here focused on the 
extent to which the participants believed a medical approach was suitable for smoking 
cessation.  
Study 2 – A qualitative study that involved semi-structured interviews with 29 
Australians who smoked daily. The interviews explored their understandings of 
addiction, their attitudes towards various quitting strategies, their awareness of the role 
of the brain in smoking, and their attitudes towards the idea that smoking is a brain 
disease.  
Study 3 – A quantitative study that involved a web-based survey with 1538 participants. 
The survey items drew on results from the qualitative studies and examined: attitudes 
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towards, and the use of, medical treatments for smoking cessation; endorsement of 
brain-based explanations of smoking; and beliefs about the consequences of the brain 
disease model of nicotine addiction.  
 
Chapter 5 presents the results of Study 1. In order to begin to assess the extent of the 
medicalisation of smoking in Australia, this analysis focused on the attitudes of members of 
the Australian public towards medical strategies for smoking cessation and their views on 
quitting unassisted. These views form part of the social environment in which smokers make 
choices about the cessation strategies to use when they make a quit attempt. The results reveal 
the extent to which a medical discourse of nicotine addiction has infiltrated public 
understandings of smoking in Australia. 
 
Chapter 6 reports findings from study 2 in which smokers were asked their views and 
experiences on various quitting strategies. This chapter explores participant attitudes towards 
a range of quitting methods, including smoking cessation medications, quitting unassisted and 
quitting using counselling or self-help resources. It also outlines the factors that smokers report 
considering when making decisions about how to make a quit attempt.  The findings in this 
chapter demonstrate the complexity of the relationship between smokers’ beliefs about 
smoking and their treatment choices.  
 
Chapters 7 and 8 also draw on results from Study 2, reporting qualitative findings on smokers’ 
understanding of the role of their brain in tobacco dependence. Chapter 7 examines the beliefs 
that smokers hold about the role of their brain in smoking and addiction. It explores how these 
beliefs might relate to treatment choices and participants’ sense of smoking self-efficacy. 
Chapter 8 considers the attitudes of the same participants toward labelling nicotine addiction 
as a “brain disease.” While use of this label is not widespread in Australia, it is increasingly 
being disseminated by leading research bodies in the USA. It is important to examine the 
possible implications of this terminology for smokers’ self-understanding.  
 
Chapter 9 reports on findings from the quantitative survey of Australian smokers about their 
attitudes towards biomedical explanations of smoking (Study 3). The analysis investigated: the 
proportion of Australian smokers who endorsed neurobiological explanations of tobacco 
dependence; the relationship between endorsement of these neurobiological explanations and 
attitudes towards smoking cessation medications; and the relationship between endorsement of 
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neurobiological explanations of smoking and quitting self-efficacy amongst Australian 
smokers.  
 
Chapter 10 draws together findings from the empirical components of this thesis. It discusses 
the extent to which participants perceived smoking as a biomedical issue and a brain disease. 
It outlines the alternative discourses about smoking that became evident during the course of 
this research. The likelihood that biomedical discourses of smoking will increase the use of 
pharmacotherapies for cessation attempts or reduce quitting self-efficacy is evaluated. It is clear 
that there is an increasing emphasis on the neurobiological aspects of addiction to nicotine in 
public discourse about smoking. The chapter concludes with recommendations about how 
brain-based information about smoking can be presented in clinical interactions and public 
health messages in ways that maximize its impact and minimize negative consequences. 
 
 Novel contribution of the thesis 
Current debates in tobacco control about the value of biomedical approaches to smoking 
cessation have neglected the views of the general public, and of those most likely to be affected 
by shifting conceptualisations of smoking and the changing nature of treatment for tobacco 
dependence: smokers themselves. This thesis addresses this gap in the literature by exploring 
attitudes in Australia towards medical approaches to smoking cessation amongst the general 
public and daily smokers. It is the first study to examine how smokers understand the role of 
the brain in their smoking, and whether they agree with the controversial description of tobacco 
dependence as a “brain disease.”  
 
In order to explore this topic the interdisciplinary thesis draws on, and contributes to, three sets 
of literature: sociological writings on biomedicalisation, public health research on lay 
understandings of health and illness, and policy debates in the tobacco control field about the 
treatment of tobacco dependence. The limitations of medical approaches to smoking cessation 
are outlined, and it is argued that biological understandings of tobacco dependence cannot be 
disentangled from wider discussions about the meaning of addiction, and the nature of smoking 
in general. Asking participants about their ideas about smoking and the brain elicits alternative 
ideas around smoking that are based on deeply held cultural ideas about the centrality of 
willpower and individual choice. In doing so, this thesis contributes to an emerging body of 
evidence which suggests that increasing public knowledge about neuroscience is unlikely to 
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revolutionise public understandings of addiction, or human nature more generally. These 
findings have practical implications for public health practitioners working in tobacco control 
and clinicians who interact with smokers. Portrayals of smoking as a medical problem with a 
medical solution may be helpful for some smokers but also has the potential to alienate others 
if everyday experiential understandings of smoking are downplayed or ignored. 
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Chapter 2. The bio/medicalisation of tobacco dependence: Evidence and 
Arguments 
 
There is an ongoing debate in the tobacco control literature about the value of a medical model 
in reducing smoking related harm. The variety of medical treatments available for smoking 
cessation are increasing and health professionals are increasingly encouraged to provide these 
medical interventions to aid smoking cessation. However, some question whether medical 
understandings of smoking will undermine the responsibility of the tobacco industry for the 
harms of smoking. Others worry that it will lead individual smokers to deny their personal 
responsibility for smoking cessation. Will it create beliefs in “magic bullets” for smoking 
cessation, or will medical understandings erode smokers’ confidence in their ability to quit? 
This chapter examines the extent to which cigarette smoking has become medicalised and 
outlines why medicalisation is contested in the tobacco control field. It also introduces the 
“brain disease model” of addiction and examines the implications of this model for tobacco 
control. 
 
 Medicalisation: A brief background 
In all societies and historical epochs, sickness has been a problem in need of an explanation. 
Anthropologists have outlined religious models of sickness, where “diagnosis and healing are 
both undertaken in a sacred context” (Turner, 2000, p.5), and where individuals are assigned 
moral responsibility for disease and ill health. In the context of the growth of empirical 
rationalism, the rise of capitalism, and discoveries in experimental medicine, religious 
explanations of health and illness began to be questioned from the 17th century onwards 
(Turner, 2000). In the 19th century, great improvements in the health of populations resulted 
from improved diet and nutrition, living conditions, sanitation, water infrastructure, and the 
communication of public health messages regarding hygiene. The “contagion” model, where 
diseases were attributed to parasites that were spread between individuals, resulted in an 
understanding of how diseases are spread via everyday practices and poor sanitary 
infrastructure, and led in the 20th century to the development of vaccines against common 
infectious diseases (Awofeso, 2004).  
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The era was followed by the “preventive medicine era”, where efforts began to be directed 
towards groups identified as being at high risk of disease or ill health (Awofeso, 2004). This 
was associated with “physicians’ enhanced ability to shape political and public perceptions of 
health policy issues” (Awofeso, 2004, p705). The enhanced influence and status of the medical 
profession, as well as the growth of pharmaceutical treatments for various disorders, influenced 
a process that has been labelled “medicalisation.”  
 
Medicalisation has been defined as “a process by which nonmedical problems become defined 
and treated as medical problems, usually in terms of illnesses or disorders.” (Conrad, 1992, p. 
209). The first discussion about the medicalisation of smoking occurred with the advent of 
nicotine replacement therapy (NRT), in the form of gum (Blum, 1984). Since then, new forms 
of NRT and prescription medications for smoking cessation have become available to help 
smokers quit.  
 
Conrad and Schneider’s seminal work on medicalisation described the key feature of 
medicalisation as the definition or labelling of a social issue as a medical condition (Conrad & 
Schneider, 1992). They wrote that “medicalization occurs when a medical frame or definition 
has been applied to understand or manage a problem” (Conrad & Schneider, 1992, p. 211). 
Many of the early writings on medicalisation focused on psychiatric diagnoses and depicted 
the use of pharmacological treatment regimes as exercising social control over those perceived 
to be deviant (e.g., Szasz, 1974). Medicalisation was typically seen as a negative process that 
increased the power of the medical profession and disempowered socially marginalised 
individuals (Ballard & Elston, 2005).   
 
Most writings on medicalisation assumed that the negative consequences of medicalisation 
outweighed the positive. Conrad and Schneider (1992) have outlined the “brighter and darker” 
sides of medicalisation. One potential benefit of medicalisation is that defining a problem as a 
medical issue may reduce stigma due to the implication that afflicted individuals do not have 
full control over it. This is a particularly pertinent issue for drug addiction, and increasingly 
relevant to smoking tobacco, where the stigmatisation of smokers is a controversial strategy 
employed to reduce smoking rates (Amonini, Pettigrew, & Clayforth, 2015; Bell, Salmon, 
Bowers, Bell, & McCullough, 2010; Brown-Johnson & Prochaska, 2015). The adoption of a 
“sick role” might reduce feelings of self-blame by lessening an individual’s sense of 
responsibility, and could increase treatment seeking. In relation to the “darker side”, the 
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fundamental criticism of medicalisation is that it “decontextualizes social problems” by 
transforming them into individual problems (Conrad, 1992, p. 223). It pathologises individual 
differences, leading to a “dislocation of individual responsibility”, and reduces efforts to 
improve social environments (Conrad & Schneider, 1992, p. 152). Critiques of medicalisation 
have been accused of underestimating the benefits of implementing medical approaches for 
previously unmedicalised problems (Ballard & Elston, 2005). 
 
Power differentials between groups are central to medicalization theory. Early work on 
medicalisation emphasised the power of the medical profession (i.e., doctors/physicians) in 
transforming social deviance into medical illness (Zola, 1972). Medicalisation now appears to 
be accelerating through the influence of institutions such as pharmaceutical and health 
insurance companies (Clarke, Shim, Mamo, Fosket, & Fishman, 2003). Clarke and colleagues 
(2003) believe that “technoscientific innovations” such as genomics and biotechnology have 
led to a fundamental transformation in the medical arena. They have labelled this 
biomedicalisation. A key characteristic of biomedicalisation is that it encompasses health and 
illness. Attaining and maintaining good health has come to be seen as a moral responsibility of 
each citizen (Crawford, 1980) and many “surveillance technologies” are now available to 
monitor one’s health (Lupton, 2012). There is some debate about whether biomedicalisation 
fundamentally departs from medicalisation, or simply represents a shift of influence and power 
(Conrad, 2005). It is clear, however, that pharmaceutical companies, biotechnology firms, and 
health insurance companies now play a key role in defining disorders and deciding which 
warrant treatment, issues previously primarily within the purview of organised medicine (e.g., 
Moynihan, 2003).  
 
Another change has been a move towards a more active role for consumers in healthcare. The 
focus on power relations in the sociological literature has often positioned the individual as a 
passive subject of those wielding institutional authority (Ballard & Elston, 2005). More recent 
work acknowledges that patients are not simply submissive recipients of medical labels and 
care. Research has documented consumer resistance, as well as advocacy for medicalised 
definitions in those affected by various disorders (Singh, 2003; Valentine, 2010). The 
considerable literature on deliberate lack of adherence to medications and treatment 
recommendations also signifies the active role of patients (Horne, 1997; Osterberg & Blaschke, 
2005). It is now generally acknowledged that patients are stakeholders who frequently take an 
active and interested role in decisions about their own healthcare (Ballard & Elston, 2005). 
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Conrad (1992) described three levels at which medicalisation can occur: the conceptual, 
institutional and interactional. The conceptual level refers to the application of a medical 
definition or label. An example is the labeling of low libido in women as “female sexual 
dysfunction” (Moynihan, 2003). Medicalisation at the institutional level involves the uptake of 
medical models by key institutions, such as the creation of medical treatment guidelines for 
national health services. The interactional level involves communication between a healthcare 
provider and their patients. Examples include diagnosing a patient with a disorder, or 
prescribing medication for a problem. Medicalisation is rarely complete, and may occur at one 
level but have little impact at another (Conrad, 1992). Conrad has therefore recommended 
assessing the degree of medicalisation, rather than classifying an issue as medicalised or not in 
a dichotomous fashion. He has listed the following factors that can influence the degree to 
which a condition is medicalised: “the support of the medical profession, availability of 
interventions or treatments, existence of competing definitions, coverage by medical insurance, 
and the presence of groups challenging the medical definition.” (Conrad, 1992, p. 220).  
 
The remainder of this chapter will consider the degree to which tobacco dependence has been 
medicalised. The following sections will focus on countries that are in the later stages of the 
tobacco epidemic, that is countries such as Australia and England where smoking prevalence 
is declining in both men and women (Lopez, Collishaw, & Piha, 1994). These countries have 
typically adopted strong tobacco control policies, such as increased taxes on cigarettes and 
smoking bans in public places.  
 Conceptions of tobacco dependence: From “bad habit” to “nicotine addiction”  
‘If [cigarettes] are behaviorally addictive or habit forming, they are much more like … Gummi 
Bears, and I eat Gummi Bears, and I don't like it when I don't eat my Gummi Bears, but I'm 
certainly not addicted to them’  J.Morgan , President and CEO of Philip Morris, 12 May 1997 US 
District Court for the District of Columbia. (Cited in Robertson & Hurt, 2010, p. 449) 
 
The first step in exploring the extent to which cigarette smoking has been medicalised is to 
look at how it is defined. A number of historians have documented the changing 
conceptualisations of cigarette smoking throughout the 20th century (Berridge, 1997; Brandt, 
2007; Hilton, 2000). Prior to the 1950s cigarettes were seen as more like a food stuff than an 
addicting drug (Berridge, 1997). While some had observed features of cigarette smoking that 
seemed to signal addiction (Tyrrell, 1998), the discourse of addiction was not widespread and 
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addiction was not recognised in official government documents on smoking. In the 1950s, the 
health risks of smoking began to be documented and publicly disseminated. This led to an 
increase in quit attempts and it became clear that many people had difficulty in giving up their 
smoking “habit.” 
 
Nonetheless, it was not until 1988 that the US Surgeon General conducted an extensive review 
of the scientific evidence and concluded that tobacco smoking was addictive, and that it was 
the nicotine in tobacco which produced its reinforcing effects. Cigarettes were thus redefined 
as a “delivery device” for nicotine, an addictive drug “in the same sense as … heroin and 
cocaine.” (US Surgeon General, 1988, p. vi). The change from describing tobacco use as 
“habituation” in the 1964 report to “nicotine addiction” in 1988 was influenced by neuroscience 
insights about how nicotine worked in the brain and evidence that nicotine replacement therapy 
reduced cravings for cigarettes (Elam, 2015b).  
 
Some commentators have also noted changes in the social context that made the labelling of 
smoking as an addiction more publicly acceptable. Firstly, by 1988 the prevalence of smoking 
was declining and the makeup of the smoking population was changing. Those of lower 
socioeconomic status continued smoking in greater numbers than the economically privileged 
who were more likely to quit. Brandt writes that “[I]n a culture prone to stigmatize its poor and 
disfavoured, changing perceptions about the ‘average smoker’ eased the growing attribution of 
addiction.” (Brandt, 2004, p. 391). Also, perceptions of “the addict” were changing, with 
increasing advocacy for reducing the stigma of addiction and a recognition that it could 
“happen to anybody” (Mars & Ling, 2008). 
 
Unsurprisingly, the tobacco industry resisted accepting that cigarettes were addictive. Even 
after the U.S. Surgeon General’s report of 1988, they continued to deny publicly that smoking 
was addictive until the late 1990s, while admitting in internal documents that people only 
smoked due to the rewarding properties of nicotine (Robertson & Hurt, 2010). The idea that 
smoking was solely an individual choice was one they could not easily give up because it was 
central to their defence against litigation (Mars & Ling, 2008). 
 
Preceding and intertwining with these debates about the role of nicotine in tobacco dependence, 
were debates about whether tobacco dependence should be included in the American 
Psychiatric Association’s Diagnostic and Statistical Manual III (DSM-III). Despite the tobacco 
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industry claim that it would be “ridiculous” to label an everyday behaviour of so many as a 
mental disorder (Hirshbein, 2014), the DSM-III included “tobacco dependence” as a diagnostic 
category. In the 1987 revision of the DSM-III, tobacco dependence was renamed “nicotine 
dependence”, a label that remained in the DSM-IV (American Psychiatric Association, 2000). 
The diagnostic criteria for nicotine dependence were based on those for other drugs. They 
included tolerance, withdrawal symptoms, compulsive use, and use despite negative 
consequences. The World Health Organisation’s International Classification of Disease (ICD) 
developed similar diagnostic criteria, but employed the label tobacco dependence (World 
Health Organisation, 2011). 
 
There was renewed debate about the value of the DSM diagnostic criteria for nicotine 
dependence in the lead up to the release of the DSM-5. Critics noted that the DSM criteria for 
diagnosing tobacco dependence were not widely used in research or in clinical practice (T. B. 
Baker, Breslau, Covey, & Shiffman, 2012; Hughes, 2006). Other measures of dependence were 
more often used, such as the Fagerstrom Test for Nicotine Dependence (FTND), and its 
shortened form, the Heaviness of Smoking Index (HSI). These measures were developed 
specifically for tobacco dependence and were more predictive of relapse than the DSM criteria 
(T. B. Baker et al., 2012). This led to a dialogue about whether the generic criteria developed 
for drug addiction were applicable to tobacco smoking. Baker and colleagues (2012) concluded 
that nicotine dependence was different enough from other addictions to warrant separate 
diagnostic criteria.  
 
One of the key differences between nicotine and other drug addictions is that nicotine produces 
only mild psychoactive effects. Smokers do not become intoxicated, and most dependent 
smokers do not suffer from the types of “behavioural harm” experienced by persons addicted 
to other drugs (Hughes, 2006). The idea of nicotine “abuse” (as opposed to dependence) is also 
not applicable to smoking, as individuals do not smoke to become intoxicated. The DSM-5 has 
addressed the last criticism by removing the distinction between substance abuse and substance 
dependence. Nicotine dependence has been renamed “tobacco use disorder.” Very similar 
diagnostic criteria apply but dependence is diagnosed along a continuum of severity, with mild, 
moderate or severe dependence, depending on the number of diagnostic criteria an individual 
meets.  
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Heirshbein (2014) has criticised the DSM-5 for being more “expansive” than previous versions. 
She believes that anyone who uses tobacco can now be diagnosed as having tobacco use 
disorder and notes the influence of the pharmaceutical company in defining smoking as a 
psychiatric disorder requiring treatment by medical specialists. In her words, “the psychiatric 
diagnosis of tobacco use disorder is more about the current social, political, and economic 
context of US medical and public health approaches to cigarettes than a valid description of a 
disease state.” (Hirshbein, 2014, p. 2082). 
 
This brief outline illustrates how smoking has increasingly come to be defined as a medical 
problem through labelling smoking as an addiction, and applying diagnostic criteria. The key 
point of such a medical diagnosis or definition, according to Robert West, “is to establish 
whether and what kind of medical treatment or care may be appropriate.” (West & Miller, 
2011, p. 863). It is to the treatment of “tobacco use disorder” that we now turn.  
 
 Pharmacotherapy for smoking cessation and the role of the health professional 
One driver of the medicalisation of tobacco use is the increased availability and use of 
pharmacotherapies for smoking cessation. Nicotine replacement therapy was first developed in 
the 1960s in the form of nicotine gum. It provides the brain with nicotine, reducing withdrawal 
symptoms. It typically uses slower acting methods of administration and produces lower blood 
nicotine levels than are obtained by smoking cigarettes. It was developed to mitigate the health 
harms of smoking by reducing cravings for cigarettes and thus preventing relapse. Initially 
there was some debate over whether NRT would be marketed as an alternative and safer way 
of consuming nicotine (a harm reduction approach) or solely as a therapeutic device for 
smoking cessation (a medical approach) (Elam, 2015b). The therapeutic approach came to 
dominate and clinical trials have since demonstrated that NRT increases the chances of a 
successful quit attempt by 50-70% (Hartmann-Boyce, Stead, Cahill, & Lancaster, 2013; Stead, 
Perera, Bullen, Mant, & Lancaster, 2008).   
 
There are a now many forms of NRT available that vary in strength and speed of nicotine 
delivery. These include: gum, patches, inhalators, lozenges, mouthspray, nasal spray, 
dissolvable oral strips and pouches that resemble a Swedish tobacco product known as portion 
snus. While initially available only via prescription, most forms of NRT are now available over 
the counter in pharmacies and at general retailers in Australia and many other countries. In 
14 
  
Australia, nicotine patches were listed on the Pharmaceutical Benefits Scheme (PBS) in 2011, 
such that the cost is publicly subsidised when NRT is prescribed by a registered medical 
practitioner. At a global level, the World Health Organisation has added NRT to the Model 
List of Essential Medicines (World Health Organisation, 2015), which encourages 
governments to provide essential medicines to their population at a low cost.  
 
Two non-nicotine prescription-only medications for smoking cessation are available in 
Australia. Bupropion (sold in Australia as Zyban and Prexaton) is an antidepressant that was 
marketed as a cessation aid after it was noticed that patients taking it for depression reported 
reduced urges to smoke. Clinical trials show bupropion to be as effective as NRT in increasing 
quit rates (Hughes, Stead, & Lancaster, 2010). The most recent prescription-only 
pharmacotherapy for smoking cessation is varenicline (marketed in Australia as Champix). 
Varenicline is a partial agonist, meaning it stimulates nicotinic receptors, but not to the same 
extent as smoking. This reduces withdrawal symptoms and the satisfaction of smoking. 
Varenicline increases the success of quit attempts up to threefold compared to a placebo 
(Cahill, Stead, & Lancaster, 2012). Bupropion and varenicline are listed on the PBS in 
Australia. Other pharmacotherapies that have been shown to be effective, but are not used 
widely in Australia, are cytisine and nortriptyline.  
 
In Australia, the use of smoking cessation pharmacotherapies has increased steadily since their 
introduction. In 2002, 32% of those who had made a quit attempt in the previous year had used 
pharmacotherapy (NRT, Champix or Zyban). This increased to 52% in 2008 (Cooper, Borland, 
& Yong, 2011). The listing of varenicline on the PBS in 2008 increased use from 5% to 24% 
between 2007 and 2008 (Cooper et al., 2011). Despite high use of pharmacotherapies, there is 
evidence of poor adherence, with many users prematurely discontinuing use (Balmford, 
Borland, Hammond, & Cummings, 2011; Fucito, Toll, Salovey, & O’Malley, 2009; Shelley et 
al., 2015). Also, despite previous studies showing NRT purchased over the counter is as 
effective as NRT bought on prescription (Hughes, Shiffman, Callas, & Zhang, 2003), more 
recent evidence suggests that NRT purchased over the counter may not increase quitting 
(Hughes, Peters, & Naud, 2011). 
 
The widespread use of pharmacotherapy contrasts with low uptake of behavioural support for 
smoking cessation, despite behavioural support being required under the PBS prescribing 
guidelines for smoking cessation pharmacotherapies.  Research shows that only 15% of those 
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who had made a quit attempt in the year 2008-2009 had used behavioural support, such as the 
Quitline or private counselling (Cooper et al., 2011). Findings from the UK are similar. A 2011 
report found that 54% of smokers who had made a quit attempt used pharmacotherapy, but 
only a small proportion attended smoking cessation clinics, where more intensive assistance 
was provided (West & Fidler, 2011). The low use of behavioural support is disappointing given 
that a combination of pharmacotherapy and behavioural intervention is the most effective way 
to quit smoking (Hartmann-Boyce et al., 2013). 
 
Tobacco treatment guidelines in the USA, Australia, and the UK all recommend that health 
professionals identify smokers and intervene by providing brief advice about smoking 
cessation and a prescription for a pharmacotherapy (Fiore et al., 2008; National Institute for 
Health and Clinical Excellence, 2008; Zwar et al., 2014). The “5 A’s” were developed by the 
U.S. Surgeon General for health practitioners. They are shown in Table 2.1. 
 
Table 2.1 - The “5 A’s” model for treating tobacco use and dependence  
 
Ask about tobacco use Identify and document tobacco use status for every 
patient at every visit. 
Advise to quit In a clear, strong, and personalized manner, urge 
every tobacco user to quit. 
Assess willingness to make 
a quit attempt 
Is the tobacco user willing to make a quit attempt at 
this time?  
Assist in quit attempt For the patient willing to make a quit attempt, offer 
medication and provide or refer for counselling or 
additional treatment to help the patient quit. 
 
For patients unwilling to quit at the time, provide 
interventions designed to increase future quit 
attempts. 
Arrange follow up For the patient willing to make a quit attempt, arrange 
for follow up contacts, beginning within the first 
week after the quit date.  
 
For patients unwilling to make a quit attempt at the 
time, address tobacco dependence and willingness to 
quit at next clinic visit.  
From Fiore et al. (2008) 
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In Australia, the Royal Australian College of General Practitioners (RACGP) recommend that 
pharmacotherapy be offered to all smokers who are “nicotine dependent.” The RACGP does 
not provide definitive criteria for diagnosing nicotine dependence but lists the following  
“indications of nicotine dependence”: smoking within 30 minutes of waking, smoking more 
than ten cigarettes per day, or experiencing withdrawal symptoms on previous quit attempts 
(Zwar et al., 2014). Brief smoking cessation advice by physicians is recommended for all 
smokers, and referral to Australia’s free smoking cessation telephone helpline (called Quitline) 
is also recommended. While the use of telephone smoking cessation counselling has been 
shown to be an effective intervention (Stead, Hartmann-Boyce, Perera, & Lancaster, 2013), the 
proportion of smokers who use this service is very low. In Australia, where the Quitline is free, 
easily accessible, advertised on television and on all cigarette packets, less than 5% of smokers 
had used the service within the last year (Miller, Wakefield, & Roberts, 2003). Moreover, of 
those who had used it, many reported that it was not helpful in their quit attempts (Hung, 
Dunlop, Perez, & Cotter, 2011). 
 
 Smoking as a chronic disease  
A number of authors have recently recommended that all smokers who come in contact with 
health professionals should receive treatment for their smoking, regardless of their desire or 
“readiness” to quit (Aveyard & Raw, 2012; Richter & Ellerbeck, 2014; Zwar et al., 2014). They 
argue that smoking should be treated as a “chronic disease” because of the propensity to 
relapse, and they compare the treatment of smoking to hypertension, diabetes, or high 
cholesterol (Steinberg, Schmelzer, Richardson, & Foulds, 2008).  For example, Aveyard and 
Raw advocate for a new paradigm where health professionals support “(nearly) all smokers 
most of the time”, rather than offering support only to those who have expressed an intention 
to quit (Aveyard & Raw, 2012, p. 255). They argued that this means treating “smoking and 
nicotine addiction like a chronic disease.” (Aveyard & Raw, 2012, p. 255). Their choice of 
words is instructive: they state that nicotine addiction should be treated like a chronic disease, 
not that it is a chronic disease. Others are more direct in the language used. The US Public 
Health Services Guidelines states that “Tobacco dependence is a chronic disease that often 
requires repeated intervention and multiple attempts to quit.” (Fiore et al., 2008, p. vi). Tobacco 
smoking is thus portrayed not only as a risk factor for disease, but as a disease in itself. 
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The use of the disease label for smoking has been influenced neurobiological research on 
addiction to cocaine and heroin that described the neurochemical changes in the brain related 
to prolonged use of these psychoactive drugs (Leshner, 1997; Volkow & Li, 2004). The same 
approach was later used to study nicotine dependence. Before outlining what has come to be 
known as the “brain disease model of addiction”, a brief summary of the neuroscience of 
nicotine addiction is now provided.  
 
 The neuroscience of nicotine addiction 
Nicotine is a natural component of tobacco that can be highly toxic to the body and cause death 
in high doses (Mayer, 2014). In small amounts, typical of that absorbed from a cigarette, it 
causes mild psychoactive and cognitive effects. Nicotine is the primary addictive agent in 
tobacco, but it is not the only chemical constituent of cigarette smoke associated with the 
clinical signs of dependence. For example, β-Carboline has been demonstrated to inhibit the 
release of monoamine oxidase, possibly contributing to the negative affect experienced by 
smokers during a period of abstinence (Bruijnzeel, 2012). However, scientific evidence 
demonstrates that nicotine is the primary psychoactive and addictive component of tobacco 
(US Surgeon General, 1988). It is also the most well-known to the public, and therefore it is 
the main focus in this thesis. 
 
Effects of smoking on cognition and mood in humans 
While smoking often produces aversive symptoms in new users, such as nausea and dizziness, 
these effects typically dissipate with continued smoking and the development of tolerance. In 
dependent individuals, smoking creates a sense of pleasure, feelings of relaxation, and 
enhanced alertness and attention. On cessation of tobacco use, withdrawal symptoms that are 
commonly reported include irritability, cravings, anxiety, sleep disturbance, and increased 
appetite (Hughes, 2007). Individuals may smoke to achieve desirable cognitive or emotional 
effects (positive reinforcement) and to relieve withdrawal symptoms (negative reinforcement).  
 
Acute effects of nicotine use on the brain  
When tobacco is smoked, nicotine is suspended in particles of tar that are inhaled into the lungs, 
where the nicotine is absorbed into the bloodstream. Nicotine travels quickly from the lungs to 
the brain, crossing the blood-brain barrier, where it binds to receptors in the brain on which the 
neurotransmitter acetylcholine usually binds, known as nicotinic acetylcholine receptors 
18 
  
(nAChRs). Nicotine binding to nAChR receptors opens ion channels in the neuron membrane 
allowing positively charged ions to enter the neuron that influences the chemical signals it 
transmits (Laviolette & van der Kooy, 2004; Stoker & Markou, 2013).  
 
While nAChRs are widely distributed throughout the brain, the effects of nicotine in the 
mesocorticolimbic reward circuit of the brain are thought to be critical to the development of 
addiction (Laviolette & van der Kooy, 2004). Specific anatomical structures of the brain that 
have been implicated are the ventral tegmental area, nucleus accumbens, corpus striatum, 
amygdala, hippocampus and the prefrontal cortex (Figure 2-1).  
 
Figure 2-1 The reward pathway of the brain1  
 
The ventral tegmental area contains a high concentration of nAChRs. Nicotinic activation of 
nAChRs in this area causes the release of the neurotransmitter dopamine in the nucleus 
accumbens shell (Benowitz, 2010). These dopaminergic neurons project to structures in the 
limbic and cortical systems, including those that play a key role in memory (hippocampus), 
emotion (amygdala), and decision-making (prefrontal cortex) (De Biasi & Dani, 2011).  
 
                                                 
1 (Kalsi, Prescott, Kendler, & Riley, 2009, p. 50). Reprinted with permission from Elsevier.  
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The neural basis of nicotine dependence 
Converging lines of evidence suggest that dopamine release in the mesolimbic area plays a 
major role in the reinforcing properties of nicotine (Pistillo, Clementi, Zoli, & Gotti, 2015). 
Dopamine release in the mesolimbic circuit is believed to signal the salience or importance of 
stimuli. Nicotine self-administration in rats decreases when the release of dopamine is inhibited 
by chemically induced lesions of the mesolimbic dopaminergic pathway or the administration 
of dopamine antagonists (Corrigall & Coen, 1991; Corrigall, Franklin, Coen, & Clarke, 1992; 
DeNoble & Mele, 2006).  
 
The brain’s stress system is also affected by chronic nicotine administration in ways that may 
contribute to the withdrawal symptoms of anxiety and irritability that many smokers experience 
on cessation. Nicotine administration has been associated with the activation of the 
hypothalamic-pituitary-adrenal axis, and the subsequent release of the hormones corticotropin 
and cortisol, hormones which are usually produced in response to stress (Bruijnzeel, 2012). 
Cessation of smoking is associated with reduced cortisol levels and smokers with lower levels 
of cortisol are more likely to experience withdrawal symptoms, although causation has not 
been established (Bruijnzeel, 2012). A review by Adrie Bruijnzeel (2012) concluded that 
nicotine exposure leads to dysregulation of the brain’s stress system, producing feelings of 
stress on withdrawal that can potentially cause relapse. 
 
Changes in the brain associated with nicotine addiction occur at numerous levels. At the 
cellular level, plastic changes in the brain, known as neuroadaptations, occur with repeated 
nicotine use. These are associated with the development of the clinical signs of addiction: 
craving, withdrawal, and tolerance. Repeated exposure to nicotine desensitizes nAChRs and 
increases the length of time that receptors are in an inactive state (Govind, Vezina, & Green, 
2009). When abstinent from nicotine, the receptors again become active and available for 
binding. 
 
Upregulation is another plastic change in the brain that is thought to result from chronic 
nicotine use. It involves an increase in the number of nAChRs that is thought to occur in 
response to the desensitization of nAChRs described above (Peng, Gerzanich, Anand, Whiting, 
& Lindstrom, 1994). Upregulation is a complex process and its role in the development of the 
signs of nicotine dependence has not been fully elucidated. It is also thought to play a role in 
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nicotine desensitisation and withdrawal symptoms (De Biasi & Dani, 2011; Govind, Walsh, & 
Green, 2012). 
 
Imaging studies have shown a number of structural differences in smokers compared to non-
smokers, including: increased grey matter in the insula; decreased grey matter volume in the 
prefrontal cortex; and thinning of the orbitofrontal cortex (Jasinka, Zorick, Brody, & Stein, 
2013). A review of human and animal brain imaging studies of the effects of nicotine on the 
brain found a general decrease in total brain activity, but a specific increase in brain activity 
in the prefrontal cortex, the visual system and the thalamus. These changes may explain the 
improved visual attention and increased reaction time in cognitive studies of the effects of 
nicotine (Brody, 2006).  
 
 The brain disease model of addiction 
The belief that addiction is a disease is not new, but the idea that it has a specific 
neurobiological basis that can be pinpointed in the brain of affected individuals is a more recent 
development. Older models of addiction framed drug dependence as a disease of the will 
(White, 1998). The brain disease model locates addiction in the brain of the individual, and 
proponents argue that this focus on biological factors will reduce moral judgements about 
addicted individuals, and enable more humane public policy responses to addiction (Dackis & 
O'Brien, 2005).  
 
According to Campbell (2010), the BDMA was enthusiastically adopted because the field of 
addiction studies was in “conceptual disarray” due to the wide variety of drugs that seemed to 
work in different ways and had varied “social histories” (Campbell, 2010, p.92). A “unifying 
framework” of addiction attracted scientists to the field, aided by the prestige of neuroscience 
and its associated funding (Campbell, 2010, p.92). Similarly, Vrecko (2010) has described the 
social context in which the BDMA emerged in America. He has argued that the field of 
addiction neuroscience was made possible due to large amounts of funding from US 
government during Richard Nixon’s “War on Drugs” of the 1970s, leading to a 
“neurobiological problem space” where “the brain and the scientist’s laboratory have become 
obligatory points of passage for those who wish to produce truths about addiction” (Vrecko, 
2010, p. 61).  
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The National Institute of Drug Abuse (NIDA) in the US defines addiction as a “chronic, 
relapsing brain disease” (National Institute on Drug Abuse, 2007) and its two recent Directors 
have actively promoted this explanation of addiction to policymakers, research funders and the 
public. They employ the metaphor of drugs “hijacking” the circuits of the brain that respond to 
natural rewards such as food and sex, overriding rational thought (Dackis & O'Brien, 2005; 
Volkow & Li, 2005). This language has been echoed by the American Association for 
Addiction Medicine, who recently redefined addiction as “a primary, chronic disease of brain 
reward, memory and related circuitry” (American Society for Addiction Medicine, 2015). The 
central tenets of the brain disease model are that:  
 chronic drug use leads to long-lasting changes in brain structure and function 
 these brain changes explain the behaviours that accompany addiction, specifically a 
loss of control over drug use and a risk of relapse, and 
 addiction is chronic and relapsing, similar to diabetes or hypertension, and should be 
treated as a chronic health problem (Dackis & O'Brien, 2005; Leshner, 1997; Volkow 
& Li, 2004).  
 
One of the key arguments for the BDMA is its potential to improve treatments for drug 
addiction. A number of novel treatments for smoking cessation informed by neuroscience 
research have been proposed. For example, transcranial magnetic stimulation is a non-invasive 
procedure in which a magnetic device placed near the surface of the skull stimulates neurons 
in a localised area of the brain. A small number of studies have used this procedure on smokers 
and findings suggest that it may reduce cravings for cigarettes in the short-term (Amiaz, Levy, 
Vainiger, Grunhaus, & Zangen, 2009; Rose et al., 2011) but there is little evidence that it 
increases cessation success in the long-term. Results from other neuroscience studies have led 
to the suggestion that brain scans could be used in the future to identify those at risk of relapse 
of smoking and to match individuals to interventions that are most likely to be effective 
(Addicott, Sweitzer, Froeliger, Rose, & McClernon, 2015; Loughead et al., 2015).  
 
 Criticisms of the biomedicalisation of tobacco smoking 
While some are optimistic about the potential for biomedical research to produce new 
treatments for smoking cessation, there are concerns about potential negative impacts of 
viewing and treating tobacco dependence as a disease in need of medical treatment.  
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Despite the effectiveness of pharmacotherapy for smoking cessation in clinical trials, there 
have been criticisms of the extent to which pharmaceutical aids for quitting have been 
promoted. While these medications increase the success rate of quit attempts, most smokers 
who use NRT or prescription medication still fail to quit (Chapman & MacKenzie, 2010). 
Moreover, many of the findings about the effectiveness of pharmaceutical treatments for 
smoking are based on clinical trials sponsored by the pharmaceutical manufacturer (Chapman 
& MacKenzie, 2010; Etter, Burri, & Stapleton, 2007).  
 
Community surveys to assess the effectiveness of cessation medications when used without 
medical supervision have produced more mixed findings on their efficacy in everyday use. 
This failure to replicate the results in clinical studies raises questions about the generalisability 
of findings from clinical trials to “real world” settings (Alpert, Connolly, & Biener, 2013; 
Walsh, 2008). However, a recent study that included data from Australia, Canada, the USA 
and the UK found that use of pharmacological cessation aids significantly increased the chance 
of a successful quit attempt (Kasza et al., 2013). The authors argue that a lack of positive 
findings in previous studies was due to a failure to control for important sources of bias in who 
uses these aids, and due to smokers’ poor adherence to guidelines on the effective use of these 
aids.  
 
Advocates of a medical model of smoking cessation argue that even if interventions are 
successful for only a minority of smokers, small improvements in quit success make these 
interventions cost effective compared to other health interventions (Parrott & Godfrey, 2004). 
Some have argued that more smokers should be encouraged to use them: “If there is a major 
failing in the UK approach, it is not that it has medicalised smoking, but that it has not done so 
enough.” (Britton, 2009).  
 
Concerns about the promotion of pharmacotherapy for smoking cessation do not solely centre 
on efficacy. There are also concerns that a biomedical model of smoking will distort public 
perceptions about how easy it is to quit smoking. For example, Chapman and McKenzie  (2010) 
believe that a focus on “treatment” for smoking neglects the fact that most of those who have 
quit have done so unaided. An emphasis on the need to use medications for smoking cessation 
may increase perceptions that quitting smoking is difficult, thereby eroding self-efficacy and 
agency (Chapman & MacKenzie, 2010; Zhu et al., 2012). Chapman and McKenzie (2010) 
argue that more research should be conducted into why unassisted quitting is so effective. 
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Chapman and McKenzie (2010) attribute what they consider an overemphasis on a medical 
approach to smoking cessation to a number of factors. The first is that most people working on 
smoking cessation interventions have a positivist approach to knowledge, meaning they 
prioritise individual level variables and experimental approaches. The alternative public health 
model takes into account more distal variables and their complex interactions. Another factor 
is the commodification of smoking cessation under the influence of the corporate interests of 
pharmaceutical companies. Lastly, there is a belief, unsupported by evidence in their view, that 
those smokers who have not already quit are “hard core” smokers in need of intensive 
assistance (Chapman & MacKenzie, 2010).  
 
Other commentators are also worried that a medical model of smoking that emphasises the 
addicted brain will have negative consequences. Caron and colleagues (2005) outlined the 
“fundamental changes” in “popular, clinical, and public health views of smoking” that may 
result from a “neurogenomic” understanding of addiction (Caron et al., 2005, p. 181). These 
include: a diminution of the role of choice in public portrayals and understandings of smoking; 
a neglect of structural and social aspects of smoking; and the potential for discrimination based 
on the neuromolecular status of individuals. Also, a shift in emphasis from the cigarette to the 
smoker may deflect attention from the tobacco industry and their dangerous products. In fact, 
there is evidence that the tobacco industry have supported genetic research on addiction as a 
strategy to deflect blame for the health consequences of smoking from the cigarette to the 
“genetic constitution” of the smoker (Gundle, Dingel, & Koenig, 2010, p. 974).  
 
The BDMA has faced similar criticisms as those levelled at the more general medical model 
of addiction. Critics argue that it is overly essentialist, emphasising biological factors at the 
expense of social ones (Dingel et al., 2011; Kalant, 2010). A key criticism of the BDMA is that 
it may marginalize other perspectives and treatment modalities by prioritizing basic science 
research on addiction at the expense of funding for social and behavioural interventions (Dingel 
et al., 2011). A focus on the treatment of individuals may reduce the emphasis on broader, 
effective population based measures. In tobacco control these include increasing tobacco taxes 
and banning smoking in public spaces (Gartner, Carter, & Partridge, 2012).  
 
There is also some evidence that biological understandings of addiction may actually increase 
the stigma directed towards addicted individuals (Kvaale, Gottdiener, & Haslam, 2013; 
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Pescosolido et al., 2010). Elam (2015a) argues that the BDMA is responsible for 
“remoralizing” addiction. Drug users are believed to have lost control of their drug use and are 
portrayed as “brain hostages”, but at the same time they are encouraged to take responsibility 
for protecting their brains and working to return them to a more healthy state. Constant 
vigilance is required in order to “avoid being terrorized by our own neural circuitry gone awry” 
(Elam, 2015a, p. 59).  
 
These potential benefits and pitfalls of the medicalisation of addiction are summarised in Table 
2.2. The pitfalls listed closely align with the “darker sides” of medicalisation described earlier 
in this chapter, namely, the individualisation of social problems and the dislocation of 
individual responsibility.  
 
Table 2.2 - Potential social effects of biomedical explanations of addiction 
Benefits Pitfalls 
Improved treatments Perception that quitting is difficult without 
medication 
Reduced stigma Increased stigma 
Reduced sense of self-blame Decreased sense of personal responsibility 
Greater treatment seeking and 
adherence 
Reduced self-efficacy and increase in 
fatalism 
Improved quit rates Decrease in quit attempts 
Increase in funding of addiction 
science 
Decrease in funding on population level 
approaches 
 
 Limits to the biomedicalisation of smoking  
There are a number of factors that have limited the extent of the biomedicalisation of smoking. 
Firstly, the tobacco control field grew primarily from epidemiology and public health 
(Berridge, 1997). A medical approach that has more recently developed has not displaced the 
population based measures that remain central in the field’s research and policy. The WHO 
Framework Convention on Tobacco Control has a strong emphasis on population-based 
measures, with only one item discussing the role of treatment for smoking cessation (World 
Health Organisation, 2005). Because many of the countries where smoking prevalence is 
increasing have limited resources, an emphasis on cost-effective population level interventions 
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is vital. It has been argued that for countries in early stages of the tobacco epidemic, the 
widespread treatment of individual smokers with pharmacotherapy is not financially viable 
(Chapman & MacKenzie, 2010), but others have advocated for NRT as a cost-effective 
medication even in developing countries (Kishore, Bitton, Cravioto, & Yach, 2010). 
 
Second, there has been a growing acknowledgement of socioeconomic disparities in smoking, 
which increasingly concentrated amongst the poor and marginalized, as the greatest decline in 
smoking has occurred amongst the wealthiest and most educated groups (Australian Institute 
of Health and Welfare, 2014). The social embeddedness of smoking has been demonstrated by 
qualitative studies which illuminate the roles and meanings that disadvantaged smokers ascribe 
to their tobacco consumption. For example, smoking is described as a means of coping with 
the stresses associated with poverty, as a means for forging social connections and identity, 
and as a form of resistance to dominant middle-class values (Pateman et al., 2016; Thompson, 
Pearce & Barnett, 2007; Wiltshire, Bancroft, Parry & Amos, 2003). This “uneven social 
geography” of smoking signifies that smoking is not simply an individual health behaviour, 
and that social context must be considered by tobacco control researchers (Poland et al., 2006). 
 
A third factor limiting the biomedicalisation of smoking is nicotine’s ambiguous place amongst 
other drugs (Keane, 2002). As previously mentioned, nicotine has only mild psychoactive 
effects, and regular smokers do not become intoxicated. Smoking does not usually adversely 
affect an individual’s ability to function in everyday life or cause the social problems associated 
with other substance use, and the adverse health effects of smoking are often delayed by 
decades. These differences are why nicotine is often considered separately from alcohol and 
illicit drugs, or even ignored in discussions of drug addiction. Hughes (2013) found that 75% 
of articles that referred to drug/substance abuse, dependence or addiction did not include 
nicotine as a focus, and few papers provided any reason for excluding it. The intensity of 
medical treatment for addiction to alcohol or illicit drugs differs from that of nicotine. 
Treatment for other drugs often involves supervised detoxification, extended rehabilitation 
programs, or long-term substitution programs (e.g., methadone maintenance therapy). It is very 
rare for smokers to receive inpatient care solely for their smoking, although there are exceptions 
(Mayo Clinic, 2015).  
 
Lastly, many healthcare practitioners are unenthusiastic about a medical approach to smoking 
cessation. Despite the clinical recommendations described above for identifying and treating 
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smokers, Australian research reveals that only half of smokers who had been to a doctor in the 
last year were advised to quit smoking (Cooper et al., 2011). Similar findings have been 
reported in the USA (Centers for Disease Control and Prevention, 2011), and the UK (West & 
Fidler, 2011). Barriers to identifying and treating smokers in general practice include doctors’ 
concern about patients taking offence, a lack of time, and a lack of confidence in addressing 
smoking (Zwar & Richmond, 2006). While the rate of pharmacotherapy use amongst smokers 
is increasing, there also seems to be resistance amongst smokers to seeking professional 
assistance with cessation. As previously described, the vast majority of smokers do not use free 
smoking cessation services such as cessation clinics in the UK and the Quitline in Australia.  
 
 The role of nicotine addiction in the tobacco “endgame”  
Virginia Berridge has written that the public health approach to smoking symbolized “an 
absolutist approach to smoking” (Berridge, 1997, p. 50) according to which nicotine addiction 
is an evil to be eradicated. The medical approach, by contrast, has been more open to employing 
nicotine substitution for harm reduction. This includes the use of nicotine in NRT, as well as 
other products such as snus, and more recently, e-cigarettes. Kozlowski (2013) describes three 
perspectives on the role of nicotine addiction in tobacco control. The first is that nicotine 
addiction is a disease in itself that needs to be eradicated. The second is that nicotine addiction 
should be eliminated, but that this is not a priority. The third perspective is that nicotine 
addiction can be employed as a tool to reduce the harms of cigarette smoking.  
 
The contradictory role of nicotine as an agent of addiction and as a treatment for addiction has 
been described by Keane in relation to NRT:  
“Thus NRT actually performs two contrasting forms of nicotine dependence: a disorder 
which is the opposite of freedom and autonomy and a component of the treatment which 
re-establishes freedom and autonomy.” (Keane, 2013, p. 191)  
Keane also notes that when NRT became available over-the-counter, there was a shift from it 
being a medicalised option for smoking cessation, to a consumer product that did not require 
the smoker to become a patient (Keane, 2013). In this sense, increasing smokers’ access to 
NRT may have played a role in the partial de-medicalisation of nicotine addiction as well as 
contributing to the medicalisation of smoking cessation.  
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Debates around the role of nicotine addiction are becoming more explicit with the increasing 
availability and use of electronic cigarettes, or e-cigarettes. E-cigarettes have been highly 
controversial in the tobacco control field because of their potential to normalise nicotine 
addiction, as well as their resemblance to smoking in appearance, hand-to-mouth action and 
visual similarity of the exhaled 'vapour' to smoke. Criticisms of e-cigarettes are often couched 
in terms of their unknown health risks and their potential to be a gateway into cigarette smoking 
for young people. Bell and Keane (2012) argue, however, that opposition to e-cigarettes is 
primarily based on the “ideological challenge” that they pose to those in tobacco control. 
Nicotine has been dichotomised into the “bad” form that is sold by tobacco companies and the 
“good” form that is sold by pharmaceutical companies. E-cigarettes cannot be neatly 
categorised into either of these categories. Moreover, they represent a potential for nicotine to 
be consumed for pleasure, rather than for therapeutic purposes, without the harms caused by 
smoking tobacco.  
 
In summary, while it is obvious that smoking has been medicalised to some degree, this has 
remained “partial and fragmented” (Rooke, 2012). Tobacco smoking has been defined as a 
chronic (brain) disease by some influential organisations, but this conception of tobacco 
dependence has not gone unchallenged and various factors may limit its reach. One thing that 
is clearly missing from the debate about the merits or otherwise of the medicalisation of tobacco 
dependence and nicotine addiction are the voices of those who smoke. 
 
 Lay understandings of smoking and nicotine addiction: the missing link?  
Much of the literature outlined above speculates about the impact of the biomedicalisation of 
smoking on public perceptions of smoking and cessation. For example, Chapman & McKenzie 
state that disempowered smokers might feel that “it would be foolish to attempt to stop unaided 
when unassisted cessation is dismissed in pharmaceutical industry-supported demonstrably 
misleading propaganda” (Chapman & MacKenzie, 2010, p. 4). Caron et al write that 
medicalising smoking “could affect smokers’ understandings of the health risks associated with 
their behaviour, their perception of the nature of their addiction, and their perception of the 
need for medical assistance in quitting” (Caron et al., 2005, p. 188).  
 
There is a dearth of research investigating whether smokers do in fact hold these fatalistic views 
and, if so, whether they are linked to beliefs about the nature of their tobacco dependence. The 
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next chapter will describe and evaluate the current evidence on lay understandings of nicotine 
addiction, attitudes towards smoking cessation treatment, and the role played by neurobiology 
in addiction to smoking.  
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Chapter 3. Lay understandings of smoking and the role of the brain in 
addiction. 
 
The previous chapter concluded that lay perceptions of smoking need to be examined to assess 
the extent to which smokers endorse biomedical approaches to smoking cessation. This chapter 
outlines research on lay understandings of addiction and smoking. It then describes a specific 
example of biomedicalisation: the brain disease model of addiction; outlines evidence on lay 
understandings of the brain; and describes the need for further research on how smokers 
understand the role of the brain in addiction and smoking.  
 Lay understandings of health and illness: A brief review of the literature 
The importance of conducting research on lay understandings of health and illness has been 
acknowledged in psychology (Furnham, 1988; Molden & Dweck, 2006), public health (Popay 
& Williams, 1996) and addiction research (Quintero & Nichter, 1996). During the 1970s, there 
was a growing emphasis on the importance of lay beliefs about health and illness, particularly 
within medical sociology. This arose from concerns that dominant biomedical and mechanistic 
models of the body excluded important experiential aspects of health and illness, and did not 
take account of socio-environmental influences on health and disease. There was a tendency 
on the part of the medical profession to characterise lay or “folk” knowledge as inaccurate, 
with public and patient education recommended to correct common “misperceptions” of health 
and illness and encourage healthier lifestyle choices. This has come to be known as the deficit 
model of lay beliefs (Popay & Williams, 1996). An alternative way of understanding lay beliefs 
is exemplified by Popay and Williams (1996), who argue that “lay expertise” should be seen 
as a valid form of knowledge with important consequences for public health: 
“…through a more or less systematic process whereby experience is checked against 
life events, circumstances and history, lay people acquire an 'expert' body of 
knowledge, different from but equal to that of professionals in the public health field.” 
(Popay & Williams, 1996, p. 760). 
The term “lay epidemiology” was introduced by Davison, Smith and Frankel in 1991 to 
describe the sophisticated “daily cultural practice” by which people account for the 
development (or otherwise) of health problems (Davison, Smith, & Frankel, 1991). They 
conducted ethnographic studies that explored how members of the public in Wales understood 
the risk of developing heart disease. While they observed overlap between aetiological beliefs 
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of laypeople and medical professionals, they also described how aetiological lay beliefs were 
“personalised modifications” of those disseminated throughout society by professional 
organisations and the media. These modifications were employed to account for the 
“anomalous deaths and unwarranted survivals” that were not consistent with public health 
campaigns about the lifestyle factors that cause heart disease (Davison et al., 1991). The 
authors argued that public health professionals were guilty of “worthy dishonesty” in 
exaggerating the risks of certain behaviours to the individual, and overstating the benefits of 
their adopting behaviour change. They noted the potential for this strategy to backfire, 
undermining public trust of public health information. 
 
In another seminal work on lay understandings of illness, Blaxter (1983) conducted interviews 
with low-income women from Wales about their beliefs about the causes of disease and illness. 
Like Davison and colleagues (1991), Blaxter emphasised the sophisticated nature of lay beliefs 
about the causes of disease. Even when wrong, these beliefs were “painstakingly” developed, 
based on social factors and an individual’s personal history. The important role of these beliefs 
in clinical interactions was highlighted. Blaxter wrote “In the surgery, the doctor’s views of 
the disease process must be reconciled with the patient’s. The diagnosis must make sense in 
terms of the patient’s models or it will not be accepted.” (Blaxter, 1983, p. 69). Much research 
since has shown that patient beliefs about illness, health, or medication can affect their health 
behaviours, treatment preferences and treatment adherence (Fucito et al., 2009; Horne & 
Weinman, 1999; S. Munro et al., 2007; Petrie, Jago, & Devcich, 2007). 
 
The field of Public Understanding of Science (PUS) is another interdisciplinary field that has 
developed in parallel with lay understandings of health and illness. Like research on lay 
understandings of health, PUS began from a deficit model in which “the public” was often 
portrayed as lacking in scientific literacy. This lack of scientific knowledge was seen as 
obstructing the acceptance of new scientific technologies. “Science literacy” was proposed as 
the solution and the role of the scientist was to educate the lay populace about science on the 
assumption that this would increase positive attitudes towards the technology (Bauer, Allum, 
& Miller, 2007). The field has since shifted to a “science and society” paradigm that 
acknowledges lay expertise (Wynne, 1992), questions key assumptions about science (e.g., that 
it is value free), and advocates for engagement between scientists and the public (Bauer et al., 
2007). It is now acknowledged that there are multiple publics made up of various stakeholder 
groups rather than a homogenous whole that includes everyone except scientists. 
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While there has been some debate about the extent to which lay knowledge should be 
considered as a form of “expert” knowledge (Prior, 2003), there is a general agreement that lay 
beliefs about disease or biotechnology can influence healthcare decision-making. Studying lay 
beliefs about health and illness is therefore an important endeavour. The following section will 
outline empirical research on lay understandings of addiction in general and then consider lay 
concepts of addiction to cigarettes specifically.  
 
 Lay understandings of addiction 
Furnham and Thomson define a lay person in relation to addiction as “a non-
medical/psychological professional who has no expert knowledge on addiction.” (Furnham & 
Thomson, 1996, p. 29). Research on lay understandings of addiction is important because it 
can elucidate public attitudes towards addicted individuals and the attitudes of addicted 
individuals towards their own addiction. Beliefs held by the public and politicians about 
addiction can influence policy regarding the most appropriate forms of treatment for addiction 
and the allocation of resources to such treatments (Broadus & Evans, 2015; Kuppin & 
Carpiano, 2006; Luty & Grewal, 2002).  
Scientific and clinical definitions of addiction are complex and contested (Campbell, 2007; 
Edwards, 2010; Howard, 2010; Sussman & Sussman, 2011; White, 1998). In the scientific and 
clinical arena, there is little agreement on whether the terms addiction or dependence should 
be used to describe the constellation of behaviour and experiences of those who struggle with 
their drug use. Diagnostic criteria and labels for addiction have changed over time. As we have 
seen, since nicotine addiction came under the purview of the DSM, it has been named “tobacco 
dependence” (DSM-III), “nicotine dependence” (DSM-IV), and “tobacco use disorder” (DSM-
5). Many researchers now use the words interchangeably, but each has differing implications 
(O'Brien, 2011). Given the debate and lack of clarity amongst experts, it is not surprising that 
lay understandings of addiction/dependence are also sometimes contradictory and varied.  
As described in the previous chapter (Section 2.2), the history of addiction to nicotine has 
differed to that of other drugs. This is reflected by differences in public perceptions of smoking 
compared to alcohol dependence and illicit drug use (Cunningham, Sobell, Freedman, & 
Sobell, 1994; Hughes, 2009). It is beyond the scope of this thesis to comprehensively review 
the literature on professional and lay understandings of all forms of drug addiction. However, 
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a number of key findings can be drawn from the literature on lay understandings of addiction 
more generally.  
 
First, clinicians, addicted individuals, and the general public hold multidimensional, and often 
contradictory, understandings of addiction. Their responses do not fit neatly into pre-defined 
theoretical models of addiction, such as the “moral model” or the “medical model” that have 
been proposed in attribution theory (Brickman et al., 1982). Even those who work in the 
medical arena do not solely explain addiction as an individual, medical problem. For example, 
Palm (2004) found that drug and alcohol clinicians supported a mixture of moral, disease and 
sociological models of addiction. Most agreed that addicted individuals had responsibility for 
the development of their addiction, and for resolving it, but many also agreed that addiction 
was a disease, particularly addiction to alcohol. Importantly, Palm (2004) notes that a major 
limitation of their research is that it is not clear how the respondents interpret the word 
“disease” in this context. While the AA (Alcoholics Anonymous) model of addiction as a 
disease does not necessarily involve a medical or biological portrayal of addiction, more recent 
descriptions of addiction as a “brain disease” highlight the biological and medical aspects of 
the disorder. It is unknown to what extent members of the general public, or addicted 
individuals themselves, locate the disease concept of addiction within this medical frame.  
 
West and Power (1995) also found that the oft-cited “helping-coping” model of addiction, 
where beliefs about responsibility for addiction are related to beliefs about the need for 
treatment, was too simplistic to account for their research findings with addicted individuals. 
The alcohol dependent patients they surveyed held contradictory beliefs about the cause of 
their addiction. For example, they thought that their addiction was their own responsibility but 
also believed that it was caused by external factors. Moreover, they often agreed that they 
needed to take control of their own recovery, but help and support from others would still be 
required. The authors found no association between beliefs about responsibility for addiction 
and beliefs about whether treatment or assistance was required. Similarly, an empirical study 
with addiction clinicians and neuroscientists found that most believed that addiction impaired 
control over drug consumption, but that individuals remained responsible for their behaviour 
(Carter, Mathews, Bell, Lucke, & Hall, 2013). 
 
The research on lay understandings of addiction has focused on survey studies, where items 
are often developed in a top-down manner based on existing scientific theories of addiction, 
33 
 
rather than arising from exploratory qualitative research with members of the public or addicted 
individuals themselves (Broadus & Evans, 2015). Where exploratory research is conducted 
with addicted individuals, they are mostly clinical populations, and thus do not represent the 
many who do not seek formal treatment, though there are exceptions (Broadus & Evans, 2015). 
Survey studies are limited because they may ask whether people think addiction is a disease, 
but it is not clear what conceptualisation of disease individuals think of when they respond to 
this question. Similarly, survey research enquires about responsibility for addiction, but it is 
unknown how responsibility is conceptualised by participants: are participants thinking about 
their moral responsibility for the choices they have made in leading to addiction, or 
responsibility for future decisions in order to overcome their addiction? To overcome the lack 
of empirical evidence on how lay people conceptualise addiction, Weinberg has recommended 
an empirical approach to addiction, with an emphasis on the “local practice” of addiction as an 
embodied experience (Weinberg, 2002, 2013).  
 
A number of qualitative studies have taken this approach. One such study asked a small sample 
of addicted males from a prison treatment program, as well as addiction experts 
(psychologists), to define addiction in their own words (Walters & Gilbert, 2000). They found 
similarities and differences between lay beliefs about addiction and “expert” definitions. For 
example the authors found that few of the addicted individuals referred to addiction as a 
biological problem, physical dependence, or a disease. They were more likely to describe 
addiction in terms of craving, pre-occupation, self-destruction, abuse and diminished control. 
The expert group were more likely to describe addiction as physical dependence, compulsion, 
and as a biological problem. The authors argue that the client group held a broader view of 
addiction that could encompass behavioural addictions, while the expert group focused more 
on the physical aspects of addiction to a substance. Nonetheless, both groups agreed that 
preoccupation with drug use, and diminished control were key aspects of addiction.  
 
A more recent qualitative study asked members of the public (not addicted individuals 
specifically) open-ended questions about what they thought addiction was. They found that 
references to character were most common in explaining addiction (Meurk, Carter, Hall, & 
Lucke, 2013). Participants described the role of choice, willpower and personality as central to 
addiction. They often referred to the emotional aspects of addiction, for example that people 
smoke to feel pleasure, or to escape boredom. Societal factors, such as family exposure and 
peers, were also cited frequently as influencing the development of addiction. Biological 
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factors were discussed frequently, with 71% talking about the role of the body in addiction, 
and 51% spontaneously talking about the role of the brain in addiction. Most participants 
ascribed addiction to more than one of these causal categories. 
 
Another important finding from the literature on lay understandings of addiction is that beliefs 
about addiction vary with socio-demographic characteristics such as age, gender and political 
affiliation. For example, Broadus and Evans (2015) found that in the US, females were more 
likely to endorse a psychological explanation of addiction, and males more likely to believe 
that addiction had a moral component (Broadus & Evans, 2015). Another study found that 
women were more likely to attribute addiction to biology than men, and also more likely to see 
value in treatment (Kauffman, Silver, & Poulin, 1997). Those who had received treatment for 
addiction were less likely to believe that addiction was a moral weakness and more likely to 
believe it was a disease. This could be because exposure to a disease model via treatment 
centres affected their beliefs (Broadus & Evans, 2015), or because those who have a pre-
existing belief that addiction is a disease are more likely to seek medical treatment.  Politically 
conservative Americans were more likely than liberals to believe that addiction was a sign of 
moral weakness (Broadus & Evans, 2015; Furnham & Thomson, 1996). Together, these 
findings show that conceptions of addiction are not uniform across social groups. Therefore 
important to examine group differences in research on lay understandings of addiction.  
 
Beliefs about addiction also vary over time and between cultures. Pescsolido and colleagues 
(2010) examined changes in attribution of the causes of addiction in the US general public 
between 1996 and 2006.  They found that the belief that alcohol dependence was caused by 
biology (genetics or chemical imbalance in the brain) increased from 38% in 1996 to 47% in 
2006. At the same time, attributions of “bad character” for alcohol dependence increased from 
49% of participants to 65%. This suggests that a moral and a biological conception of addiction 
are not necessarily mutually exclusive in lay understandings of addiction. They also found that 
accepting a neurobiological conception of alcohol dependence did not reduce the stigma of 
addiction, as has been predicted by proponents of the BDMA. Indeed, it was associated with 
increased levels of stigma. Compared to other mental illnesses and physical illnesses such as 
cancer and myocardial infarction, those addicted to alcohol are seen as more responsible for 
their illness, and the public express a desire for social distance from alcohol-dependent 
individuals (Pescosolido et al., 2010; Schomerus, Matschinger, & Angermeyer, 2006). This 
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suggests that addiction to drugs or alcohol is not seen as a “disease like any other” by the 
public. 
 Smokers’ understandings of nicotine addiction 
The literature on lay understandings of addiction to smoking spans numerous disciplines and 
encompasses varied methodological approaches. Most tobacco control research uses validated 
measures of tobacco dependence that are based on smoking behaviours. For example, the 
Heaviness of Smoking Index (HSI) measures level of nicotine dependence using two questions: 
the time to first cigarette of the day after waking and the number of cigarettes smoked per day. 
These items provide a more objective measure of dependence than subjective ratings of self-
reported addiction (Heatherton, Kozlowski, Frecker, Rickert, & Robinson, 1989). A smokers’ 
subjective assessment of their own level of addiction to cigarettes is often neglected, even 
though it may have implications for treatment choices. This is particularly pertinent in the case 
of pharmacotherapy for smoking cessation. Nicotine replacement therapy is predicated on the 
assumption that the individual smoker has a physiological addiction to nicotine, and that 
replacement of nicotine via NRT will reduce their withdrawal symptoms and craving and 
increasing their chance of quitting. However, if an individual smoker does not believe that they 
are addicted to nicotine, it is unlikely that they will find NRT an appealing option, or comply 
with recommended ways of using it, if it is prescribed.  
Surprisingly few quantitative studies have examined smokers’ subjective assessment of their 
addiction to smoking. Those that have assessed subjective views on smoking have used 
inconsistent terminology to enquire about addiction. Studies have asked about addiction to 
tobacco (Carpenter et al., 2009; Hughes, 2009; Okoli, Richardson, Ratner, & Johnson, 2009), 
to smoking (Levinson et al., 2007; Martin, 1990), and to cigarettes (Stippekohl et al., 2012; 
Torchalla, Okoli, Malchy, & Johnson, 2011; Weinstein, Slovic, & Gibson, 2004). Interestingly, 
only one quantitative study found in the literature asked about subjective assessments of 
nicotine addiction (Zinser, Pampel, & Flores, 2011). Studies also differ in whether they ask 
participants if they are addicted to smoking, or the more general statement that smoking is 
addictive. Despite these methodological variations, the results of these studies show that most 
daily smokers report that they are addicted to smoking, and that smoking is addictive. In the 
majority of these studies, 70% or more daily smokers report that they are addicted to smoking. 
The proportion of people who agree that they are addicted to smoking is lower in younger 
smokers (Arnett, 2000; Weinstein et al., 2004), in those who don’t smoke daily (Edwards, 
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Bondy, Kowgier, McDonald, & Cohen, 2010) and in Latino smokers in American studies 
(Zinser et al., 2011).  
 
Despite the fact that many smokers report that they are addicted to smoking the fact that 
pharmacotherapies for smoking cessation are widely available, approximately 50% of quit 
attempts are made without assistance. When pharmacotherapy is used, it is often discontinued 
early or used in lesser amounts than recommended (Balmford et al., 2011; Shiffman, Ferguson, 
Rohay, & Gitchell, 2008). A number of studies looking at smokers attitudes towards NRT have 
provided some insight into why this may be.  
 
Three main themes have emerged from this research. Firstly, many smokers do not believe that 
NRT is effective for smoking cessation (Hammond, McDonald, Fong, & Borland, 2004; 
Shiffman et al., 2008; Willems, Willemsen, Nagelhout, & de Vries, 2013). This is partly 
attributable to a belief that NRT does not help with cravings (Vogt, Hall, & Marteau, 2008). 
While some clinicians see this as a misperception that requires correction (Shiffman et al., 
2008; Vogt et al., 2008), others believe it to be a realistic assessment based on the past 
experiences of many smokers who have failed to quit using pharmacotherapy.  
 
Smith, and colleagues (2015) conducted qualitative interviews with 21 Australian ex-smokers 
who had quit without assistance about their experiences. They identified a number of reasons 
why smokers had rejected a medical approach to cessation, and chosen to quit without medical 
assistance. Participants often evaluated the efficacy of pharmacotherapy based on their 
personal experiences, rather than on information from health professionals or pharmaceutical 
companies. As previously noted, although pharmacotherapy does marginally improve one’s 
chances of quitting, it is not successful for the majority of those who use it, especially as many 
do not adhere to the recommended dosage or treatment duration. This means that smokers can 
easily draw to mind instances where pharmacotherapy for smoking cessation has not been 
successful. Also, the authors describe the way participants engaged in a cost-benefit analysis 
in relation to quitting methods. Because unassisted quitting is free, immediate, and safe, it was 
often preferred over methods that required more preparation, financial cost and had risks of 
side effects. Cultural beliefs about personal responsibility, strength, and self-control were also 
influential in decisions to quit unassisted. However, it must be noted that this study interviewed 
only those who had quit unassisted, so was likely to recruit those with negative views or 
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experiences of assisted quitting. Those who had successfully quit with assistance were 
excluded from the study.  
 
Second, many smokers express concerns about the health risks of pharmacotherapy for 
smoking cessation. A number of studies have found that smokers mistakenly believe that 
nicotine is harmful to the body and causes cancer (Bansal, Cummings, Hyland, & Giovino, 
2004; Cummings et al., 2004; Mooney, Leventhal, & Hatsukami, 2006; Shiffman et al., 2008). 
This is likely to have occurred because of the close association between nicotine, cigarettes 
and the health harms of smoking (Shiffman et al., 2008). It may be difficult for people to 
reconcile the idea that the harmful effects of nicotine addiction in the form of cigarette smoking 
are much reduced when they obtain their nicotine in the form of NRT (Keane, 2013; Smith et 
al., 2015). Concerns about health risks are even more pronounced in relation to prescription 
pharmacotherapies for smoking cessation. Vogt, Hall and Marteau (2008) found that many 
participants believed that NRT had mild side effects while bupropion had serious and life-
threatening side effects. The stringent requirements for labelling of side effects of 
pharmacotherapies have been suggested as one reason for concern about the health risks of 
pharmacotherapies (Shiffman et al., 2008). Unfortunately, there is little research on smokers’ 
attitudes towards varenicline, where potential health harms (e.g., increased suicide risk and 
suicidal ideation, depression and aggression) have been prominently reported in the media. 
While recent phamacoepidemiological evidence suggests that varenicline is safe (Kotz et al., 
2015), the FDA in the US have maintained a “black box” warning on medication packaging 
alerting consumers to potential neuropsychiatric side effects. No such warning is required in 
Australia. Interestingly, though prescription medication for smoking cessation has relatively 
low use in Australia, a sample of recent quitters from Australia found that those who had used 
it rated it as having high helpfulness (Hung et al., 2011).  
 
Efficacy and safety are not the only reasons why smokers do not use cessation medications. A 
number of qualitative studies report that willpower and personal responsibility are key terms 
in smokers’ discourses about their smoking and cessation (Katainen, 2006; Kayser & Semenic, 
2013; Smith et al., 2015; Vogt et al., 2008). The use of NRT may be discordant with smokers’ 
conceptualisations of quitting that centre on the key role of internal strength and willpower. In 
addition, some smokers reject the idea that they have a physiological dependence on nicotine 
(Vogt et al., 2008), while others believe that this is only a part of their addiction (Wiltshire et 
al, 2003). Other aspects of smoking that are central in smokers’ accounts of their smoking are 
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the pleasure that they experience from smoking, the use of smoking as a tool for emotional 
regulation (e.g., to deal with stress or boredom), and the embeddedness of smoking in their 
everyday life and social relationships (Amos, Wiltshire, Haw, & McNeill, 2006; Bancroft, 
Wiltshire, Parry, & Amos, 2003; Laurier, McKie, & Goodwin, 2000; Parry, Thomson, & 
Fowkes, 2001; Thompson, Thompson, Thompson, Fredickson, & Bishop, 2003). Smoking is 
often described by smokers as having a powerful behavioural or psychological aspect that 
cessation medications do not address (Uppal, Shahab, Britton, & Ratschen, 2013; Vogt et al., 
2008; Wiltshire et al., 2003). The key common finding in these studies is that smokers believe 
that the physiological aspect of their addiction only partly explains why they continue to 
smoke.  
 
A small number of studies have examined smokers’ attitudes towards a biomedical model of 
smoking. A very early study by Eiser and Van Der Pligt (1986), presented participants with 20 
items about their perceptions of smoking. Based on the results the authors suggested that there 
were two key ways that smokers understood their smoking. The first was as a “sickness”. The 
participants who scored highly on this factor were more concerned about the health 
consequences of smoking and more likely to seek treatment from health professionals. The 
second factor was being “hooked”. These smokers had low quitting self-efficacy and resented 
efforts by others to convince them to quit. Eiser and Van Der Pligt (1986) hypothesised that 
these beliefs could influence behaviour change and suggested that health professionals could 
tailor their message to the beliefs that their patients held.  
 
A more recent study with British smokers identified four “smoking identities” (Farrimond, 
Joffe, & Stenner, 2010). The authors related the first two identities, “addicted smoker” and “in 
control smoker” to the biomedical model of smoking. Like Eiser and Van Der Pligt (1986) 
these authors found that “addicted smokers” were concerned about the health risks of smoking, 
agreed that smoking was a medical problem, and felt they had low levels of control over their 
smoking. Smoking was perceived as a negative behaviour that was nonetheless functional, in 
that it helped them to deal with emotions such as stress and boredom. The “in control” smokers 
also believed that smoking was addictive and detrimentally impacted health, but were more 
likely to describe smoking as a “habit” or as a social tool, and believed that they were in control 
of their smoking. Another smoking identity was labelled the “no big deal” smoker. These 
smokers were more likely to question the health harms and the addictiveness of smoking. 
Smoking was seen as a luxury, a means of escape and as a way to deal with boredom. Smoking 
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was not a central aspect of identity but a behaviour that could be controlled. Lastly, they 
described the “proud” smoker, who did not hold strong views about the health or addictive 
aspects of smoking, and endorsed positive aspects of a smoking identity, such as “smoking is 
sexy” and “rebellious.” Smoking was seen as a choice and as a “right.” Those who fell into this 
category were more likely to say they enjoyed smoking. The authors suggest that different 
smoking interventions may be more suitable for different types of smoker identities (Farrimond 
et al., 2010).  
 
Another study that interviewed ex-smokers who had quit unassisted, found that one of the 
common reasons for rejecting pharmacotherapy and medical treatment was that they did not 
see smoking as a medical issue (Smith et al., 2015). Instead they described smoking as a matter 
of willpower and gave primacy to individual responsibility and autonomy. 
 
Lastly, a study by Hughes (2009) looked at current smokers’ preparedness to endorse 
biomedical explanations of smoking. The participants were asked why they thought people 
continued to smoke. The results showed very high levels of agreement with the ideas that an 
inability to stop smoking was caused by addiction (88%) and was due to habit (also 88%). 
Interestingly, despite high agreement that smoking was addictive, there was low agreement 
that inability to quit smoking was caused by biological factors (21%), or that smoking was a 
“disease” (10%). Hughes concludes that:  
“In terms of significance, although scientists may argue that certain concepts are anti-
thetical (e.g., addiction vs. habit), many, if not most, smokers appear to not see 
contradictions in simultaneously endorsing what appear to be very different causes: i.e., 
addiction, habit, willpower and motivation, as causes of the inability to stop smoking. 
Thus, one implication of our results is that scientists cannot assume that smokers have 
the same network of concepts or the same denotative or connotative meanings of terms 
that scientists do”. (Hughes, 2009, p. 1008).  
Hughes recommended conducting more qualitative research to explore the meanings that 
smokers attach to terms such a “habit” and “addiction.”  
 
Together, these findings show that for many smokers addiction is a very broad concept that 
encompasses more than a physiological dependence on nicotine. Smokers do not necessarily 
equate addiction to smoking with addiction to nicotine, or believe that the addiction is 
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biologically-based. When reflecting on their smoking, they give prominence to factors such as 
personal choice, the social aspects of smoking, pleasure, and the roles that cigarettes play in 
their everyday lives.  
 Lay beliefs about the brain and behaviour  
As described in the previous chapter, there is an increasing emphasis on the role of the brain in 
the development and maintenance of all forms of addiction. Some have claimed that addiction 
is a brain disease, and that describing it in this way will lead to widespread changes in the way 
that the public, and addicted individuals themselves, perceive addiction. More specifically, it 
is hypothesised that it will lead addicted individuals to see their addiction as a medical problem 
requiring medical treatment.  An increasing number of studies have investigated stakeholder 
knowledge and attitudes towards neurobiological technologies and their implications for 
various facets of human existence, including adolescence (Choudhury, McKinney, & Merten, 
2012), mental illness (Borgelt, Buchman, & Illes, 2011; Bröer & Heerings, 2012; Pescosolido 
et al., 2010) and addiction (Meurk, Carter, et al., 2013; Meurk et al., 2016; Netherland, 2011). 
Neuroscience findings are increasingly being reported in mainstream media (O'Connor, Rees, 
& Joffe, 2012). Public interest has often focused on brain imaging studies using functional 
magnetic resonance imaging (fMRI) and positron emission tomography (PET) (Racine, Bar-
Ilan, & Illes, 2006; Racine, Waldman, Rosenberg, & Illes, 2010). While in-depth 
anthropological studies have outlined the complex decisions and judgements involved in 
producing these images (Dumit, 2003; Joyce, 2005), they are often mistakenly portrayed in the 
media as objective “snapshots” of an individual’s brain function (Beck, 2010; Fine, 2010). 
They have been used to demonstrate the “realness of a disorder” (Racine, Bar-Ilan, & Illes, 
2005) and to compare the characteristics of “normal” and “disordered” brains (see Figure 3-1).  
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Figure 3-1 Image comparing non-drug user and cocaine user brain scans.  
From NIDA webpage Cocaine: Abuse and Addiction 
(http://www.drugabuse.gov/publications/research-reports/cocaine-abuse-addiction/what-
are-long-term-effects-cocaine-use). 
 
Although neuroimaging does not currently have the power to diagnose individuals with an 
addiction or a psychiatric disease, there is hope that it will one day provide reliable biomarkers 
to diagnose individuals or to identify those at greatest risk of becoming addicted (Agarwal, 
Port, Bazzocchi, & Renshaw, 2010). To explore patient knowledge and attitudes towards 
neuroimaging, Buchman, Whiteley and Iles (2013) conducted interviews with those diagnosed 
with major depressive disorder or bipolar disorder. Participants typically believed that 
neuroimaging would reduce the stigma of their mental illness and make it more “real” in the 
eyes of others. Explanations of mental illness involving a “chemical imbalance” in the brain 
were central to many of these participants, who were optimistic that their illness might be better 
treated if their brain scans could show this in an objective way (Buchman et al., 2013). 
Ethnographic research has similarly shown that those with mental illnesses often see brain 
scans as legitimizing their disorder, by providing evidence that it has a physical basis (Cohn, 
2010; Dumit, 2003). Simon Cohn (2010), who conducted such research at scanning sites, 
describes informants who carried their brain scans in their handbag, presented their brain scans 
to their family or friends, or framed them and put them on display.  
 
The “persuasive power” of brain images has been demonstrated experimentally. McCabe and 
Castel (2008) provided a sample of undergraduate students with a number of invented news 
articles about cognitive neuroscience findings in which the conclusions in the articles were 
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inconsistent with the data. Each article was accompanied by a brain image, a bar graph, or no 
image. Participants were asked to provide ratings of the validity of the scientific reasoning in 
each article. Ratings were highest when the article was accompanied by a brain image. A more 
recent study however, did not support this conclusion, finding no significant difference in 
participants’ judgments of articles accompanied by no image, a brain image or alternative 
images (e.g., an artistic representation of a head) (Gruber & Dickerson, 2012). A related 
experiment showed that satisfaction with an explanation increased when adding textual 
neuroscientific information to explanations of psychological phenomena, even when the 
neuroscientific information was irrelevant. This was true even when the original explanation 
was a circular restatement of the original report and thus did not add any explanatory 
improvement (Weisberg, Keil, Goodstein, Rawson, & Gray, 2007). These results indicate the 
potential for neurobiological information to influence reasoning about human behaviour, but 
the conflicting findings indicate that more research is required on how it may do so (Baker, 
Ware, Schweitzer, & Risko, 2015). 
 
Other studies have revealed more ambivalence among the public about neuroscientific 
explanations of human behaviour. Choudhary, McKinney and Merten (2012) conducted focus 
group and surveys with young people about the “neurological adolescent”, the idea that the 
brains of teenagers are different from those of adults in ways that can account for adolescents’ 
greater risk taking and reduced attention to the consequences of their behaviour. While some 
young people thought that neuroscience might help adults to better understand their behaviour, 
they were also concerned that it would reinforce negative stereotypes. It was common for these 
young people to widen the explanatory frame by providing alternative explanations that did 
not rely on brain science. The authors conclude that: 
“…neuro-identity formations are more fractured, resisted and incomplete than some of 
the current social science literature on neuro-subjectivities seem to suggest and that the 
effects of public policy and popular education initiatives in this domain will be more 
uneven and complex than currently imagined.”(Choudhury et al., 2012, p. 565) 
This finding is supported by other research demonstrating that persons with ADHD combine 
explanatory frameworks in understanding their disorder. Neurobiological explanations of 
ADHD are common but do not dominate; psychological and social explanations remain central 
(Bröer & Heerings, 2012).  
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Pickersgill, Cunningham-Burley and Martin (2011) interviewed various stakeholder groups 
about their ideas regarding neuroscience. These included: patients with a brain-based disorder 
such as epilepsy or dementia; professionals expected to come into contact with neuroscience 
ideas in their work; and neuroscientists themselves. They found that many of those affected by 
a brain-based disorder expressed interest in neuroscience and in understanding how their brain 
worked. However, they often resisted accounts that ascribed dominance to their brain in their 
identity or actions. Pickersgill and colleagues conclude that the brain is “an object of mundane 
significance”, and that is only one factor in the complex process of identity formation 
(Pickersgill et al., 2011, p. 361). 
 
Pickersgill (2009) has found that even amongst scientists involved in neurobiological research, 
their ideas about the aetiology of mental disorders are complex, often acknowledging the 
importance of social factors such as family upbringing, socioeconomic status and the social 
environment. He conjectures that:  
“Long-standing critiques of biological reductionism are rendered problematic by the 
complex linkages scientists make between psyche, soma and society” (Pickersgill, 
2009, p. 58).  
 
A systematic review by O’Connor & Joffe (2013) investigated the impact of neuroscience on 
various aspects of personhood. They identified three primary claims made about the impact of 
brain-based understandings of human behaviour: (1) that biology will become central to 
individual identities; (2) that people will become more fatalistic about their behaviour; and (3) 
that there will be a reduction in stigma associated with certain groups and behaviours.  They 
conclude that empirical evidence to date does not support any of these claims. Rather, they 
suggest that people incorporate beliefs about neuroscience into pre-existing worldviews in 
creative and often unpredictable ways.  Cliodhna O’Connor (2013) also conducted interviews 
with members of the public about their ideas about neuroscience. She found that neuroscience 
was not considered to have much relevance in most participants’ lives. When they did 
deliberate on brain research, those interviewed often described the brain as “a tool over which 
individuals could exert control, and as a source of human variation invoked to articulate and 
explain social differences” (O'Connor, 2013, p. 249). 
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 The place of neurobiology in public understandings of addiction 
Most research conducted thus far on lay understandings of the brain has focused on mental 
illness. There is little comparable research on how addicted individuals make sense of addiction 
in light of brain-based models, although such research has been recommended (Caron et al., 
2005; Fry & Buchman, 2012; Weinberg, 2013). One recent study has explored the potential of 
brain-based explanations to influence the ways in which addicted individuals understand their 
drug use. In interviews conducted with 37 opiate addicted participants treated with 
buprenorphine (a synthetic opiate used for replacement therapy of opioid addiction), most 
participants did not express a scientific account of the effect of drugs on their brain, despite 
their heavy exposure to a medical model of addiction via their opiate substitution treatment 
regime (Netherland, 2011). Rather, they discussed ideas such as pleasure, normality and 
rationality/irrationality, and provided explanations of their addiction that focused on external 
factors that influenced their drug use and lifestyle (Netherland, 2011).  
Another study examined how US addiction counsellors attributed responsibility for the 
development of addiction and recovery in light of their exposure to addiction neuroscience 
(Steenbergh, Runyan, Daugherty, & Winger, 2012). The study found that addiction counsellors 
were more likely to agree that biological factors caused addiction than social factors, spiritual 
factors and individual choices. They also found that exposure to neuroscience was associated 
with lower ratings of personal responsibility for developing addiction, but this was not true for 
personal responsibility for resolving addiction. This may be due to the personal experiences of 
counsellors who assist addicted individuals to make the choice to reduce or cease drug use, and 
for whom it is necessary to believe that their profession can influence addicted persons to 
become abstinent. The authors conclude that “A view of addictions that balances biological 
factors with personal agency, like the one espoused by our sample of counsellors, seems 
necessary for successful intervention.” (Steenbergh et al., 2012, p. 427). Other research with 
addiction professionals, including clinicians and researchers in Australia, has similarly found 
that the professionals did not uncritically support the brain disease model of addiction. They 
were also cognisant of the potential adverse impacts of the model such as an increase in stigma 
and a reduction in quitting self-efficacy (Barnett & Fry, 2015; Bell et al., 2013). 
 Smoking and the brain: Public portrayals  
As described above, brain-based explanations of smoking are increasingly being presented in 
the popular media. Media reporting on neuroscience has been criticised for portraying brain 
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scans as a direct representation of reality, and for speculating on unlikely or infeasible policy 
implications of neuroscience research (O'Connor et al., 2012; Racine et al., 2010). In Australia, 
the mainstream media have reported on neuroscience findings about smoking. Some excerpts 
are provided in Figure 3-2.  
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 Figure 3-2. Examples of media reporting on the neuroscience of smoking in Australia.  
 
Smokers’ addiction all in the brain (Courier-Mail, 23 March 2002, Ronald Kotulak) 
Working to unravel a long-standing puzzle of cigarette addiction, University of Chicago 
researchers have discovered why smoking is uniquely pleasurable and why nicotine has such 
ferociously addictive powers. Published in the scientific journal Neuron, the research shows 
nicotine stimulates pleasure in the brain's reward centre and also has the unique ability to "turn 
off" the "switch" that subdues good feelings. 
 
The new evidence helps explain how one cigarette quickly teaches the brain cells of a first-time 
smoker to crave nicotine. And for the thousands who try to quit smoking each year and fail, the 
findings show why breaking the habit is so hard. Drug companies' efforts to develop anti-
addiction medicines have been hampered because they didn't know how the brain became 
addicted, says John Dani, a Baylor College of Medicine neuroscientist and one of the first to 
show nicotine's effect on dopamine. "McGehee's work will allow both academic and 
pharmaceutical researchers to focus on the mechanisms of addiction with a greater 
understanding of how they work." 
 
Science pinpoints smoking addiction (The Advertiser, 27 January 2007, Radowitz & Kleinig) 
Smokers have been warned not to rely on medical research to deliver them from addiction after 
U.S. scientists pinpointed the brain part responsive to the drug. Quit SA manager David 
Edwards said the discovery, by U.S. scientists, could help to develop a quit-smoking drug. "But 
the reality for smokers in the medium to short-term is still dealing with the challenge of breaking 
the link between nicotine and their bodies and brains," he said yesterday. "Getting advice and 
coaching from places like Quit and nicotine therapies are still the best combination." 
 
The journal Science yesterday reported the discovery of a 2.5cm wide pleasure centre deep 
within the brain. The insula, in the cerebral cortex, has been described as a "platform for feelings 
and emotion". Researchers found smokers who suffered damage to this part of the brain were 
able to quit easily. They suspect the insula may also be involved in other forms of addictive 
behaviour that keep people hooked on drugs or excessive eating. Understanding the link could 
lead to new strategies and treatments for addiction. 
 
Quitting is a brain game (The Gold Coast Bulletin, 19 March 2011, Author unattributed) 
Researchers are finding evidence that parts of the brain are involved in gaining control over 
smoking and nicotine addiction, and that different areas may be important for each individual. 
Two recent reports look at the neural systems from various angles. One study found that people 
who had a stronger brain response in certain brain regions when getting tailored smoking-
cessation messages were more likely to quit four months later. 
The second study also used brain imaging to watch three specific brain regions known to affect 
inhibition of unwanted or habitual behaviour. The brain scans showed how well each person 
activated their “response inhibition'' regions. “The more you activate those three brain regions 
when you are engaging successfully in stopping, the more likely you are to successfully deal 
with your cravings in real life,'' said Elliott Berkman, a researcher and co-author of the study. 
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These examples attribute addiction to smoking to brain mechanisms that have been altered by 
nicotine consumption. They then link these brain changes to difficulty quitting and individual 
differences in quit success. The example from The Advertiser (27/1/2007) is of particular 
interest, as the Cancer Council spokesperson counsels smokers to quit using traditional means 
rather than waiting for brain-based therapies to become available, anticipating that unrealistic 
expectations may be raised by media reporting on neuroscience.  
It is not only the media who disseminate brain-based explanations of smoking. A number of 
scientific journals have published papers suggesting that clinicians inform smokers of the 
neurobiological basis of nicotine addiction to increase their use of medications for smoking 
cessation. For example, Leone and Evers-Casey recommend turning the personal and 
“visceral” experience of addiction into a “tangible story that can be discussed and 
deconstructed” (Leone & Evers-Casey, 2012, p. 56). They specifically suggest that “a short 
conversation about the biological basis of motivation helps to minimize the exaggerated sense 
of self-blame and responsibility that smokers often feel, validates the patient’s position, and 
provides a viable framework for working through inevitable obstacles during the quit process.” 
(Leone & Evers-Casey, 2012, p. 56).  
 
Raupach et al (2010) describe an intervention in which smokers enrolled in a cessation program 
were presented with information about the neural mechanisms of addiction using the metaphor 
of a pizza delivery service. Those exposed to this physician-run education session were more 
likely to use NRT than those who did not receive the education session. Unfortunately, the 
study was not sufficiently powered to detect a difference in cessation rates. Also, as the authors 
note, it was possible that physician presence in the “neural education” group, rather than the 
information itself, was responsible for the difference in NRT use. Lastly, Finnell (2000) has 
recommended that addicted individuals be provided with information on the neurobiological 
basis of addiction in order to “empower patients, ease their defences, and reduce the stigma 
they experience” (Finnell, 2000, p. 157). Only anecdotal evidence was presented that doing so 
would produce these positive outcomes.  
 
Despite a lack of empirical evidence on how smokers incorporate neuroscience information 
into their understandings of addiction, Australian health promotion materials have begun to 
include information about the brain’s role in smoking. For example, a project aimed at 
Indigenous Australians called “Brain Stories” has been developed by Menzies School of Health 
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Research. The resources developed as part of the Brain Stories project emphasise the role of 
the brain in addiction to smoking, with the aim of overcoming the stigma of addiction and 
“empowering people with knowledge” (see Figure 3-3) 
 
Figure 3-3. Image from the “Tobacco Stories” resource by Menzies School of Health 
From: http://www.menzies.edu.au/page/Resources/The_Tobacco_Story/  
 
Pharmaceutical companies are also using brain-related imagery and information to promote 
their smoking cessation products. On Pfizer’s “Nail Quitting” website visitors are first 
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presented with the text: “Some things are too hard to do on your own.” The website contains 
an animated video of a brain smoking a cigarette (See Figure 3-4) accompanied by the words:  
 
“Cigarettes contain nicotine. When you smoke, the nicotine releases chemicals in the 
brain, producing feelings of pleasure. If the levels of these chemicals drop, you start to 
crave yet another cigarette. It’s called nicotine addiction. That’s why it’s so hard to quit 
smoking, even when the enjoyment is gone. Quitting isn’t easy. Your doctor has a range 
of quitting options, with and without nicotine.” (http://www.nailquitting.com.au/quit-
now/) 
 
Figure 3-4. Image of a smoking brain from Pfizer’s “Nail Quitting” website  
 
How might such public portrayals influence lay understandings of smoking? A number of 
theories articulate potential links between media representations and lay understandings of 
illness. For example, social representations theory states that representations are images or 
understandings that allow classification of people or phenomena (Jodelet, 1991). Various 
competing representations exist in relation to a particular phenomenon such as addiction, and 
people can confirm such representations, reject them or re-articulate them based on existing 
representations (Howarth, 2006). Smoking as a brain disease could be conceptualised as a 
novel social representation that becomes “anchored” to existing understandings of addiction. 
Anchor points are typically “core meanings” that underpin societies’ “overarching systems of 
ideologies, beliefs, maxims and categories.” (O’Connor, 2013).  
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In a less constructivist vein, many health behaviour theories conceptualise the way that people 
respond to health promotion messages that aim to change behaviour. For example, the health 
belief model proposes that people make health-related decisions by balancing ideas about the 
severity of the illness, their susceptibility, the effectiveness of taking action, and the social 
consequences of taking (and not taking) action. Media or health promotion messages may 
influence perceptions of severity or reduce perceptions of the cost of action in order to prompt 
a desired health behaviour (Becker, 1974).  While such theories differ in terms of terminology 
and epistemology, they concur that new information about health and illness is not passively 
accepted, but is incorporated in complex ways into existing understandings, which are 
themselves drawn from a combination of cultural representations and everyday experiences.  
 The place of neurobiology in lay conceptions of smoking 
There is currently insufficient evidence to evaluate the impact of neurobiological explanations 
of addiction on smoking cessation. Only one study identified in this literature review directly 
examined smokers’ ideas about the role of the brain in their smoking. This study described the 
experiences of people living with alcohol or nicotine dependence, with particular emphasis on 
how neurobiological and genetic explanations of addiction fitted into their personal narratives 
(Hammer, Dingel, Ostergren, Nowakowski, & Koenig, 2012). They found that over half of 
their 63 participants provided an explanation of addiction that included a biological component. 
Importantly, they noted that those recruited from treatment centres that emphasised the 
biological basis of addiction in patient education material were more likely to explain addiction 
in terms of the brain or genetics (Hammer et al., 2012). Given that most smokers do not seek 
formal assistance for quitting, this sample is unlikely to be representative of the general 
population of smokers.  
Results from studies that provide smokers with information about the genetic basis of their 
nicotine dependence have found no clear evidence that this leads to either a significant increase 
in quit rates or an increase in fatalism, although it is conceivable that such information may 
reduce the perceived efficacy of quitting using willpower alone (Cappella, Lerman, Romantan, 
& Baruh, 2005; Wright et al., 2007; Wright, Weinman, & Marteau, 2003). More recently, a 
number of studies have explored the impact of providing “personalised” pharmacotherapy for 
smoking cessation based on genetic test results.  Results suggest that such treatment does not 
result in fatalism or a reduction in sense of control over smoking (Marteau et al., 2012; McClure 
et al., 2013).  
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There are important differences between genetic and neuroscience explanations of addiction 
(Green 2006) and this thesis will examine whether providing neurobiological information 
about nicotine addiction has similar effects on smokers’ perceptions of control over their 
smoking given. The research conducted thus far on how individuals respond to neurobiological 
explanations of behaviour has mostly been based on clinical populations. It is important that 
research also elicits the views of non-treatment seeking individuals, who may differ from 
treatment seekers in many important ways. The current research will address this gap in the 
literature by recruiting a community-based sample of smokers to explore their knowledge and 
understandings of smoking in light of brain-based explanations of addiction. It will address 
questions such as: Do smokers view their nicotine addiction as a “chemical imbalance” or a 
“brain disease”? In what ways do they incorporate neurobiological understandings into their 
everyday explanations for their smoking? And what implications might these brain-based 
understandings of smoking have for a smokers’ sense of quitting self-efficacy, and treatment 
preferences? 
 
 Original contribution of literature review chapters 
 
This chapter, and Chapter 2, have outlined the literature relevant to understanding how smokers 
conceptualise the role of nicotine in their smoking, and the extent to which they accept 
biomedical treatments and explanations of their smoking behaviours.  
 
Chapter 2 focused on the literature around biomedicalisation and applied this to cigarette 
smoking. Critics of medicalisation are concerned about the portrayal of smoking as a chronic 
disease that requires medical treatment. They believe that this approach will negate free will 
and neglect alternative non-medical approaches to quitting. The brain disease model of 
addiction is an example of a strong biomedical approach which has been widely critiqued. I 
argued in Chapter 2 that these concerns are likely to be overstated as there are a number of 
factors that limit the extent of the medicalisation of smoking cessation. These include the 
historical emphasis in tobacco control on population based measures (and their success in 
reducing smoking prevalence); the clear social inequalities that influence smoking rates in 
different groups; the ambiguous place of nicotine amongst other drugs; and a resistance among 
healthcare practitioners to adopting a medical approach to smoking cessation. Moreover, many 
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of the claims about the negative impacts of biomedical models of addiction have not been 
empirically investigated. The aim of this thesis was to contribute to the emerging literature on 
lay understandings of addiction neuroscience by investigating how addicted individuals 
understand the role of the brain and biology in their addiction. Further, this issue has not been 
explored in relation to nicotine addiction and smoking, and one aim of this study was to address 
this neglect.  
 
To inform the methodological approach of this study, the literature on lay understandings of 
health and illness, and the related field of PUS, were explored in Chapter 3. This chapter 
outlined the importance and impact of everyday understandings of health and illness. There 
was a focus on studies that investigated the meanings that patients ascribe to their health issues, 
their treatment, and their interactions with health care practitioners. Interrogating the existing 
literature on lay understandings of smoking, it became clear that medical understandings did 
not dominate. While most smokers acknowledged that they were addicted, the meaning of 
addiction varied widely, and was not synonymous with nicotine dependence. Across numerous 
studies, the themes of willpower, personal choice and motivation were present. However, this 
chapter also outlined recent examples where the role of the brain and biology was brought to 
the fore in media and health promotion materials that are being presented to smokers. It was 
therefore important to investigate the impact that these materials may have, without assuming 
in advance that they will be incorporated into lay understandings in predictable ways. Because 
there is very little empirical research that has detailed smokers’ understandings of nicotine, or 
their acceptance of neurobiological explanations of nicotine addiction, an exploratory approach 
was employed that is outlined in the following chapter.  
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Chapter 4. Method 
 
As outlined in Chapters 2 and 3, little research exists about the extent to which smokers are 
prepared to endorse biomedical models of smoking, or the implications that accepting these 
beliefs has for quitting attitudes and treatment preferences. The research presented in this thesis 
aims to explore the extent to which biomedical understandings of nicotine addiction have 
infiltrated lay discourse on smoking. The research questions I aimed to answer were:   
1) To what extent do smokers and non-smokers accept biomedical understandings of 
smoking and smoking cessation? 
2) How do smokers understand the role of the neurobiology in tobacco dependence? 
3) What proportion of Australian smokers are prepared to endorse the BDMA, and how 
does this affect their self-efficacy or treatment choices? 
 
A mixed methods research design was used to examine the extent to which Australians endorse 
a biomedical model of tobacco dependence. This chapter will provide a brief outline of mixed 
methods research and provide my justification for choosing one particular form of mixed 
methods research: the exploratory sequential design (Creswell & Plano Clarke, 2011). Because 
further details about the methods are described within papers embedded in the following 
chapters, this methods section will provide a more detailed description of the method that was 
not possible in published papers because of space constraints. There is a particular focus in this 
chapter on the use of mixed methods, thematic analysis, and the use of online panels for 
conducting quantitative surveys.  
 
 Mixed methods research: Introduction and justification 
Mixed methods research involves the use of both qualitative and quantitative methods of data 
collection to study a research question, as well as the integration of the qualitative and 
quantitative results. The rationale for using a mixed methods approach is that the combination 
of qualitative and quantitative methods can to some extent overcome the limitations of each 
individual method, producing richer and more rigorous understandings of the topic being 
studied.  
“Its central premise is that the use of quantitative and qualitative approaches, in 
combination, provides a better understanding of research problems than either approach 
alone.” (Creswell & Plano Clarke, 2011, p. 5)  
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Because quantitative data typically uses large samples that are systematically selected, we can 
be reasonably confident that the results from the sample can be generalised at a population 
level. However, because of the large sample sizes and the use of standardised questions in 
survey collection instruments, quantitative data often does not capture the detailed voices and 
stories of individual participants, or illuminate the assumptions and motivations behind their 
answers. Qualitative research, by contrast, allows the voices of individual participants to be 
heard, but the findings most often cannot be generalised to a population because of small 
sample sizes and the contextual embeddedness of narratives. Combining quantitative data with 
personal narratives allows a research question to be viewed from “multiple standpoints” 
(Greene, 2007, p. 20).  
 
The combination of various methods to study one research question has often been referred to 
as “triangulation.” Triangulation has been defined as “the combination of methodologies in the 
study of the same phenomenon” (Denzin, 1978, p.291). There has been some debate in the 
mixed methods literature about the use of the word triangulation, as it is seen by some as a 
catch-all word that has been “overused to the point where it means nothing” (Teddlie & 
Tashakorri, 2009, p.32). While earlier work on triangulation focused on justifications for the 
use of multiple methods, more recent work emphasises the practical aspects of how to combine 
different methods in meaningful ways. A common misperception of triangulation is that its 
purpose is to validate the findings of one method by searching for similar findings using a 
different method. Patton takes issue with this view, stating instead that finding inconsistencies 
across methods “ought not be viewed as weakening the credibility of results, but rather as 
offering opportunities for deeper insight into the relationship between inquiry approach and the 
phenomenon under study” (Patton, 2002, p.248).  
 
Greene, Caracelli and Graham (1989) have outlined more specific purposes for conducting 
mixed methods research, with triangulation being just one of them (see Table 4.1). The 
purposes most relevant to this project are “development” and “complementarity”. 
Complementarity refers to the enhancement of one set of results by reference to results from 
another method that overcomes some of the limitations of the other. Development means that 
one method is used to inform the construction of measures in another method. A key outcome 
from this project is the development of a survey to assess smokers’ endorsement of biological 
explanations of smoking. As outlined in Chapters 2 and 3, my review of the literature 
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demonstrated that very little research existed to inform the development of such a survey. 
Qualitative research was therefore required to explore how smokers understand addiction to 
cigarettes, and the language that they use to describe the role of biology and brain in their 
smoking.  
 
Table 4.1 - The purposes of mixed methods research 
Purpose Rationale 
Triangulation To increase the validity of constructs and inquiry results by counteracting 
or maximising the heterogeneity of irrelevant sources of variance 
attributable to method bias. 
Complementarity To increase the interpretability, meaningfulness, and validity of constructs 
and inquiry results by both capitalizing on inherent method strengths and 
counteracting inherent biases in other methods and other sources 
Development To increase the validity of constructs and inquiry results by capitalizing on 
inherent method strengths. 
Initiation To increase the breadth and depth of inquiry results and interpretations by 
analyzing them from the different perspectives of different methods and 
paradigms. 
Expansion To increase the scope of inquiry by selecting the methods most appropriate 
for multiple inquiry components.  
Adapted from Greene, Caracelli & Graham (1989) 
 
 Methodological orientation 
Whether acknowledged or not, all researchers have a methodological orientation that includes 
assumptions about what can be studied, and how it should be studied. Quantitative research 
typically aligns with a positivist paradigm, where there is belief in an external reality that can 
be “discovered” through the use of rigorous experimentation. Qualitative research often takes 
a more constructivist approach, believing that reality is created by individuals, including 
researchers. Most researchers position themselves somewhere between these two extremes. 
While some believe that these two research paradigms are incompatible and should not be 
combined, it is increasingly common to take a pragmatic approach that accommodates both 
methodologies within a single research project.  
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Tashakkori and Teddlie define pragmatism as a “deconstructive paradigm that debunks 
concepts such as ‘truth’ and ‘reality’ and focuses instead on ‘what works’ as the truth regarding 
the research questions under investigation.” (Tashakkori & Teddlie, 2003, p. 713). The shift 
towards a pragmatic approach has been particularly marked in the field of public health, due to 
an emphasis on applied research and the desire for practical outcomes, a desire to apprehend 
the multi-causality of health and illness, and acknowledgement of the need to incorporate 
patient perspectives in healthcare (Baum, 1995; Forthofer, 2003). Fran Baum has written that 
researchers in public health are “faced with a smorgasbord of methods from which they can 
select those methods likely to produce the most comprehensive and valid answers” (Baum, 
1995, p. 463). A pragmatic approach moves towards understanding and improving, rather than 
just describing, the health needs of communities (Baum, 1995). For a fuller explanation of the 
pragmatic perspective on questions of epistemology and ontology, interested readers can refer 
to Morgan (2007). For this project, I have adopted a pragmatic approach in my exploration of 
smokers’ understandings of the biomedical model of tobacco dependence. My rationale for the 
study design chosen is provided below.  
 
 Overview of study design 
Methodologists have outlined various mixed methods research designs. They vary in the 
emphasis placed on: 1) whether the researcher prioritises the qualitative or quantitative stage 
of the project; 2) the order in which the research is conducted (concurrent, sequential or more 
complex designs); and 3) how the two methods interact (Creswell & Plano Clarke, 2011).   
 
The exploratory sequential design was selected for this research project. This method involves 
exploratory qualitative research as the first stage. The results from this qualitative research 
guide the development of a quantitative stage of study, typically informing the construction of 
a survey. This method is suitable for research questions that are relatively unexplored and 
where quantitative measures do not currently exist. Creswell and Plano Clarke (2011) outline 
the conditions under which this method is appropriate:  
 There is not an existing quantitative instrument that measures the variables of 
interest. 
 There is little existing research to guide the variables you select to measure. 
 There is no clear theory or framework by which to guide the development of a 
survey.  
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This was certainly the case for the research questions examined in this thesis, where there was 
very little quantitative or qualitative research, and the interdisciplinary nature of the topic 
meant there was no single theory that could be used to guide the development of a survey.  
 
A summary of the study design for this project is shown in Figure 4-1. This research project 
began with an analysis of pre-existing data from 55 face-to-face interviews conducted with 
members of the Australian public, including smokers and non-smokers. I analysed interview 
data relating to their views on the best treatment method for smoking cessation. Study 2 
involved 29 face-to-face interviews with Australian smokers about their views on various 
strategies for quitting smoking, and their beliefs about the role of the brain in their smoking. 
The last phase of the project (Study 3) was the development of a survey examining treatment 
behaviours and beliefs around smoking and their relationship to neurobiological beliefs about 
smoking. This survey was completed online by 1,538 Australians who smoked daily. Each 
phase of the project will be described in more detail in the following section. 
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Figure 4-1. Research design 
 
 Study 1: Public attitudes towards smoking cessation treatments 
 
Rationale 
The first stage of the research reported in this thesis involved an analysis of a subset of 
previously collected qualitative data. This data was collected via 55 semi-structured interviews 
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with members of the Australian public on their understandings of addiction to heroin, alcohol 
and nicotine, and their beliefs about the role of the brain in addiction. The primary analysis of 
this data is reported elsewhere (Meurk, Hall, Morphett, Carter, & Lucke, 2013). Based on 
debates about the medicalisation of smoking as outlined in Chapter 1, I explored the extent to 
which members of the Australian public perceive medical treatment as suitable and effective 
for smoking cessation. The aim was to assess the claim that as smoking cessation becomes 
more medicalised, there will be a reduced emphasis on quitting unassisted, and 
pharmacotherapy will come to be seen as the best, if not the only, way to quit.  
 
Design and recruitment 
The analysis was conducted on pre-existing data that had been collected in 2011. Face-to-face, 
semi-structured interviews were conducted with 55 members of the public from the Greater 
Brisbane area. A market research company was contracted to recruit participants, carry out the 
interviews, and provide verbatim transcripts of the interviews.  
The market research company recruited the participants from their existing nationally 
representative database of Australian households. Households from the Greater Brisbane area 
were randomly selected from this database and contacted by phone. One participant from each 
household was asked to participate. In order to correct for the underrepresentation of young 
people in such research, preference was given to the youngest male aged over 14, followed by 
the youngest female aged over 14. In order to obtain a cross-section of Australian smokers, 
quotas were set in relation to age and gender.  
 
Participants were asked their ideas about addiction to heroin, alcohol and nicotine, as well as 
their thoughts about the best treatments for these addictions. My analysis looked at participant 
responses to questions about what participants thought was the best treatment for “nicotine 
addiction”. 
 
Interviews ranged in length from 20 minutes to one hour and were conducted where convenient 
for participants. Participants were provided with a gift voucher to reimburse them for their 
time. All participants provided informed consent and the study received ethics approval from 
the University of Queensland Human Research Ethics Committee (Approval number: 
2009001022). Demographic information about participants can be found in Chapter 5. 
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The secondary analysis of qualitative data 
 
As described above, the data for this study were drawn from already completed interviews that 
were part of a larger project about neuroscience and addiction. The aim of the original study 
was to examine public understandings and knowledge around the role of the brain in addiction. 
Nicotine was just one of the drugs that participants were asked about, and the questions around 
treatment for smokers were included to elicit participants’ endorsement of a biomedical 
approach to treating addiction. While not originally intended to be analysed independently 
from the other data, it became apparent that nicotine addiction was sufficiently different from 
other drug addictions to warrant a separate, more detailed analysis. In addition, the topic was 
very relevant to the subject matter of this thesis, and it was not being utilised by other 
researchers. The researchers involved in data collection provided permission to access and 
analyse the data.  
 
Advantages of secondary data analysis include fuller utilisation of data that is time and resource 
intensive to collect, the opportunity for validation of research findings, and allowing 
researchers more time for dedicated and comprehensive data analysis (Ziebland & Hunt, 2014). 
While the secondary analysis of quantitative data is common and various data archives 
facilitate such sharing of data, the secondary analysis of qualitative data is more controversial.  
 
There are a number of reasons for this. One is the epistemological position that qualitative 
research is a “joint construction” between a researcher and a participant. An “outsider” 
analysing the data will not have access to the experiences of the researcher who undertook the 
initial fieldwork, and thus the contextual nature of the interview (or other form of fieldwork) 
may be neglected. Relatedly, there is also the possibility that focusing on only one component 
or stage of an interview will decontextualize the data, which has been shaped by surrounding 
topics and questions.  
 
There are also issues around consent, confidentiality and ownership of data when data is 
accessed by researchers without the permission or knowledge of the research participant (Parry 
& Mauthner, 2004). Consent forms which allow for data archiving and the future use of data 
for other purposes have been deemed problematic, as participants are unable to foresee the 
purposes to which the information will be put to use. In the case of the research reported here, 
these ethical concerns were mitigated by the fact that the data was only used by the university 
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and the research group to which the participants originally consented. Confidentiality was 
maintained as only de-identified interview transcripts were provided.  
 
While there is the potential for secondary analysis of qualitative data to result in validation of 
the original findings, there is also the potential for disparate findings to result when researchers 
hold differing theoretical perspectives and frame their analysis in diverse ways. While this was 
not a significant issue for this study, as the data analysed here had not been reported elsewhere, 
it is becoming very topical in qualitative research with the increasing expectation that data will 
be made publicly available.   
 
Many of these issues around secondary analysis of qualitative data are unresolved. 
Nonetheless, it has been argued that a “pragmatic approach” is employed that balances the 
potential for harm against the potential for informed decision making in health (Ziebland & 
Hunt, 2014).  
 
Thematic analysis 
Thematic analysis was used to analyse results from all qualitative data in this thesis. Thematic 
analysis is widely employed in the health sciences. Like other forms of qualitative analysis, it 
involves identifying and interpreting patterns in data (Braun & Clarke, 2006). While some 
describe thematic analysis as a process to be used within a broader method, Braun and Clarke 
argue that it is a method in its own right, and should be seen as a “a foundational method for 
qualitative analysis.” (Braun & Clarke, 2006, p. 78). 
Braun and Clarke’s seminal 2006 paper outlines six steps for conducting a thematic analysis, 
which are reproduced in Table 4.2. Although they are presented as linear steps, it must be 
acknowledged that qualitative research is a recursive process and during the course of the 
analysis, and I moved backwards and forwards between these steps, as recommended by Braun 
and Clarke (2006).  
 
The two main products of thematic analysis are codes and themes. Coding in thematic analysis 
refers to chunking the text into “repeated patterns of meaning” (Braun & Clarke, 2006, p. 86).  
These codes are then collated into broader themes. While there is no clear definition about what 
a theme is, or how to decide whether something should be labelled as a theme or not, Braun 
and Clarke state that the key characteristics of a theme are that it “…captures something 
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important about the data in relation to the research question, and represents some level of 
patterned response or meaning within the data set.” (Braun & Clarke, 2006, p. 82). Including a 
pattern as a theme is not determined by its prevalence within the dataset but rather by a 
researcher’s judgements about its salience to the research question (Joffe, 2012). For all 
qualitative analysis, the computer program NVivo 9 or NVivo10 was employed to aid the 
coding of data and to collate the codes into themes. 
 
 
Table 4.2 - Braun and Clarke’s steps for thematic analysis 
Phase Description of the process 
1. Familiarizing yourself 
with the data 
Transcribing data (if necessary), reading and rereading the data, 
noting down initial ideas. 
 
2. Generating initial codes Coding interesting features of the data in a systematic fashion across 
the entire data set, collating data relevant to each code. 
 
3. Searching for themes Collating codes into potential theme, gathering all data relevant to 
each potential theme. 
 
4. Reviewing themes Checking if the themes work in relation to the coded extracts (Level 
1) and the entire data set (Level 2), generating a thematic ‘map’ of 
the analysis. 
5. Defining and naming 
themes 
Ongoing analysis to refine the specifics of each theme, and the 
overall story the analysis tells, generating clear definitions and 
names for each theme. 
 
6. Producing the report The final opportunity for analysis. Selection of vivid, compelling 
extract examples, final analysis of selected extracts, relating back of 
the analysis to the research question and literature, producing a 
scholarly report of the analysis.  
 
Reproduced from Braun and Clarke (2006) 
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While I conducted the majority of the analysis in all studies presented, another author was 
always involved to ensure the reliability of the coding and thematic extraction. A subset of 
transcripts was examined by this second investigator, who independently coded the data and 
identified themes. Results were systematically compared and any discrepancies or major 
differences were discussed and negotiated until a consensus about themes was reached 
(Hansen, 2006). Further details about the process of analysis for each qualitative study that 
comprised this thesis are provided in Chapters 5, 6 and 7, and 8.  
 
 Study 2: Smokers attitudes towards quitting strategies and neurobiological 
explanations of smoking 
 
Rationale  
The aim of Study 2 was to explore how smokers understand the concept of nicotine addiction, 
their views about assisted and unassisted quitting, and to assess how they interpreted 
information about the neurobiology of addiction.  
Design and recruitment 
Study 2 involved semi-structured, face-to-face interviews with 29 current smokers. Eligibility 
criteria were: currently smoking daily and aged 18 years or older. Purposive sampling (Patton, 
1990) was used to recruit a wide variety of smokers in relation to age, gender, heaviness of 
smoking and socioeconomic status. Recruitment was limited to the greater Brisbane area. A 
number of recruitment methods were employed in order to obtain a diverse sample, including: 
handing out and posting flyers on community noticeboards and at neighbourhood centres; 
advertisement on the online classified site Gumtree; UQ staff newsletter; and a university 
registry of older adults. The demographics of participants are presented in Chapter 6.  
Participants were given a $20 Coles Myer voucher in appreciation for their time.  
Ethical considerations 
 
The Human Research Ethics Committee of the University of Queensland granted ethics 
approval for this study (Approval number: 2009001022). The main ethical considerations were 
around informed consent, the maintenance of confidentiality and anonymity, and the potential 
for distress during the interviews.  
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In relation to informed consent, participants were provided with verbal information about the 
project over the phone or via email. Prior to the interview, an information sheet was emailed 
to all eligible participants who had an email address. The information sheet is included as 
Appendix B. It contained information about the purpose of the research, what participant would 
involve, discussion about their right to withdraw at any time, and details about the maintenance 
of confidentiality and anonymity.  
 
The interviews were audio recorded and sent to an external company for transcription. This 
company was not provided with the names or details of participants, and were asked to remove 
names from the transcripts where they had arisen during the interviews. Participant names and 
details were stored separately from the data, and all records were password protected for 
electronic files or stored in a locked filing cabinet for paper copies. No identifying information 
about participants was included in published papers or other reporting on the data.  
 
Only minimal discomfort was expected to be associated with this study (e.g. anxiety due to 
being interviewed). The study did not aim to collect any personal information that would be 
expected to cause discomfort. Participants were made aware of the nature of the interview prior 
to consenting and were informed that they were able to stop the interview at any time, leave 
the study and ask for their responses to be deleted, if they wished. Also, it was made clear that 
participants were free to refuse to answer any question they were not comfortable with.  
 
It was deemed unlikely that participants would become distressed during the interview. In the 
event that they did become distressed, they were to be provided with pamphlets with the 
number of the Quitline and encouraged to see their general practitioner. If participants 
requested information on quitting smoking they were provided with a pamphlet for the 
Quitline.  
 
The consent form contained a space where participants could leave an email or postal address 
if they wanted to receive a summary of the results of the research.  
 
Semi-structured interviews and study materials 
Semi-structured interviews are the most common method of data collection in qualitative 
research in the public health field. According to Patton, qualitative interviewing assumes that 
“the perspective of others is meaningful, knowable, and able to be made explicit” (Patton, 1990, 
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p. 341). All interviewing techniques lie on a continuum from structured interviews, which are 
akin to a quantitative approach, to unstructured approaches that allow participants to entirely 
construct their own narrative about the research topic. As Patton notes, different types of 
interviewing can be used in different stages of the interview (Patton, 1990, p.347). In semi-
structured interviews, the researcher asks the participant interview questions that are typically 
pre-determined and structured in the same way for all participants. While the questions and the 
basic structure are predetermined, semi-structured interviews provide flexibility to delve 
deeper when unforeseen topics arise, to alter the order of questions dependent on how the 
interview progresses, and to skip questions that have already been answered. Semi-structured 
interviews have been described as “guided conversations” that provide a space for the co-
creation of meaning (DiCocco-Bloom & Crabtree, 2006).  
 
Semi-structured interviews were deemed the best way to collect data for this project as they 
allowed an initial exploratory stage of the interview, where participants were asked their 
general thoughts about smoking and addiction, before moving to more direct questions 
designed to explore specific issues that have been raised in the literature. This strategy allows 
participants’ understandings of addiction to smoking to emerge, before “scientific” 
understandings of addiction were presented, as these had the potential to bias results. Towards 
the end of the interview participants were shown a short PowerPoint presentation outlining 
current knowledge about the effects of nicotine on the brain and its role in addiction. 
Participants were asked to give their thoughts about whether they were previously aware of 
this information and whether it influenced their understanding of their smoking or their ideas 
about treatments for smoking.  
 
Interviews took place primarily in coffee shops at locations convenient to the participant, 
although a small number occurred in university meetings rooms. The coffee shop as an 
interview site was particularly conducive to the conversational nature of the interview. Coffee 
shops are typically viewed as “casual” places where people gather to talk with friends. The 
initial meeting and ordering of drinks also allowed the building of rapport prior to the beginning 
of the interview.  
 
The PowerPoint presentation (see Appendix A) was based on resources developed by the 
National Institute of Drug Abuse (NIDA) in the USA, one of the most influential disseminators 
of information about drugs and the brain. As the study aimed to recruit a wide variety of 
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smokers with varying demographic and educational backgrounds, it was important that the 
information presented to participants was understandable to those who do not have extensive 
education or scientific knowledge. NIDA’s online resource “Mind Over Matter: Tobacco 
Addiction” brochure designed for high school students, and the associated resource for teachers 
(National Institute on Drug Abuse, 2006) were used as the basis for the presentation. The 
presentation was piloted with people without a scientific background, drawn from the 
researchers’ social networks, and refined to maximise clarity and comprehensibility. Audio 
narration was added to cater for participants with poor reading comprehension.  
The interview schedule (see Appendix C was developed from themes identified in the literature 
review, as well as those identified from prior studies (Meurk, Hall, et al., 2013; Meurk et al., 
2014). It was piloted with five volunteers and minor refinements were made to question 
wording.  
 
The main topics covered in the interview schedule were:  
 Smoking history and thoughts about their own smoking 
 Understandings of addiction, including issues of control and responsibility 
 Questions about the treatment and prevention of smoking, including public health 
measures and individual treatment options 
 Participant responses to the aforementioned presentation on the neurobiology of 
nicotine addiction 
 Attitudes toward the idea that nicotine addiction is a “brain disease”  
 
In addition, a short demographic and smoking history survey was completed by participants 
prior to completing the interview (See Appendix C).  
 
Data analysis 
All interviews were audio recorded and transcribed verbatim. Data was imported into NVivo 
9 or 10 and analysed using thematic analysis, as described in Section 4.4.  
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 Study 3 – Survey of Australian smokers’ endorsement of brain-based explanations 
of smoking and relationship to treatment intentions and self-efficacy 
A survey was undertaken with a sample of Australian smokers in order to assess whether the 
results of the qualitative studies generalised to a larger population, and to investigate the 
relationship between biomedical understandings of smoking, demographic variables and 
smoking-related behaviours and preferences 
 
Eligibility criteria 
Current smokers who were aged 18 or over, smoked daily, and had smoked at least 100 
cigarettes in their lifetime were recruited to the study. Participants must also have been 
Australian citizens or residents to ensure data were reflective of the Australian population.  
Survey development and design  
Survey items were developed from a review of the literature and from themes identified in the 
qualitative phase of the research project. Survey development was the key phase of the study 
where integration of the qualitative and quantitative components occurred. The key themes and 
observations from the qualitative studies that informed the development of the survey are 
described in Chapter 9. The relevant items from each section of the survey are described below. 
The full survey is included as Appendix D. 
Ethical considerations 
 
The Human Research Ethics Committee of the University of Queensland granted ethics 
approval for this study (Approval number: 2009001022). No personal information of a 
sensitive nature was collected as part of this study and the major ethical issues raised in doing 
this survey were: 1) ensuring that participants provided free and informed consent to participate 
in this study; and 2) ensuring the confidentiality of any information provided by participants.  
 
In accordance with standard practice for online questionnaires, participants were presented 
with a screen that contained information about what the study involved prior to commencing. 
This included information that:  
 Participants were free to withdraw from the study at any time by exiting the survey 
webpage.  
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 The University of Queensland would not receive any personal information about 
participants, including name, address or email.  
 Once the survey was completed, the University would be unable to delete responses, 
as we could not link the respondent’s name with the survey data.  
 That participation will involve completing one 20 minute questionnaire about 
smoking, and thoughts about quitting methods and addiction.  
Respondents needed to agree to proceed to the survey.  
 
In relation to confidentiality and anonymity, the market research panel was bound by the 
National Privacy Principles (on Market and Social Research Privacy Principles), approved by 
the Federal Privacy Commissioner. Further detail on the privacy policy is included as Appendix 
E.  Only de-identified data was provided by the market research company.  
 
Eligibility criteria and basic demographics 
This included age, gender, number of cigarettes per day, and citizenship status. This data was 
collected in order to determine eligibility.  
 
Section 1 – Smoking variables 
This section asked standard questions about smoking history and behaviour. The two items of 
the HSI were included to assess nicotine dependence (Heatherton et al., 1989). Quitting history 
was assessed by number of previous quit attempts in the last year, as well as longest quit period.  
Other questions included plans to quit (Australian Institute of Health and Welfare, 2011) desire 
to quit, and enjoyment of smoking (West & Fidler, 2011). Self-efficacy was measured using a 
5 point item that has been used in other national surveys (Bonevski et al., 2015; Hyland et al., 
2006). A number of novel items measuring beliefs about the brain and smoking were also asked 
in this section, including endorsement of the idea that nicotine addiction is a brain disease. 
These items were drawn primarily from common statements made in the interviews, and are 
described in more detail in Chapter 9. 
 
Section 2 – Attitudes towards quitting methods 
A list of common methods of quitting were adapted from the National Drug Strategy 
Household Survey (Australian Institute of Health and Welfare, 2011). Questions measured the 
perceived effectiveness of these methods, prior use of the method, and intention to use each. 
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Participants were given the opportunity to name other quitting strategies they had used but 
which were not listed.  
 
Section 3 – Reasons for smoking 
An existing scale was adapted to assess participants reported reasons for smoking (Fidler & 
West, 2009). Further questions were then included about the BDMA. A statement from a recent 
book by Robert West, a leading smoking researcher, about the role of the brain in smoking was 
presented (West, 2013). This quote emphasised the neurobiological basis of tobacco 
dependence. Items measured the extent to which this participants thought this explanation 
explained the smoking of themselves, and of other smokers. A set of items were developed to 
assess beliefs about the consequences of accepting a neurobiological understanding of smoking 
in relation to stigma, self-efficacy and treatment seeking. Lastly, participants were again asked 
if nicotine addiction was a brain disease, to assess whether providing more detail about the 
claim, in the form of the Robert West excerpt, changed the participant’s level of endorsement. 
A number of additional items explored opinions about the use of pharmaceutical nicotine as a 
harm reduction strategy. These items will not be explored in this thesis.  
 
For most questions, each item was presented on a separate page in order to reduce response 
bias and satisficing. Pilot testing was conducted to refine the presentation of the questions.  
 
Sampling and recruitment 
The sample for the quantitative component of the project was drawn from an opt-in online 
panel of Australians. The use of online panels for social research has become common in the 
social and health sciences, but remains controversial. This section will outline the advantages 
and disadvantages of using online research panels and the steps that were taken in this research 
project to ensure the highest quality data for the survey.  
Benefits and drawbacks of online research panels 
Online panels have been defined as “a pool of registered persons who have agreed to take part 
in online studies on a regular basis.” (Goritz, Reinhold, & Batinic, 2002, p. 27). The primary 
advantage of using an online panel is time and cost efficiency. A large “ready-made” sample 
of participants is available, with the bulk of the recruitment process undertaken by the market 
research company. Whilst this saves the researcher time, it also means ceding control of 
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recruitment to an external body. Most online panels do not randomly select potential panel 
members. Rather, panel members self-select to join the panel, usually after exposure to 
advertising. Thus, an online panel cannot be said to be representative of the general population, 
but is rather a form of “convenience” sampling.  
Because of this, there are certain biases that may result from using online panels. The most 
obvious is that only those with internet access can join an online research panel, leading to 
coverage error. In Australia, internet penetrance is high, with 83% of Australian households 
having internet at home (Australian Bureau of Statistics, 2014). However, internet access does 
vary according to certain sociodemographic variables. For example, households with children, 
and higher income households, are more likely to have an internet connection at home 
(Australian Bureau of Statistics, 2014). In relation to personal internet use, younger people are 
more likely to use the internet than older adults (97% of 15-17 year olds compared to 46% of 
people aged 65 or over (Australian Bureau of Statistics, 2014). In the USA, those who join 
online panels have higher education levels, more frequent internet use, and are less likely to 
belong to an ethnic minority (American Association for Public Opinion Research, 2010).  
 
Whilst these sampling issues cannot be overcome entirely, the use of online panels can still 
provide meaningful data, and their use is becoming common in addiction research (Buykx, 
Gilligan, Ward, Kippen, & Chapman, 2015; Hughes, 2009; Quaak, Smerecnik, van Schooten, 
de Vries, & van Schayck, 2012; Vogt, Hall, & Marteau, 2010; Willems et al., 2013). Firstly, 
the issues raised above are not unique to studies that employ market research companies. There 
are also problems with alternative means of obtaining samples for social research. Response 
rates in surveys using population-based sampling are typically low, and hence the recruited 
sample may no longer be representative of the whole population (Fogliani, 1999). Random 
digit dialling has been the traditional way to obtain a probability sample. However, the use of 
landlines is declining rapidly in many countries because of increased use of mobile phones. 
The Australia Institute reported that samples from online surveys were very similar in 
representativeness to samples produced by a random telephone sample (Bambrick, Fear, & 
Denniss, 2009). The Australian Communications Media Authority reported that 25% 
Australians no longer have a landline, and that those without a landline are younger (Australian 
Communications and Media Authority, 2014). In addition, there are benefits to this type of 
online research which have led to rapid growth in its use (American Association for Public 
Opinion Research, 2010). These include reduced response rates for random digit dialling, 
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flexibility of web-based questionnaire design, and quick turnaround times for online data 
compared to traditional probability samples. Also, the expense of conducting random mail-out 
surveys or random digit dialling makes it unfeasible to use these methods for many smaller 
projects with limited budgets. The American Association for Public Opinion Research 
recognise that nonprobability online surveys are suitable for certain types of research:  
“There are times when a nonprobability online panel is an appropriate choice. Not all 
research is intended to produce precise estimates of population values and so there may 
be survey purposes and topics where the generally lower cost and unique properties of 
Web data collection is an acceptable alternative to traditional probability-based 
methods.” (American Association for Public Opinion Research, 2010, p. 5).  
 
While the limitations of online panels need to be recognised and acknowledged, there are many 
steps that can be taken in order to ensure that the best quality data is collected. One 
recommendation from a report of the American Association for Public Opinion Research on 
online panels was that potential panels are researched and assessed rigorously (American 
Association for Public Opinion Research, 2010). 
 
Selection of online panels  
There are many commercial operators that maintain and advertise online panels for social 
research. These vary in terms of the size of their panels, their recruitment methods, and the 
panel makeup. Reputable companies can provide potential clients with an Esomar 28 
document, which answers 28 questions relating to the quality of their panel. The Esomar 28 
document for the panel that was selected for this project, The Online Research Unit (ORU), is 
available upon request. Taverner Research was the company that liaised and administered the 
survey via the ORU. The key factors that influenced the selection of the online panel are 
described below.  
Size of panel  
It is important to ensure that the company selected can provide the required number of 
participants. Many companies use “panel partners”, where they make commercial 
arrangements to supplement their own panel members with that of another panel in order to 
obtain the desired sample. This practice can be problematic, as an individual may be a member 
of both panels, raising the potential for duplication. Whilst there are generally processes in 
place for identifying duplicates, it is better practice to source all participants from a single 
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panel. For this project, companies that could not provide all participants from a single panel 
were excluded from consideration.  
 
Recruitment 
While it is self-evident that all participants in an online panel must have internet access, it is 
preferable for recruitment purposes for the panel to be advertised via both online and offline 
channels in order to increase exposure by harder to reach groups. The ORU uses a combination 
of online and offline advertising measures, with 53% of their advertising using offline methods 
such as telephone, mail, and print advertising. 
 
In relation to joining procedures, most online panels now use a double opt-in process, whereby 
participants initially express an interest in joining the panel by clicking on a link, responding 
to an email, or calling the membership department of the company. They are then sent an email 
asking them to confirm that they wish to join the panel. At this point, they are usually directed 
to a profile page, where they can answer questions about themselves that allow the panel to 
direct surveys to certain types of people. The use of a double opt-in process was a requirement 
for this study. The selected panel also conducts periodic “panel maintenance” where inactive 
members, duplicate members, or members identified as fraudulent, are removed. 
 
Quality standards for online research 
There are two standards that online opt-in panels can adopt. These have been developed by the 
International Organization for Standardization and are labelled ISO20252 and ISO26363. 
Many Australian panels conform to requirements for ISO20252. The panel selected for this 
survey meets standards for ISO20252 and ISO20363. ISO20363 is a more recent standard 
(2009) with higher quality standards (e.g., the use of a double opt-in recruitment process). In 
addition, the ORU is endorsed by the Association of Market and Social Research 
Organisations, which place stringent privacy and ethics requirements on members.  
 
Incentives 
Online research panels typically provide participants with incentives for completion of surveys. 
The incentives are often in the form of “panel points” which can be converted to cash or gift 
cards. For this research, participants were provided with panel points.  
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Sampling strategies 
For this research, we required a sample of smokers that was similar to that of the population of 
smokers in Australia. In order to meet this requirement, a target population structure was set 
based on age and gender data about smokers obtained from the National Drug Strategy 
Household Survey (Australian Institute of Health and Welfare, 2014). The distribution of 
participants was checked daily, and invites and reminders managed in order to keep the sample 
screened as close as possible to the population targets. The only group that was slightly under-
represented was younger males, which are recognised as being a difficult group to recruit. 
Demographic details about survey participants are provided in Chapter 9. 
 Summary 
This chapter has outlined the rationale and design of the research project. Mixed methods were 
chosen as the most appropriate means to assess the extent to which a biomedical model of 
tobacco dependence has infiltrated lay conceptualisations of smoking and quitting among a 
sample of Australians. Two qualitative studies employed semi-structured interviews to explore 
attitudes about the use of medications for smoking cessation. This qualitative research also 
investigated the ways that lay discourse incorporated the role of the brain into explanations of 
smoking.  Based on findings from these qualitative studies, a quantitative measure was 
designed in order to investigate to prevalence of neurobiological beliefs about smoking 
amongst a large sample of Australian smokers, and their impact on treatment intentions and 
other relevant smoking variables. The following chapter will expand on the rationale for 
interviewing a random sample of the Australian public, and present the results of these 
interviews.  
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Chapter 5. Public attitudes toward the treatment of nicotine addiction 
 
As discussed in Chapter 1, the key components of medicalisation are: 1) the labelling of 
individuals as having a medical problem with subsequent surveillance by health practitioners; 
and 2) the provision of medical treatment for a condition.  
 
Chapter 1 outlined the current debate in the tobacco control field about the value of biomedical 
definitions and treatments for smoking cessation. Some believe that an emphasis on medical 
treatment is misguided, as it reduces the emphasis on unassisted quitting. They are concerned 
that if a biomedical approach to cessation comes to dominate, people will come to see 
unassisted quitting as an ineffective and inappropriate means of quitting smoking (Chapman & 
MacKenzie, 2010). Meanwhile, smoking cessation pharmacotherapies have only modest 
effectiveness, and their promotion, particularly by pharmaceutical companies, may provide the 
public with unrealistic expectations regarding their efficacy (Wakefield & Durrant, 2006). The 
alternative interpretation is that smokers should be encouraged to quit with pharmacotherapy 
and counselling, as current scientific evidence suggests that this is the most effective cessation 
strategy (Hartmann-Boyce et al., 2013). Proponents of a biomedical approach argue that even 
small increases in the chance of a successful quit attempt are worthwhile, and that the provision 
of medical treatment for cessation is a cost-effective intervention at the population level 
(Britton, 2009). 
 
The aim of the study described in this chapter was to explore the extent of medicalisation of 
smoking cessation in Australia by examining how the public believes nicotine addiction should 
be treated. Have medical definitions and treatments for tobacco dependence filtered into lay 
explanations of smoking cessation? Does the Australian public see medical treatment as the 
best way to quit smoking? It is often assumed that a medical view of smoking will be passively 
accepted by the Australian public and smokers themselves, however this has not been 
empirically investigated. The evidence outlined in Chapter 2 suggests that alternative 
discourses of smoking are common in lay discourse.  
 
This chapter presents an analysis of qualitative data drawn from a pre-existing dataset on public 
understandings of addiction. It aims to explore the views of the general public about what is 
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the best method to use to quit smoking and why. The remainder of this chapter is primarily 
comprised of a paper that was published in Nicotine and Tobacco Control in 2013, followed 
by a summary of its implications for this thesis.  
 
Citation: Morphett, K., Lucke, J., Gartner, C. E., Carter, A., Meurk, C., & Hall, W. (2013). 
Public attitudes toward the treatment of nicotine addiction. Nicotine and Tobacco Research, 
15(9), 1617-1622. Published by permission of Oxford University Press. 
 
 
Abstract 
 
Introduction: The increasing use of medications for smoking cessation has concerned some 
commentators, who believe that emphasising medications for smoking cessation may lead to a 
belief that there are “magic bullets” for nicotine dependence, or alternatively that quitting 
smoking is very difficult, thereby discouraging unassisted quit attempts. There is little evidence 
on which to test these speculations. This article aims to address this gap by examining public 
understandings of nicotine addiction in order to assess the extent to which medical explanations 
of smoking have permeated public beliefs about treatments for smoking cessation. Methods: 
Interviews were conducted with a representative sample of 55 members of the Australian 
public that included smokers, ex-smokers and non-smokers. The data were analyzed using a 
standard content analytic method to identify recurrent themes. Results: The results revealed 
that although pharmacological cessation aids were the most commonly mentioned method for 
quitting, they were often recommended alongside methods such as behavioural strategies or 
counselling. Unassisted quitting was mentioned frequently, but there were mixed views on its 
effectiveness. Seeing a doctor was rarely recommended. Two common themes were that 
smokers had to “really want to quit”, and that the best treatment method would depend on the 
individual. Conclusions: Medical discourse of smoking cessation does not dominate public 
understandings of smoking cessation. Rather, ideas about individual choice, motivation and 
willpower are emphasised.  
 
 Introduction 
Smoking is increasingly described and treated as a medical issue. One indicator of this is the 
growing number of smokers who use pharmacological treatments such as nicotine replacement 
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therapy (NRT), varenicline and bupropion for smoking cessation. In 2003, 32% of Australians 
who had made a quit attempt in the previous year reported using a pharmacological aid. This 
proportion rose to 52% in 2009 (Cooper et al., 2011). The use of medications for smoking 
cessation has also risen in the USA and the UK and is associated with increased over-the-
counter availability of NRT, the marketing of pharmacological cessation aids by 
pharmaceutical companies and government subsidies for cessation medications (West, 
DiMarino, Gitchell, & McNeill, 2005; Zhu et al., 2012). Associated with the growing use of 
medical cessation aids is the increasing role of health professionals in the identification and 
treatment of smokers (Fiore et al., 2008; Zwar et al., 2014).  
 
Despite evidence for the effectiveness of pharmacotherapy for smoking cessation (Cahill et al., 
2012; Eisenberg et al., 2008; Hughes et al., 2010; Stead et al., 2008), some public health 
researchers have criticized the prominence given to pharmaceutical aids over unassisted 
cessation (Chapman & MacKenzie, 2010). These critics argue that although such medications 
increase the success rate of quit attempts in clinical trials, overall success rates are lower, with 
the majority of smokers who use NRT failing in their quit attempt (Chapman & MacKenzie, 
2010). Moreover, evidence on the effectiveness of pharmaceutical treatments for smoking are 
often based on clinical trials sponsored by pharmaceutical companies (Chapman & MacKenzie, 
2010; Etter et al., 2007). Studies on the use of NRT in community samples have shown more 
mixed results. One population-based study of smokers in the US, Canada, UK and Australia 
found that smokers who had used pharmacological cessation aids were more likely to remain 
abstinent than those who did not use medications (Kasza et al., 2013). Other studies however, 
have failed to show such benefits (Alpert et al., 2013; Walsh, 2008), raising questions about 
the generalizability of findings from clinical trials to “real world” settings. 
 
Chapman and MacKenzie (2010) contend that the emphasis on cessation aids such as NRT has 
overshadowed the fact that most smokers quit unaided. They argue that the pharmaceutical 
industry has a vested interest in promoting the view that quitting is difficult without medical 
help, thereby making smokers think that quitting is harder than it is. These concerns are shared 
by researchers in the USA (Pierce, Cummins, White, Humphrey, & Messer, 2012). An opposite 
concern has been expressed about the unintended consequences of increased availability and 
promotion of medicines for smoking cessation, namely that it may lead smokers to believe that 
there are ‘magic bullets’ for nicotine addiction that will enable them to quit easily should they 
choose to do so (Dingel et al., 2011). This may be of particular concern for young people, with 
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one study suggesting that young people at risk of becoming smokers thought that quitting 
smoking would be easier after viewing ads for NRT and bupropion compared with ads 
promoting the Quitline (Wakefield & Durrant, 2006).  
 
A number of commentators have framed these issues as reflecting the risks of increased 
medicalisation of smoking (Blum, 1984; Caron et al., 2005; Chapman & MacKenzie, 2010; 
Dingel et al., 2011). Medicalisation refers to the process by which issues not previously under 
the purview of medicine come to be conceptualised in terms of illness and health. Concerns 
about medicalisation have typically centred on issues of power, such as the power of medical 
professionals to diagnose an individual as “healthy” or “ill” thereby creating deviant identities 
(Conrad, 1992). More recently concern has centred on the power of “technoscientific” 
industries, particularly pharmaceutical corporations and biotechnology companies (Clarke et 
al., 2003), to redefine behaviour as illness in order to increase profits.  
 
Finally, these critics argue that medicalising smoking may overemphasise the treatment of 
smokers and overlook the well-documented social influences on smoking uptake and 
maintenance. For example, developments in pharmacogenetics, which involve tailoring 
treatments for smoking cessation based on the results of individual genetic tests, may reduce 
support and funding for population wide tobacco control strategies that have proven effective 
in reducing smoking prevalence (Caron et al., 2005; Gartner et al., 2012).  
 
These claims about the potential adverse impact of medicalisation on individual beliefs and 
smoking behaviour are not typically based on empirical research. There is little research 
examining the extent to which medical views of smoking have penetrated the understandings 
of the public in general and smokers in particular. Survey data suggest that there is considerable 
public ambivalence about the idea that smoking is a medical problem. For example, both the 
general public and smokers tend not to support the view that smoking is caused by biological 
factors, and are more likely to endorse the idea that smoking is a habit (Cunningham et al., 
1994; Hughes, 2009). Qualitative and quantitative research has demonstrated some resistance 
to treating smoking as a medical issue, with many smokers emphasising the importance of 
willpower and expressing a belief that using medication to quit smoking is sign of weakness 
(Balmford & Borland, 2008; S. Carter, Borland, & Chapman, 2001).  
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Public health researchers have acknowledged the importance of understanding how lay 
concepts of health, illness, and treatment may affect health behaviour (Kuppin & Carpiano, 
2006; Popay & Williams, 1996). In light of the increasing use and promotion of medications 
for smoking cessation, there is a need for research exploring lay attitudes toward smoking 
cessation and the role that drug treatments play in it. This article outlines findings from 
qualitative research undertaken with a cross section of the Australian population that included 
smokers, ex-smokers and non-smokers and explored participants’ views about treatments for 
nicotine addiction. Although the views of non-smokers are rarely solicited in smoking research, 
they are important to explore because research shows that the attitudes of non-smoking family 
and friends towards smoking can influence the motivation of smokers to quit (Australian 
Institute of Health and Welfare, 2011; Fiore et al., 2008; Patten et al., 2011). This study aims 
to explore the opinions that the public hold on the role of treatments in smoking cessation, 
examine the extent to which medical explanations of smoking have affected the understandings 
of the public, and describe alternative conceptualisations of smoking that may influence 
attitudes in relation to treatment options for nicotine addiction.  
 Method 
The data analysed in this article were drawn from a study exploring public understandings of 
addiction. Findings about the ways in which the public describe the causes of addiction and 
their ideas about the brain disease model of addiction have been published elsewhere (Meurk, 
Carter, et al., 2013). The study involved face-to-face semi-structured interviews with 55 
participants, exploring their ideas about addiction to heroin, alcohol, and nicotine. A market 
research company was contracted to recruit the participants and conduct the interviews using 
an interview schedule designed by the researchers.  
 
Potential participants were selected from a representative database of Australian households 
developed by Roy Morgan Research. Households from the database located in the Greater 
Brisbane area were randomly selected. Once households were selected, the youngest male aged 
more than 14 years (or if not available, the youngest female aged more than 14 years) was 
asked to participate. This approach increased the representativeness of the sample of young 
people, particularly young males who are the hardest to recruit. Quota sampling was used to 
ensure that the sample was age and gender representative (Table 5.1).  Semi-structured 
qualitative interviews, followed by a brief quantitative survey, were conducted with willing 
participants at a location of their choice. All participants received a gift voucher in appreciation 
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for their time. The findings in this article were drawn from participants’ responses to the 
question “What do you think is the best way to treat someone who is addicted to nicotine, and 
why?” Of the 55 participants, 14 reported being current smokers (10 were daily smokers, 2 
weekly smokers, and 2 less than weekly smokers) and 40 were non-smokers at the time of the 
interview. One participant did not answer this question. Of the 40 non-smokers, 11 reported 
being ex-smokers.  
 
Table 5.1 - Sample characteristics for Study 1 
Gender Male Female 
47% (n=26) 53% (n=29) 
Age  Under 50 years of age 50 years and older 
51% (n=28) 49% (n=27) 
Highest 
level of 
education 
No formal 
qualificatio
n 
Secondary 
school  
Post-secondary 
qualifications 
(e.g. trade 
training) 
University/ 
college degree 
4% (n=2) 40% (n=22) 30% (n=17) 26% (n=14) 
 Data analysis 
Interviews were transcribed and imported into qualitative research software NVivo 9 (QSR 
International Pty Ltd., 2010). Each treatment method mentioned by a participant was coded as 
a category. In addition, thematic data analysis was used in order to identify recurrent themes 
across treatment methods. Categories were verified by an iterative process that involved 
reading each interview in light of the categories developed, and amending or adding categories 
as required. Each participant quoted is referred to by their age, sex, and whether they are a 
current smoker, an ex-smoker or have never smoked.  
 Results 
The most commonly mentioned treatment for smoking cessation was the use of 
pharmacological cessation aids (n=30). Although not strictly a “treatment”, unassisted quitting 
was the next most frequently described strategy for quitting (n=24). The use of behavioural 
strategies (n=10) and counselling (n=7) were also discussed relatively frequently, although not 
as often as pharmacological cessation aids or unassisted quitting. An important observation 
was that participants often recommended a number of treatment strategies, as outlined below.  
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Pharmacological cessation aids 
When asked what they thought was the best treatment for nicotine addiction, participants most 
often mentioned pharmacological cessation aids, mainly in the form of NRT patches. This, no 
doubt, reflects the fact that NRT is the most widely used pharmacological cessation aid in 
Australia (Cooper et al., 2011) and the only pharmacological cessation aid that can be 
advertised directly to consumers. It was less common for participants to mention prescription 
medications and those that did often referred to “tablets.” Very few participants mentioned a 
specific prescription medication. This suggests that most Australians have only a vague 
knowledge of cessation medications, which is not surprising given that they are not allowed to 
be advertised directly to consumers in this country. 
 
Although a few participants mentioned pharmacological methods as a sole treatment for 
nicotine addiction, it was more common for pharmacological cessation aids to be discussed 
alongside behavioural strategies, counselling, and hypnotherapy. The following quote is 
typical: 
Well the nicotine patches are quite good. There’s a couple of medications that 
are used that are quite good. Having a plan; having a friend doing it with you 
helps. And often you can make a plan of when you’re going to stop, whether 
you’re going to use patches. (male, 50-59, never smoked) 
The belief that medications were useful did not necessarily displace the importance of 
alternative methods, such as counselling: 
Well obviously these alternatives - nicotine patches and all that are successful 
to a great degree. But I think there’s a need for counselling in that regard too. 
Why are you smoking? Let’s get to the bottom of it, et cetera. (male, 70 or over, 
never smoked) 
Patches were seen as effective, but insufficient because they did not address the underlying 
reasons why someone smoked. Another common theme was that different methods would work 
for different people. Again, pharmacological cessation aids were situated as one method among 
others:  
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I think that depends on the person a lot of times. With the things that I’ve seen, 
sometimes hypnosis works, you know, sometimes those tablets that they take 
work. That book by that guy Carr, or whatever, that I gave my brother because 
he couldn’t give up, that worked for him. Yeah, I think it depends on the person. 
(female, 40-49, never smoked)  
Both smoking and non-smoking participants commented that “really” wanting to quit was a 
prerequisite for successful quitting, regardless of whether pharmacological cessation aids were 
used or not:  
I think there are some medicines, some type of tablets or something, people have 
– somebody taking that tablets you don’t feel is – you want to smoke or 
something, but the rest is on the people. Like me, if I want to quit I should quit, 
should say to myself that’s okay, it’s enough, I want to quit. So that’s up to the 
people, if they want really want to quit, they would quit. (male, 25-29, current 
smoker) 
This approach portrayed individual decision making, motivation, and willpower as the key 
factors in successful quitting, not medical assistance. For example, one smoker, after an 
unsuccessful attempt using patches, developed a side effect from prescription medication. 
However, she blamed her lack of success on a deficiency in willpower, rather than any 
limitations of the medication:  
Yeah, no that didn’t help – and I had some pills I got from the doctor and they 
just  - I just came out in boils everywhere – they were no good. It’s just 
willpower, I got no willpower. (female, 50-59, current smoker) 
Another smoker who had been given prescription medication by their doctor was reluctant to 
use it for fear of side effects. She expressed a preference for quitting unaided:  
Yes well there’s quick – there’s a lot of different things you can do.  And as I 
said I’ve got tablets but I’m reluctant to take them.  But hopefully I’ll be able to 
do what I did before and just stop.  But I can’t answer that.  I hope I do for my 
own sake. (female, 60-69, current smoker) 
This ambivalence toward cessation aids was not expressed by all smokers. One long-time 
smoker expressed a fear of quitting, but seemed to gain encouragement from the availability of 
cessation aids:  
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Well for me I’m sort of – I want to give it up but I’m scared to because I’ve 
smoked all my life. So it’s also a fear factor there – I know I couldn’t give it up 
cold turkey but with those Nicorette’s and all this sort of stuff- no I’m going to 
give it up. (male, 49-49, current smoker)  
Unassisted quitting 
In asking participants about the best “treatment” for nicotine addiction, there was the potential 
to bias responses toward medical or psychological interventions. Nonetheless, participants still 
referred to unassisted quitting, which was often positioned as the ideal method for smoking 
cessation. The use of cessation aids was sometimes described as a secondary option, to be used 
only where unassisted quitting had been unsuccessful:  
I mean maybe you try what my husband did, the cold turkey, and if that doesn’t 
work you try the patches or whatever. (female, 60-69, never smoked) 
After you’ve made that decision, be consistent, follow through with it, persist.  
And – well of course some people might need medical additional help, patches 
but personally I never had that problem so I can’t empathise with – put myself 
in their place but I believe it’s best to just drop it instead of just slowly trying 
to. (male, 60-69, never smoked) 
Participants often talked about how difficult or easy it would be to quit unassisted. Respondents 
were divided on this point. Some believed that quitting unassisted would be very difficult and 
that only strong-willed people would be able to stop smoking this way:  
My parents just stopped like that and I always find that incredibly impressive 
when people do that. So I can appreciate it can be done but at the same time I 
do appreciate that it is very hard and some people will try over and over again 
before they finally make it. (female, 40-49, never smoked) 
This fitted with the idea that different methods work for different people. Quitting cold turkey 
was often described as a method suitable only for some people, typically those with willpower 
or “strong minds”: 
Yeah, there’s a lot of help out there and I have seen people with strong minds 
just stop, even though it’s hard. But there’s other people that need more help. 
(female, 40-49, never smoked)  
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Others expressed the belief that unassisted quitting would be the easiest way to quit. These 
views were often expressed by those who saw smoking as a habit that smokers can and should 
“just stop”: 
I just think nicotine is probably a mental thing, not so much as your body 
probably needs it. I just think it’s more like a habit. You just walk downstairs; 
have a coffee and a cigarette. Whereas walk downstairs, have a coffee and have 
a chocolate bar instead or something and then do that for five days in a row 
and you’ll probably be cured from wanting to smoke anymore. (female, 25-29, 
never smoked)  
The above quote illustrates the way in which an individual’s explanatory model of nicotine 
addiction influenced a participant’s views about the most appropriate way to quit. 
Understanding smoking as a habit, rather than a physiological dependency, led the participant 
to see quitting as a matter of replacing one habit with another. A small number of those who 
saw smoking as a habit rejected the idea that smokers needed any treatment for nicotine 
addiction because they did not believe that nicotine was as addictive as claimed:  
I actually don't think they're really addicted to tell you the truth.  I don't think 
nicotine is as an addictive drug as everybody makes out. (male, 50-59, ex-
smoker)  
The concept of motivation and the importance of personal decision making were again 
emphasized in discussions around unassisted quitting:   
He has to help himself. He wants to do it. Throw it away, don’t just go through 
the stages, just throw it away, make a decision, publicise it, tell everybody that 
counts. (male, 60-69, never smoked)  
Best way to treat them is you can’t treat them. It’s up to them whether they want 
to give up or not. You’re not going to force anyone to do anything that they 
don’t want to. (male, 40-49, ex-smoker) 
Behavioural strategies 
The use of behavioural strategies was also mentioned often as a treatment option for nicotine 
addiction. The strategies described under this heading included reducing the intake of 
cigarettes, replacing smoking with another behaviour, recruiting social support for abstinence, 
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and avoiding environments where smokers were exposed to tobacco smoke or other smoking-
related cues:  
You just need to take them out of the environment, so that they - well, take them 
out of the environment and even into a neutral environment where there’s no 
need for temptation and something that won’t - teach them not to be drawn to it 
kind of thing. (female, 18-24, never smoked)  
I don’t know, hey.  I reckon to – because my dad was addicted.  The way- how 
he got off smoking was to keep himself busy and not just sit around.  So he just 
keeps himself busy every day, every day.  And chew a bubble-gum.  [Laughs].  
Chew a bubble-gum, ‘cause that will keep your mind off smoking. (female, 18-
24, current smoker)  
Counselling 
Counselling was one of the most commonly discussed methods for treating nicotine addiction. 
Generally, a less intensive form of counselling was thought to be required for smokers than for 
those addicted to alcohol or heroin.  
Well nicotine is not really – I mean, someone who takes nicotine’s not 
completely – just – they can be a functioning member of society.  So you don’t 
need a rehab, but possibly a counselling or somebody to help like a motivational 
coach, or something like that.” (male, 18-24, current smoker)  
Seeing a doctor 
Seeing a doctor was rarely mentioned by participants, with only one participant describing 
doctors as having a supervisory role in relation to smoking. Several participants described the 
cost of seeing a doctor and the cost of medications for smoking cessation as a barrier to seeking 
medical assistance for smoking. 
 Discussion 
These results suggest that although the medicalisation of smoking cessation has occurred to a 
degree, the process is far from complete. Pharmacological cessation aids were the most 
frequently mentioned treatment for smoking cessation, but unassisted quitting was often 
described as the ideal method. Participants often recommended that medications only be used 
when unassisted quitting had been unsuccessful. Even then they often articulated that 
behavioural methods that dealt with the social and emotional aspects of smoking, for example 
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counselling, were also desirable to reduce relapse. The finding that the public ascribe 
prominence to unassisted quitting is strengthened by the fact that the wording of the question, 
in which respondents were asked what they thought was the best “treatment” for nicotine 
addiction might have biased their answers towards medical options. 
 
There was also little evidence that medications for smoking cessation were perceived as “magic 
bullets”. Doctors were rarely mentioned in relation to smoking cessation, perhaps reflecting 
the market dominance of NRT, which is available over the counter and so does not require a 
doctor’s visit. It may also partially reflect the commonly held belief that smoking is a habit, or 
at the least a much less serious addiction than other drug addictions, and hence that smokers 
are not in need of medical assistance.  
 
It is clear that the Australian public has not uncritically accepted the idea that smoking requires 
medical treatment. Early theorising about medicalisation described it as a one-way process, 
with the public portrayed as passive instruments of institutional power (Ballard & Elston, 
2005). However, more recent research has emphasised the active ways in which people respond 
to this process, including the ways in which the public resists medical discourse (Ballard & 
Elston, 2005). The results of this study are more supportive of the latter view in revealing some 
resistance to the medicalisation of smoking. Only a small number of participants believed that 
nicotine was not as addictive as commonly thought and that smokers should “just stop.” But 
the idea that smoking is a habit remained a common theme in public discourse about smoking 
that has not been purged from the lexicon, as suggested in the first issue of the journal Tobacco 
Control (Davis, 1992).  
 
The tobacco industry has promoted the idea that “habit” and “addiction” are mutually exclusive 
terms (Davis, 1992) but smokers appear willing to accept both of these explanations of smoking 
(Hughes, 2009). The results suggest that ideas about the biological bases of smoking have not 
displaced the idea that smoking is a habit. This may explain why participants in this study often 
recommended cessation medications and behavioural strategies or counselling.  
 
The belief that smokers have to “really want to quit” to be successful was a commonly 
expressed belief in this study as it has been in others (Balmford & Borland, 2008; Carter et al., 
2001). This belief was expressed by smokers, non-smokers and ex-smokers. Balmford and 
Borland (2008) note that this belief may discourage quit attempts if individuals believe that it 
86 
 
will be fruitless unless they feel no ambivalence about their smoking and are “ready” to give 
up, a point that many smokers may never reach. Another important idea about smoking 
cessation expressed by participants was that the best treatment “depends on the individual”. 
What works for one smoker will not necessarily work for another. This view of nicotine 
addiction implies that smokers may need to try a number of methods in order to find one that 
suits them. Pharmacological cessation aids are positioned within this discourse as one method 
among others. Given that these two discourses circulate widely in public discourse, it is likely 
that smokers are frequently exposed to them. Further research should be conducted exploring 
the potential behavioural consequences of the commonly held beliefs that smokers must “really 
want” to quit to be successful and that the best method for quitting depends on the individual. 
In addition, attention should be given to the implications for how clinicians should deal with 
smokers who express these views.  
 
This study examined the views of the general public about treatments for smoking cessation. 
This is important given that smokers do not make decisions in isolation, but are influenced by 
their social environment, including family, friends, and messages in the media. Although some 
smokers were part of this sample, their recruitment was incidental. Further qualitative research 
specifically targeting smokers and exploring their attitudes toward medications for smoking 
cessation would complement this research. It is important that qualitative research about 
smoking continues to be conducted in order to capture the complexity of public beliefs around 
smoking and quitting. It is also important that this research be conducted at multiple timepoints 
in order to explore changes in public discourse about smoking in the face of new treatment 
developments and continued promotion and increased availability of medical aids for smoking 
cessation. 
 
 
 
 Concluding remarks on Chapter 5 
This paper revealed that medications for smoking cessation are widely acknowledged as an 
appropriate treatment for smoking, but are not seen as magic bullets for quitting. Medications 
for smoking cessation are seen as one method among many, and are seen as particularly suitable 
for those who find it difficult to quit unassisted. Unassisted quitting was typically viewed 
positively, and associated with traits such as willpower and personal strength.  
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One of the features of biomedicalisation is that it places a moral responsibility on each 
individual to constantly assess and address their own risk factors and health status (Clarke, et 
al, 2003. The individual is judged morally responsible for illnesses that are deemed preventable 
(Lupton, 1993). As smoking is a key risk factor for many serious diseases, there is significant 
moralising around cigarette smoking, to the point where advertisements shaming smokers have 
been recommended as a strategy to encourage quit attempts (Amonini et al, 2015). For those 
interviewed for this study, this focus on individual responsibility was central to narratives about 
smoking cessation. The individual was deemed responsible for making a decision to stop, and 
this was associated with cultural beliefs about self-sufficiency, personal strength and 
willpower. Less emphasis was placed on how someone stopped and it was thought that the best 
method would “depend on the person.”  
 
While a medical approach was rarely rejected outright, medications were generally seen as 
insufficient on their own for dealing with nicotine addiction. The role of motivation and desire 
to quit were central to public talk about smoking cessation. It was felt that if an individual was 
not “ready” to quit, then any attempt would be unsuccessful, regardless of the method used. 
This suggests that the individualisation described in works on the social science of biomedicine 
can be dissociated with the process of medicalisation. In relation to smoking at least, an 
emphasis on taking personal responsibility for one’s health does not necessarily mean engaging 
with a medical model of treatment. It is perceived as more about motivation than means.  
 
The results from this study suggest that, contrary to concerns outlined in Chapter 1, a medical 
view of smoking cessation does not predominate in discussions about smoking cessation with 
the Australian public. A more complex discourse exists in public talk about smoking cessation. 
The medicalisation of smoking has occurred to some extent, but older discourses of habit, 
readiness to quit, and willpower remain dominant in lay understandings of smoking and 
quitting. This may limit the uptake of smoking cessation pharmacotherapies in Australia. 
However, as medical technologies develop, and neuroscience knowledge about how nicotine 
works in the brain is more widely disseminated, it is possible that increasing expectations will 
be placed on smokers to use existing or emerging medical treatments. This possibility will be 
discussed further in forthcoming chapters.  
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 Original contribution of Chapter 5 
There is little qualitative research conducted in Australia that explores public attitudes towards 
treatments for smoking cessation, and the research reported in this chapter begins to address 
this gap. As new medical treatments for smoking cessation become available, and public 
portrayals of smoking change over time, it is important to monitor the shifting attitudes towards 
smoking and cessation. Lay attitudes towards smoking have changed drastically over decades, 
leading to reduced smoking prevalence and an increased stigmatization of smoking.  Chapter 
1 described a shift from smoking being portrayed as a “bad habit” that can be overcome with 
willpower, to a “nicotine addiction” that should be treated by medical professionals. This 
research reveals that even when smoking is described as nicotine addiction, the former view of 
smoking still holds much sway in public discourse. Lay understandings of smoking and quitting 
amongst the general public draw strongly on cultural beliefs about self-sufficiency, personal 
strength and willpower. Medications are seen as suitable for those lacking in these typically 
admired traits. Rather than being dismissed or wholeheartedly accepted, medications for 
smoking cessation are incorporated into already circulating ideas about smoking and nicotine 
addiction. This is consistent with Nancy Campbell’s assessment that the impact 
of medicalisation on addiction has been limited because addiction is a “hybrid cultural 
construct that conveys sociocultural meanings that persist in ways that work against full 
bio/medicalization.” (Campbell, 2012, p. 6). 
 
Exploring public attitudes towards addiction is important because such attitudes are part of the 
social climate in which smokers make decisions about whether and how to quit. Examining 
public attitudes can indicate the uptake of messages from the media and policy statements. 
While some smokers participated in this study, their recruitment was incidental. Chapter 6 will 
outline the results of qualitative research conducted with a sample of Australians who smoke 
daily about their views on a variety of quitting methods, including medications and unassisted 
quitting. 
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Chapter 6. Why don’t smokers want help to quit? A qualitative study of 
smokers’ attitudes towards assisted versus unassisted quitting  
 
The previous chapter reported on qualitative data from interviews with members of the general 
public. While some current smokers were included in this sample, their recruitment was 
incidental. This chapter reports data from Study 2, a qualitative study that involved semi-
structured interviews with current daily smokers. The data reported here looks at the attitudes 
of these current smokers towards assisted versus unassisted quitting. Assessing views about 
medications for smoking cessation amongst smokers provides further insight into the degree 
that smoking has become medicalised in Australia. There is little qualitative research on 
Australian smokers’ views on specific quitting methods. Some studies have examined attitudes 
towards assisted and unassisted quitting in Australia (Balmford & Borland, 2008; Hung et al., 
2011) but these are quantitative studies that do not reveal the factors that smokers consider 
when making judgments about quitting methods. In addition, the majority of these survey 
studies on smoking cessation do not gather data on attitudes towards unassisted quitting (Smith, 
Chapman, & Dunlop, 2013). As demonstrated in the previous chapter, attitudes towards 
quitting with medication are often constructed in light of existing ideas about quitting “cold 
turkey”. Therefore neglecting to ask about this quitting method is a serious shortcoming of 
many studies on smoking cessation.  
 
A recent exception is a study by Smith and colleagues (2015)2. They conducted qualitative 
interviews with Australian former smokers who had quit without assistance on theirs views of 
assisted and unassisted quitting. Not surprisingly, those who had successfully quit unassisted 
had positive views of this method. They also found that people chose to quit unassisted held a 
strong belief that quitting was a personal responsibility, thought that quitting unassisted more 
closely aligned with their identity as a smoker, and stated that quitting without assistance was 
a rational choice based on an assessment of the costs of benefits associated with different 
methods. As only smokers who had quit without assistance were included in their sample, we 
cannot apply these findings to all smokers and former smokers. There may also be a 
retrospective bias, whereby the difficulty of quitting unassisted is minimised by those who have 
                                                 
2 Data collection for the Smith et al (2015) study began in December 2012 and was completed in December 2013. 
The data that makes up this thesis was collected between October 2012 and July 2013.  
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been successful. Another possibility is that those who are successful at quitting unassisted may 
be those who had less difficulty quitting due to lower nicotine dependence.  
 
The remainder of this chapter contains a paper published in 2015 in the International Journal 
of Environmental Research and Public Health. The paper reports results from in-depth 
interviews with Australian daily smokers, exploring their views and experiences of a variety 
of quitting strategies, including nicotine replacement therapy (NRT), prescription medications, 
counselling, self-help materials and unassisted quitting. The aim was to evaluate claims that an 
increasing emphasis on assisted cessation will lead to a concomitant decrease in positive 
attitudes towards unassisted quitting. Have smokers come to see unassisted quitting as too 
difficult? Do they view quitting with medications as the best way to quit? This study also 
provides insight into the way that smokers’ views about cessation strategies are formed. 
Attention is given to the justifications and examples provided by participants to explain their 
inclination or disinclination to use certain cessation methods.  
 
Citation: Morphett, K., Partridge, B., Gartner, C., Carter, A., & Hall, W. (2015). Why don’t 
smokers want help to quit? A qualitative study of smokers’ attitudes towards assisted vs. 
unassisted quitting. International Journal of Environmental Research and Public Health, 
12(6), 6591-6607.  
 
 
 
Abstract: The development of prescription medication for smoking cessation and the 
introduction of evidence-based guidelines for health professionals has increasingly medicalised 
smoking cessation. There are debates about whether medicalisation is a positive development, 
or whether it has devalued unassisted quitting. In this debate the views of smokers have been 
neglected. This study explored the attitudes of smokers towards a range of quitting methods, 
and their considerations when judging their value. We conducted semi-structured interviews 
with 29 smokers and analysed data using thematic analysis. The results show that the perceived 
nature of an individual smoker’s addiction was central to judgments about the value of 
pharmacological cessation aids, as was personal experience with a method, and how well it 
was judged to align with an individual’s situation and personality. Unassisted quitting was 
often described as the best method. Negative views of pharmacological cessation aids were 
frequently expressed, particularly concerns about side effects from prescription medications. 
91 
 
Smokers’ views about the value of different methods were not independent: attitudes about 
cessation aids were shaped by positive attitudes towards unassisted quitting. Examining 
smokers’ attitudes towards either assisted or unassisted quitting in isolation provides 
incomplete information on quitting preferences.  
 Introduction 
Smoking cessation has become increasingly medicalised since the introduction of nicotine 
replacement therapy (NRT) in the 1970s. More recently, increased knowledge about the 
physiological mechanisms of nicotine dependence have led to the development of new 
medications, such as varenicline, that increase the chances of successful cessation (Cahill, 
Stevens, Perera, & Lancaster, 2013; Hartmann-Boyce et al., 2013). Clinical guidelines now 
encourage health professionals to identify smokers and facilitate quit attempts by prescribing 
pharmacological cessation aids and/or referring smokers to counselling services (Fiore et al., 
2008; National Institute for Health and Clinical Excellence, 2008; Zwar et al., 2014). A recent 
commentary has called for treatment to be provided to all smokers who attend a health provider, 
not just those who express readiness, or an interest in quitting (Richter & Ellerbeck, 2014).   
 
A number of commentators have been critical of this medicalised approach to smoking 
cessation. Some have concluded, based on population-based observational studies, that 
pharmacological cessation aids are no more effective than no treatment (Alpert et al., 2013). 
Others have argued that while pharmacological treatments have demonstrated efficacy in 
clinical trials, these individually focused treatments have not significantly reduced smoking 
prevalence (Pierce et al., 2012; Smith et al., 2013). It has also been suggested that the promotion 
of cessation aids by pharmaceutical companies may imply that quitting without formal 
assistance is more difficult than it is, thereby undermining smokers’ willingness to try to quit 
and their belief in their ability to stop (Chapman & MacKenzie, 2010; Pierce et al., 2012; Zhu 
et al., 2012) Chapman and McKenzie argue that unassisted quitting, or “cold turkey”, has the 
greatest impact on reducing smoking prevalence and accordingly should receive greater 
clinical and research attention (Chapman & MacKenzie, 2010). 
 
This debate has implications for public health messages about how smokers should quit, and 
how smoking cessation is discussed in clinical interactions. Should people who smoke be told, 
as has been recently suggested, that they have a “chronic, relapsing disease”? (Wolff, Hughes, 
& Woods, 2013). Should they be informed that it is difficult to quit and relapse is likely? Do 
92 
 
we want them to believe that smoking cessation requires treatment by a health professional? 
Or should they be informed that the majority of people quit unaided; that quitting is often easier 
than anticipated; and that with motivation and willpower, they can quit on their own?  
 
The aim of this paper is not to conclusively answer these questions, but to explore how smokers 
themselves evaluate, and deliberate on, different methods for quitting smoking. Public health 
researchers have long recognised and examined the influence of lay beliefs about health and 
illness on health-related behaviours such as treatment choice and adherence (Lawlor, Frankel, 
Shaw, Ebrahim, & Smith, 2003; Milburn, 1996; Popay & Williams, 1996). For example, Horne 
and Weinman and Hankins (1999) found that treatment adherence was predicted by the 
difference between beliefs about the necessity of treatment and concerns about side effects. 
Research conducted with smokers on their beliefs about smoking cessation has typically 
surveyed their attitudes towards specific quitting methods, usually with the aim of identifying 
barriers to the use of pharmacological cessation aids. These studies have shown that smokers 
often display negative attitudes towards pharmacologically assisted cessation and express 
concern about their safety and efficacy (Ferguson et al., 2011; Gross et al., 2008; Mooney et 
al., 2006). Not surprisingly, these negative perceptions predict a lower intention to use 
pharmacotherapies and poorer adherence in those smokers who do use them (Bansal et al., 
2004; Etter & Perneger, 2001; Fucito et al., 2009; Shiffman et al., 2008).  
 
Quantitative research on perceptions of safety and efficacy may provide an incomplete view of 
the factors that smokers consider when making choices about how to quit. In addition, few of 
these studies have examined views on the most common method that people use to quit: “cold 
turkey” or quitting unassisted. A systematic review of the Australian literature on how smokers 
quit found that only 19 of 185 studies included data on unassisted quitting (Smith et al., 2013). 
A recent study that did include data on unassisted quitting found that NRT and prescription 
medications were rated as helpful by those who had used them. However, unassisted quitting 
was used substantially more often than either, and also rated as helpful (Hung et al., 2011). 
 
Qualitative research may provide a more nuanced account of smokers’ attitudes towards 
treatment for smoking.  For example, smokers have reported that NRT did not reduce their 
cravings and that they were concerned about becoming addicted to it (Bott, Cobb, Scheibmeir, 
& O'Connell, 1997; Vogt et al., 2008). Also, NRT was not seen to address the critical role of 
willpower in quitting smoking, or the ways in which cigarette smoking was intertwined with 
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routine and social aspects of everyday life (Wiltshire et al., 2003). Many young smokers felt 
they did not require NRT because they did not see themselves as physiologically addicted 
(Amos et al., 2006).  
 
While the existing qualitative research has provided insight into smokers’ thoughts about 
quitting in general, there is little that has compared smokers’ views about multiple different 
quitting methods. This paper addressed this gap by providing a nuanced view of (1) smokers’ 
attitudes towards assisted and unassisted quitting, and (2) the factors that smokers take into 
account when evaluating and comparing different methods of quitting.  
 
 Method 
Semi-structured interviews were conducted with 29 daily smokers aged 18 years or over from 
a large metropolitan Australian city. We employed purposive sampling in order to document 
the breadth of ideas about quitting methods. Prior to the interview commencing, a short survey 
with questions about demographics and smoking history was completed by participants (see 
Appendix C). The recruitment strategy was periodically adjusted as required to obtain a 
“maximum diversity” sample in relation to age, sex, education, and socioeconomic status 
(Patton, 1990). For example, flyers were distributed to neighbourhood community centres in 
order to recruit socially disadvantaged smokers. A university mailing list was employed to 
recruit university educated smokers, and a seniors database used to recruit older participants. 
Other methods included handing out flyers in person, advertising via an online classified site, 
and placing the adverts on community noticeboards. We judged that thematic saturation had 
been reached at 29 interviews, when a sufficiently diverse sample had been obtained and no 
new themes were emerging from ongoing analysis. Participants were provided with a gift 
voucher in appreciation for their time. All recruiting and interviewing was conducted by KM 
between October 2012 and July 2013.  
 
The interview questions reported here are a subset from a larger project about neurobiological 
understandings of nicotine addiction. Participants were asked about their attitudes toward 
various methods for quitting smoking, specifically: “What is your view on the following 
methods for people trying to quit?” This initial exploratory question was designed to elicit 
unprompted views about the methods, in order to ensure a space for emergent themes. Prompts 
were then provided where appropriate. Example prompts were: “Do you have any experience 
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using [insert method]? Do you think it is safe? Do you think it is effective? Participants were 
asked what method they would choose if they were to make a quit attempt and why; and were 
asked to describe any previous quit attempts.  
 
All participants were asked about each of the following methods for quitting: 1) no treatment 
(prompt: cold turkey); 2) nicotine replacement therapy (prompt: gum, patches); 3) prescription 
medication (prompt: Champix, Zyban); 4) counselling, including the Quitline; and 5) self-help 
materials (prompt: books, information pamphlets). We also asked whether participants had 
thoughts on any other methods not mentioned.  
 
Interviews were recorded and transcribed verbatim. They ranged in length from 25 minutes to 
one hour and 20 minutes. The confidentiality and anonymity of participants was maintained at 
all times through adherence to standard ethical procedures (National Health and Medical 
Research Council, 2007). All participants provided informed consent and the study was 
approved by the Human Research Ethics Committee of The University of Queensland.  
 
We employed thematic analysis, as described by Braun and Clarke, to analyse the data (Braun 
& Clarke, 2006). Thematic analysis has been described as the most useful method for 
“capturing the complexities of meaning within a textual data set.” (Guest, MacQueen, & 
Namey, 2012) and it is well suited to exploratory studies using interview data. An inductive 
approach was utilized, whereby KM developed descriptive codes based on patterns observed 
in the data and conducted a critical analysis of these codes in order to collate them into major 
themes. Data coding was conducted using NVivo 10 software (QSR International Pty Ltd., 
2010). Another author (BP) read the transcripts and developed themes independently. There 
was good agreement about the themes and any discrepancies were discussed until a consensus 
was reached. In addition, another member of the research team conducted double-coding of a 
subset of data in NVivo in order to ensure that the final coding scheme had adequate reliability.  
 
 Results 
Participants 
Participant demographics are presented in Table 6.1. 
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Table 6.1 - Participant demographics for Study 2 
Demographic Number 
Gender 
   Male 
   Female 
 
15 
14 
Age (yrs) 
   18-25 
   26-40 
   41-54 
   55+ 
 
9 
11 
4 
5 
Highest level of education 
   No formal qualification 
   Secondary school 
  Post-secondary qualifications 
(e.g., trade training) 
   University degree 
 
4 
4 
10 
 
11 
Employment status* 
   Employed 
   Unemployed 
   Student 
   Retired/Pensioner 
 
15 
5 
7 
3 
Cigarettes per day** 
   1-10 
   11-20 
   21-30 
   31+ 
 
10 
11 
3 
4 
*Multiple selections permitted. **Missing data = 1. N= 29. 
 
In order to gain an overview of participant experience with quitting methods, basic data was 
collected in the pre-interview survey about quitting history. Participants were presented with a 
list of methods adapted from the Australian National Drug Strategy Household Survey 
(Australian Institute of Health and Welfare, 2014) and asked to select the methods that they 
had used. Multiple selections were permitted. Four participants reported that they had not 
previously made a quit attempt. The quitting strategies that the remaining participants reported 
having used are listed in Table 6.2. Though NRT was the method that the most participants 
reported having used, a significant proportion of the participants had no direct experience with 
pharmacological cessation aids.  
 
 
96 
 
Table 6.2 - Strategies used on previous quit attempts 
 
  
 
 
 
 
 
 
 
 
 
 
Unassisted quitting 
Unassisted quitting was frequently described as the best way to quit smoking and it was 
participants’ overwhelmingly preferred method for their next quit attempt. A number of 
justifications were provided for this preference. First, there was a belief that if someone had a 
strong desire to quit and was “ready” for it, then assistance would not be required. Desire and 
motivation was seen as the foundation of quitting success:  
You’ve really got to want to do it and have that courage, strength, determination to do 
it. You’ve really got to have that thinking in your mind, this is what I want. I personally 
believe that the mind has a most powerful part in this whole process. (female 55+, 21-
30 cigarettes per day (CPD)) 
This was tied to the belief that cold turkey would only be effective at a time when someone 
had reached a point where they “really wanted” to quit. Many of our participants said that 
willpower, or a strong desire to quit, was a necessary condition for a successful quit attempt. 
However this seemed to imply that that if a person failed in their attempt to quit cold turkey, 
then this meant that they hadn’t really wanted to quit; that they weren’t strong enough; or that 
they didn’t have the right “mindset”. For example, the participant quoted below had stopped 
smoking and relapsed a number of weeks later. She attributes this relapse to not “wanting” it 
enough.  
Because I always imagined if you'd stopped for a few weeks, how would you go about 
having that first cigarette? You would be just like no it's not worth it, but I did. I don't 
even know when it was. It was probably I was out with my friend and I didn't even 
Method Number of 
participants 
 
Discussed smoking and health at home 10 
Contacted the “QUIT” line 3 
Asked your doctor to help you stop smoking 4 
Used nicotine gum, nicotine patch, or nicotine inhaler 11 
Used a smoking cessation pill (e.g., Zyban, Champix) 3 
Bought a product other than nicotine patch, gum or pill 2 
Read “How to Quit” literature 9 
Used the internet to help you quit 5 
Done something else to help you quit?  7 
None of the above 8 
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realise I did it. You know I just - yes. I think if you want, I think that's the main way. If 
you don't want to do it, you're not going to do it.(female, 18-25, 1-10 CPD) 
Another participant implied that his failed quit attempts were due to a lack of internal strength 
or desire.  
It depends how strong you are and how much you want to.  If you are strong, if you 
really want it, you know.  I couldn't do it.  Simple as that, I'm still smoking. (male, 41-
54, 31+ CPD) 
High value was placed on the sense of achievement that was anticipated as a result of quitting 
unassisted. This was more common amongst younger male participants, who saw quitting 
smoking as a challenge or a competition with oneself. Seeking assistance in the form of other 
cessation aids was seen as a “crutch” or a form of “cheating” that would mean you hadn’t won 
against smoking:   
I think it would be more of a trial for myself.  Like a goal setting thing.  I’m a very goal-
orientated person.  If I can go cold turkey that would be like a big achievement for me.  
(male, 18-25, 1-10 CPD) 
The role of personal experience was a salient consideration when participants spoke about 
unassisted quitting. Most participants had tried to quit cold turkey, so could reflect on their 
own experience with this strategy of smoking cessation. As described above, some attributed 
past failures to personal weakness or a lack of desire to quit. There were other participants who 
considered past unassisted quit attempts successful, despite the fact that they had relapsed and 
were still smoking.  
Interviewee:   I'll just determine that I want to quit and I can.  
Facilitator: Why would you use that method now?  
Interviewee: Because I've tried it before and it's working for me. Yeah, so I think that's 
the easiest one. (male, 26-40, 1-10 CPD) 
The experiences of friends and family were sometimes used to justify an inclination or 
disinclination to use unassisted quitting.  
Terrified. I know people who've done it but they've usually gone back to smoking again. 
They've often really struggled. I've seen people be very stressed and distressed during 
the cold turkey. So clearly some are able to do it but it looks pretty difficult. (female, 
55+, 11-20 CPD) 
Despite many stating a preference for quitting cold turkey, it was common to acknowledge the 
difficulties associated with it. Indeed, cold turkey was sometimes seen as both the hardest and 
best way to quit. The major difficulties were attributed to withdrawal symptoms and cravings. 
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Some smokers, particularly those with a history of failed cold turkey quit attempts, thought 
that the method was better suited to those who were stronger or who had more willpower than 
themselves.  
It depends on the person.  I mean some people can do that and some people have the 
willpower or the determination to do it.  They don't need aids but yeah most people 
would.  (female, 26-40, 31+ CPD) 
The perceived level of addiction was another factor participants saw as important for unassisted 
quitting. Unassisted quitting was seen as most suitable for those who were not heavily addicted 
to cigarettes. The participant below equates heavy smoking with dependence. 
I have friends who quit like that, cold turkey, and it worked out pretty well.  But then 
again, they're not those really heavy ones so I guess it works for people like us who 
aren't that hooked on that shit yet. (male, 18-24, 1-10 CPD).  
Assisted cessation 
NRT is the most commonly used pharmacotherapy for smoking cessation. In Australia, the 
cost of NRT is heavily subsidised if participants attend their doctor and receive a prescription. 
Despite this, only four of 29 participants intended to use NRT on their next quit attempt. Cost 
was mentioned as a barrier to the use of NRT by some participants, which could indicate a lack 
of awareness about government subsidisation. However, a more common consideration was 
the individual’s assumption about the nature of a smoker’s addiction. NRT was thought to be 
most appropriate for those with a “physical” or “physiological” addiction. Many described 
themselves as addicted to the act of smoking and saw their addiction as “psychological”, or as 
a habit built into their daily routine. These participants did not necessarily have negative views 
of NRT; but thought it was more suitable for smokers who had a “real” physiological addiction.  
[NRT] might be extremely effective on people who are very physically addicted.  If 
they're psychologically addicted I don't see how it's going to have any effect. (female, 
41-54, 11-20 CPD) 
NRT was seen by some of these smokers as failing to deal with the psychological or routine 
aspects of smoking that they considered central to their dependence.  
I think it could help some people, but still it's because it's such a habit to smoke it's not 
just the nicotine. ... Each cigarette we smoke is the fact of doing it, is having the pack 
in your bag, it's like all those things should be replaced and so probably replacing it 
could help the craving for those people who are very hooked up.  But I don't think it 
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would completely solve the issue and it wouldn’t definitely help 100% to quit smoking, 
there are a lot of other things involved.  (female, 18-25, 1-10 CPD) 
A small number of participants who had experience using NRT acknowledged the role of 
physiological dependence in their smoking and thought that NRT had been effective for them 
because it dealt with the physiological aspect of smoking. It allowed “breathing space” to deal 
with the more habitual, routine aspects of smoking.   
Yeah, I think that does help because it does take away that initial physical withdrawal 
feeling so that you can concentrate on trying to manage the habit part of it.  That, for 
me as I said, it only took a couple of weeks for me to get that clearing out of my system 
and then it was just a matter of trying to manage the ritual habit part of it.  So that 
definitely made it a lot easier. (female, 26-40, 31+ CPD) 
As with unassisted cessation, an individuals’ experience with NRT played a key role in their 
attitudes towards it. Participants rarely reported using NRT as directed. Rather, participants 
were more likely to use NRT short-term during long-haul flights or short-term stays in hospital. 
It was also used by a small number of participants as a one-off “experiment” to see what would 
happen:  
The patches - we've got the patches on and we've just - we'll see if that works. We're 
not trying to give up smoking. I've just left them on there and thought, right I'll have a 
cigarette when I want a cigarette. (male, 41-54, 31+ CPD) 
Personal experience was particularly salient in relation to side effects. Those who had used 
NRT and experienced unpleasant side effects reported that they would not use it again. Even 
hearing about someone else’s experience of side effects was enough to dissuade people from 
using NRT: 
I’m kind of skeptical on all the other stuff - the products on the market to stop it, patches 
and stuff like that.  I’m kind of - I don’t know.  Because I had a friend who used the 
patches and he used to have nightmares and - yeah, stuff like that.  So I’m not too keen 
on it.   (male, 18-25, 1-10 CPD) 
A small number of participants were concerned about developing dependence on NRT. They 
saw dependence on nicotine as a negative state, with there being no essential difference 
between whether they consumed nicotine via smoking cigarettes or via NRT.  
At some point you do need to just stop.  You can't just keep feeding your body this drug 
that you're addicted to, you might as well be smoking. (female, 26-40, 11-20 CPD) 
The prescription medications bupropion and varenicline are publicly subsidised forms of 
pharmacotherapy for smoking cessation in Australia. Approximately one third of participants 
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were unaware of the existence of these prescription medications for smoking cessation. 
Because direct to consumer advertising of prescription medications is not permitted in 
Australia, this is perhaps not surprising. Amongst our participants, those who were older and 
heavier smokers were more likely to be aware of these medications. Those who did know of 
these medications frequently expressed concern about their safety. Cost was mentioned less 
often, perhaps because the fear of side effects dominated considerations of costs. While only a 
few had tried the prescription medications for smoking cessation, many had heard reports about 
adverse side effects from their friends, family or acquaintances. The most commonly 
mentioned were mental health issues and nightmares. These side effects were cited as the main 
reason why most would not consider using prescription medication.  
Then they try and tell me that these medications will stop me smoking although I'll have 
nightmares, I'll have all the other side effects. I heard about one, I can't remember the 
name of it, and my dad had it - reckoned he nearly died.  Made him really sick.  I've 
heard about people having the nightmares and things, so that really makes me question 
what they're giving you other than nicotine.  You might stop smoking, but you're just as 
irritable from not sleeping.  So, I don't know.  I just don't agree with the 
pharmaceuticals.  If you're going to quit, quit. (male, 26-40, 11-20 CPD) 
This dislike of prescription medications for smoking cessation was sometimes an expression 
of a more general dislike of “relying” on any sort of medication. The participant quoted below 
positioned “taking pills” as an extreme measure for smoking cessation, especially when 
quitting without assistance was a realistic alternative. It may be that a “reliance” on medication 
conflicts with the value of self-reliance that many participants identified with.  
I'm really against, not against, but I think like taking pills and taking things like that 
should be done only if it's really needed and as long as I feel like I could do it without, 
it would always be better option than relying on medicine.  (female, 18-25, 1-10 CPD) 
As with NRT, some participants thought that prescription medication would be more suitable 
for “other” smokers with a more serious addiction; they were not inclined to use these 
medicines themselves. Medications were associated with “illness” and “sickness” that heavier 
and older smokers might develop.  
I personally just can't get my head around doing something like a pharmaceutical pill 
or something like that … It seems over the top but I understand that some people who 
are really ill and continue smoking will probably need that. (male, 26-40, 11-20 CPD) 
As with NRT, perceptions of efficacy were also closely tied to the experiences of family and 
friends who had used these medications.  
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…some of my friends have tried both of those and I still find that they're smoking so 
I've seriously questioned that.  Maybe their commitment wasn't strong enough or 
whatever.  But yeah I'm just still hoping for the wonder drug to be out there or 
something. (female, 55+, 11-20 CPD) 
As the quote demonstrates, having sufficient willpower was still perceived as important, even 
when medication was taken. The participant expressed a hope that a “wonder drug” would be 
developed that, presumably, would overcome this need for willpower or sustained effort. 
However, medication was not generally seen as replacing willpower and mindset, which were 
seen as essential ingredients of a successful quit attempt:  
I'd probably have to go to the doctor and ask to go for the Champix or something 
because as I said I'm on patches at the moment, that's not effective.  But I do know that 
I have to change my personal situation so that's helpful and my mindset changes too. 
(female, 55+, 11-20 CPD) 
Interestingly, the few participants who had used prescription medication found it effective and 
reported positive attitudes towards it, despite a subsequent relapse.  
Yeah, I reckon that Champix, like that helped me.  I slowed down so much in the first 
two weeks like from going to 20 a day I might have like one in the morning, one at night 
sort of thing and then maybe, and then a bit further on maybe just one at lunch, that's 
it.  Then I stopped taking it, like I sort of messed up, muddled up and yeah then I just 
started smoking more and smoking more and you go oh, I'm smoking again. But I think 
if I had have continued with it I probably - I want to give it another go, so. (male, 26-
40, 11-20 CPD) 
 
As already described, guidelines for treating tobacco dependence recommend that counselling 
is combined with pharmacotherapy. Few participants in this study reported any personal 
experiences with counselling for smoking cessation. This is despite the widespread promotion 
of Australia’s Quitline: a free, government-funded telephone counselling service that can be 
accessed by any smoker. The number for the Quitline is displayed prominently on all 
Australian cigarette packs, and health professionals are encouraged to refer smoking patients 
to the Quitline. In addition, referral to a counselling service, which is typically the Quitline, is 
a necessary condition for doctors to prescribe subsidised NRT or prescription medications for 
patients. Participants reported a number of negative perceptions of the Quitline, including that 
it was “preaching”, that there was nothing Quitline counsellors could tell smokers that they 
didn’t already know, and that it was scripted and impersonal.  
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Again I think that is completely dependent on the person.  I'm far too stubborn to ever 
listen to anything like that.  I think it would just make it worse if someone was preaching 
to me, which is the way I would see it, whether it was actually like that or not. (female, 
26-40, 1-10 CPD) 
It was common for participants to state a preference for “personal” support from family and 
friends.  
 
A less commonly discussed theme was a lack of interest in counselling. A number of 
participants said that they “weren’t talkers” and therefore were not inclined to use counselling 
to quit smoking. Even those who expressed positive views of counselling were reluctant to use 
it for smoking cessation. Only one person intended to use the Quitline on their next quit 
attempt, and two said that they would use generic counselling.  
 
Participants were also questioned about their views on self-help material such as books, 
pamphlets, and online information. While participants had moderately positive views about 
self-help materials, they did not hold strong views about them. A handful of participants 
described specific materials that they had found useful. The framing of the message was 
described as being important, with some complaining about “scare-mongering” in self-help 
materials. Self-help materials were perceived by a few as insufficient for quitting smoking. 
Others were not interested in them because they did not enjoy reading.  
Could be good, yeah. Depends on individual - if someone is having reading as a hobby, 
could be helpful. People like me who is not really into reading, yeah, could be waste of 
time for me. (male, 26-40, 1-10 CPD) 
 
 Discussion 
We found that smokers’ attitudes towards cessation options were shaped by several factors, 
some of which were consistent across different methods for smoking cessation. Many 
participants believed that the best method for quitting would “depend on the person”. 
Dispositional or character-based factors were often cited when evaluating the potential of a 
quitting method. Unassisted quitting was seen as suitable for those with willpower, strong 
motivation or internal strength. The nature of an individual’s addiction to smoking was also 
seen as important when smokers deliberated about cessation options, as was perceived efficacy, 
which was typically assessed on the basis of their own experience, or that of family and friends. 
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Negative experiences of friends and family were frequently reported, perhaps because such 
experiences are more salient than positive ones.  
 
Practical factors such as cost or side effects were regarded as significant for some quitting 
methods. Cost was mainly mentioned as a barrier to using NRT, less often for prescription 
medication. Side effects were discussed frequently in relation to NRT and prescription 
medication. The number of side effects mentioned by study participants, particularly in relation 
to prescription medication, was higher than what would be expected from epidemiological 
evidence (Gibbons & Mann, 2013; Svanström, Pasternak, & Hviid, 2012). This may be because 
smokers misinterpret nicotine withdrawal symptoms as side effects of smoking cessation 
medications; or because people are more likely to discuss experiences of medication use where 
they have experienced side effects than those in which they haven’t.  
 
Our finding that some participants did not use NRT in accordance with clinical 
recommendations is consistent with evidence from quantitative surveys. The latter have found 
that most smokers do not use NRT as directed and few use a full course of NRT as 
recommended (Balmford et al., 2011). This lack of adherence increases the likelihood that 
withdrawal symptoms will be experienced and perhaps mistaken for side effects.  
 
The fact that not all participants were aware of the existence of prescription medications is not 
surprising given the lack of direct to consumer advertising of prescription medications in 
Australia. Additionally, since one of the indications for the prescription of smoking cessation 
medications in Australia is smoking more than ten cigarettes per day, it should be expected that 
lighter smokers will have less awareness of prescription medications for smoking cessation 
(Zwar et al., 2014). Research in the UK has shown that young and healthy smokers who attend 
their doctors are less likely to be prescribed pharmacotherapy for smoking cessation than older 
smokers with existing health problems (Huang, Britton, Hubbard, & Lewis, 2013). While our 
research was not able to assess this possibility, it may be that different types of smokers are 
being provided with different information about their quitting options by health practitioners.  
 
It is interesting that smokers’ concerns about side effects usually trumped efficacy, especially 
in the case of prescription medications. Even if smokers perceived prescription medication to 
be helpful, this was weighed against the risk of side effects that many decided made the 
potential benefits not worth the risk. The literature on risk perception in smoking shows that 
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the distal nature of the health risks are a deterrent to quitting, particularly for young people, as 
they often hold optimistic beliefs about their ability to quit smoking prior to developing any 
smoking related health problems (Weinstein et al., 2004).  Any side effects from using 
pharmacological cessation aids for smoking cessation are more immediate, and may therefore 
take precedence over the longer-term health risks of smoking. This is consistent with evidence 
on the use of medications more generally, where the difference between the perceived necessity 
of a medication and concerns about its use predict poor medication adherence (Horne et al., 
1999). It is important that future research assessing smokers’ attitudes towards quitting 
methods take their more general views on the use of medications into account in the study 
design. 
 
Beliefs about addiction were influential in our smokers discourse on smoking cessation. For 
example, those who believed that they were not physiologically addicted to nicotine, or who 
did not consider themselves to be “heavy” smokers, did not see pharmacological cessation aids 
as appropriate for them. These participants were more likely to hold positive views about cold 
turkey quitting. This is a complex topic for health practitioners to negotiate. One potential 
implication of this finding might be that smokers need to be educated about nicotine addiction 
in order to convince them that they have a physiological dependence that can be treated using 
medications. However, as Chapman and McKenzie (2010) argue, such an approach may 
unintentionally devalue unassisted quitting, and produce a counterproductive effect in which 
smokers who are told how difficult it will be for them to quit smoking, are less inclined to try 
to quit. Indeed, a recent paper suggests that health practitioners “emphasize the difficulty of 
quitting without assistance” in order to promote uptake of medications for smoking cessation 
(Myers, Strong, Linke, Hofstetter, & Al-Delaimy, 2015). We suggest that a more sensitive, 
tailored approach is employed by healthcare practitioners. Where patients are very averse to 
medications, it would be counterproductive to emphasize the difficulty of quitting unassisted. 
Probing patients about their views on nicotine addiction and their attitudes towards medications 
may aid doctors in designing individualised treatment plans for patients who have tried and 
failed to quit cold turkey on a number of occasions.  
 
Our study shows that smokers evaluate a given method for quitting in light of a range of 
alternatives and contingencies. For example, when thinking about varenicline, smokers might 
think that it will be effective, but believe that the side effects are not worth it. Unassisted 
quitting is seen as a particularly salient alternative to pharmacological cessation aids because 
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it is free, safe and perceived by many smokers to be the most effective way to quit.  This point 
has been neglected in the smoking cessation literature, where smokers’ views on unassisted 
quitting have not often been sought (Smith et al., 2013). Males in particular preferred cold 
turkey quitting because they anticipated a strong sense of achievement from quitting without 
help. The value placed on this sense of achievement from quitting unassisted has been observed 
in another study (Vogt et al., 2008). It may be helpful to take this into account when designing 
interventions aimed specifically at men.  
 
Our research suggests that it was common for smokers to believe that quitting cold turkey will 
only be effective if the smoker is “ready” to quit, and has the right “mindset”. This idea that 
smokers need to be ready to quit has also been prominent in smoking cessation literature and 
programs, thanks to the influence of the transtheoretical model of behaviour change. The 
transtheoretical model posits that individuals pass through a set of ordered stages in their 
journey to behaviour change, and that different interventions are suitable for different stages 
of change. For example, those in the “pre-contemplation” stages are not yet psychologically 
ready to change their behaviour. Interventions aimed at people in this stage are primarily 
informational and aim to increase desire and motivation to move smokers into the next stage – 
contemplating a quit attempt- rather than promoting an immediate attempt to quit. The 
transtheoretical model has been strongly criticized on the grounds that behaviour change is 
more dynamic and complex than the model assumes (West, 2005) and that unplanned, 
spontaneous quit attempts may be more successful than planned ones (Ferguson et al., 2011; 
Medbo, Melbye, & Rudebeck, 2011; West & Sohal, 2006). Moreover, the belief that an 
unqualified desire to quit is required prior to a successful quit attempt has been identified as a 
barrier to making quit attempt (Balmford & Borland, 2008; Richter & Ellerbeck, 2014). Our 
research is consistent with this view, with many smokers stating that they would quit at some 
precise point in the future when they were “ready”. It may be effective for stop smoking 
campaigns to challenge the idea that you need to achieve a “readiness to quit.” Along these 
lines, a recent commentary has recommended that all smokers presenting to their primary 
health physician should be provided with treatment, regardless of their expressed readiness to 
quit (Richter & Ellerbeck, 2014).  
 
The results of this study are also consistent with previous qualitative research in showing that 
smokers consider willpower, strength, and motivation as central to successful quitting 
(Kishchuk, Tremblay, Lapierre, Heneman, & O'Loughlin, 2004; Vogt et al., 2008; Wiltshire et 
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al., 2003). Cessation aids were not perceived as “magic bullets” for cessation. Rather smokers 
emphasised that willpower and personal choice were necessary, even when cessation aids were 
used. This discourse of “willpower” has long been central to lay accounts of smoking. It aligns 
with Western cultural values of free choice and individual strength. It is a view that has been 
heavily promoted by the tobacco industry to argue for fewer government interventions to 
prevent or discourage smoking (White et al., 2013).  
 
Even with the increasing biomedicalisation of smoking cessation, it seems highly unlikely that 
the discourse of willpower will disappear from public discourse on smoking.  Therefore 
incorporating beliefs about willpower into smoking cessation campaigns and clinical 
interactions may be of value. For example, messages that tell people who are using 
pharmacological cessation that willpower is still required may allow successful quitters to 
attain the sense of achievement that was valued by some in our study. It also provides more 
realistic expectations about the efficacy of current pharmacological options. Relatedly, only a 
small minority of participants believed that cessation aids would be necessary and sufficient to 
quit smoking. This finding should allay the concerns of those who fear that the medicalisation 
of smoking cessation will creates a sense of fatalism and decrease smokers’ sense of control 
over their smoking.  
 
The negative views of the Quitline expressed by participants are consistent with evidence of 
low uptake of counselling in general (Kaufman, Augustson, Davis, & Finney Rutten, 2010; 
Miller et al., 2003). This may be of concern, given that counselling is required in conjunction 
with the prescription of pharmacological cessation aids in clinical practice guidelines. Despite 
many acknowledging the psychological and behavioural aspects of smoking, few participants 
expressed an interest in counselling and only one participant intended to use the recommended 
combination of pharmacotherapy and counselling for their next quit attempt. 
 
One limitation of this study was that participants were asked about their views of unassisted 
quitting using the prompt “cold turkey.” Cold turkey is generally taken to mean quitting 
suddenly, rather than gradually cutting down on the number of cigarettes. Cutting down is a 
method of quitting that is commonly used by smokers but we did not directly ask about it. 
Future research in this area should ask about cutting down separately from quitting “cold 
turkey”, or more clearly describe methods of unassisted quitting before questioning 
participants.  
107 
 
 
Lastly, although nicotine replacement products are widely advertised in Australia, there is no 
direct to consumer advertising of prescription medications. It would be useful to examine 
attitudes in countries where direct to consumer advertising for prescription stop-smoking 
medications is permitted (e.g., New Zealand, USA) to see if advertising influences smokers’ 
attitudes towards prescription cessation aids or unassisted quitting.  
 
It should be noted that this was qualitative research and no inferences about the prevalence of 
these beliefs in the larger population of smokers can be drawn. However, these findings provide 
an insight into the range of factors that smokers consider when evaluating quitting methods. 
This information is useful to inform future work in this area. Specifically, smokers’ judgments 
about which methods to use for smoking cessation are not simply based on perceived safety 
and efficacy. They reflect their ideas about the nature of their addiction, how well a given 
method suits their perceived situation and personality, and their own and others’ experiences 
with the method. Their views about different methods are often not independent. For example, 
views about NRT are shaped by very positive attitudes towards quitting cold turkey. Looking 
at attitudes towards assisted or unassisted quitting in isolation may provide incomplete 
information on quitting preferences. It is therefore important that the above-mentioned factors 
are considered when conducting research into treatment preferences for smoking cessation. 
Smokers’ views should be compared across different quitting methods and at the very least, 
include quitting unassisted as a comparator.  
 
 
 Concluding remarks on Chapter 6 
This chapter examined Australian smokers’ views on assisted and unassisted cessation. 
Because these participants were daily smokers, this sample is more likely to have been exposed 
to medical models of smoking cessation than those interviewed in Chapter 5. Current smokers 
are likely to pay more attention to advertisements for smoking cessation medications and to 
have interacted with health professionals where possible strategies for quitting were discussed. 
Despite this, their attitudes largely echoed those of the general public. Unassisted quitting was 
often portrayed as the best method for quitting and it was the method against which other 
methods were judged. Unassisted quitting was frequently seen as convenient, safe, and free of 
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cost. In addition, it seemed to align more closely with many participants’ understandings of 
their smoking as a personal choice that they were responsible for dealing with.  
 
Concerns that the increasing biomedicalisation of smoking will lead smokers to perceive 
unassisted quitting as extremely difficult, and too hard to attempt, were not supported by this 
data. While many acknowledged that quitting cold turkey is difficult, this was usually based 
on past personal experience. Moreover, perceptions of difficulty did not did not seem to lessen 
the appeal of unassisted quitting for many smokers. In fact, for some, particularly males, the 
difficulty of quitting unassisted seemed to contribute to the appeal of unassisted quitting, 
because they anticipated a sense of achievement from using one’s own resources of willpower 
and strength to quit without help.  
 
This is consistent with other qualitative research on lay understandings of health and illness 
that show a disinclination to take or medications or adhere to recommended dosage regimens. 
Pound et al (2005) conducted a synthesis of qualitative studies on “lay experiences of medicine 
taking.” They found that people often “tested” medicines in order to be able to conduct a 
cost/benefit analysis. Patients evaluated a medicine based on side effects, how the treatment 
regime fit into their everyday life, and how well it dealt with any symptoms. There were also 
concerns about becoming dependent on medications. In relation to smoking, this is often seen 
by smokers as replacing one addiction with another (Vogt, Hall & Marteau, 2007).  
 
The fact that the few participants who had used prescription pharmacotherapies in the past had 
positive perceptions of them, despite having relapsed to smoking, could have implications for 
smoking cessation. It may mean that attitudes towards particular medications are not just based 
on long-term smoking abstinence, but may be influenced by other factors such as a reduction 
in the number or strength of cravings, a reduction in the number of cigarettes smoked, or the 
ability to remain abstinent for some period of time. Further research is warranted on how 
smokers evaluate the efficacy of pharmacotherapies as they are using them, and what they 
judge as a successful quit attempt is warranted.  
 
A lack of clarity in the literature of what constitutes assisted versus unassisted quitting presents 
a significant problem. According to Chapman, assisted cessation encompasses 
pharmacotherapy or “any individual or group behavioural or cognitive intervention” (Chapman 
& MacKenzie, 2010, p. 1). However, in another paper speaking to the Quitline on a one-off 
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basis is classified as unassisted quitting, as is the use of stop smoking internet-based 
applications for quitting (Smith et al., 2013). It can be unclear whether a particular quit attempt 
should be defined as assisted or unassisted, and there is variation in studies as to how quit 
attempts are classified (Smith et al., 2013). In the interviews reported here, smokers were asked 
their views on “cold turkey, or unassisted quitting.” However, they were not asked what they 
thought these terms meant. Further research could explore what laypeople define as assisted 
quitting, unassisted quitting, and cold turkey. 
 
For example, the ambiguity about whether use of the Quitline is a form of assisted or unassisted 
quitting was reflected in participant opinions about the Quitline. Participants generally held 
unfavourable opinions about the Quitline. Quitline counselling was viewed as someone telling 
them what they “already knew” or “lecturing” them about their smoking, which they disliked. 
This is likely to be associated with the self-reliance that participants valued, but could also be 
associated with their ideas about authority. Quitline staff are labelled on Quit websites as “quit 
specialists”(http://www.quit.org.au/preparing-to-quit/choosing-best-way-to-quit/quitline), and 
smokers may be uncertain about the background or qualifications of those who staff phone 
lines. By stating that Quitline staff would not be able to tell them anything they didn’t know, 
many smokers were positioning themselves as the authority on their own smoking, and 
questioned the ability of others to offer additional insight or assistance.  
 
Lastly, the presence or absence of free will in drug dependent individuals has long been debated 
in the addiction field (White, 1998). The increasing interest in the neurobiological basis of 
addiction has increased interest in this question. The head of NIDA has stated that drug 
addiction should be understood as a “disease of free will,” (Volkow, 2015), while others argue 
that negating free will is inaccurate and will lead to fatalism amongst addicted individuals 
(Lewis, 2015). In addiction, disease models based on brain science are often associated with 
abstinence-based approaches, while harm reduction approaches acknowledge the existence of 
free will and give drug dependent individuals information about managing their addiction 
(Szott, 2015).  Szott (2015) has shown that health care practitioners who work with injecting 
drug users often combine a disease model that abrogates responsibility from the individual, 
with a harm reduction model that grants them autonomy to make choices about safe drug use. 
The research presented in this chapter with smokers shows that concepts of free will and 
autonomy are the central concepts underlying smokers’ understandings of their own smoking. 
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How these beliefs influence attitudes towards a disease model of nicotine addiction will be 
elucidated in later chapters.  
 
 Original contribution of Chapter 6 
As outlined by Smith and colleagues (2013) there are few studies in tobacco control that 
explicitly examine smokers’ views on unassisted quitting. Furthermore, there is very little 
qualitative research on their views on prescription medications for cessation. This study begins 
to address these gaps in the current literature on smoking and cessation. In relation to unassisted 
quitting, evidence has been presented in this chapter that some smokers do not see themselves 
as having a physiological addiction to nicotine, or see this as only a small part of the reason for 
their continued smoking. These smokers reject a medical approach to smoking cessation and 
state a preference for unassisted quitting, which is seen as convenient, cheap and appropriate 
for their “type” of addiction. Attitudes towards prescription medication tended to be negative. 
There were strong concerns about the safety of these medications, and most participants 
thought they should be used as a last resort. Interesting, the few participants who had used 
prescription medications found them helpful, despite the fact they had not led to long-term 
cessation.  
 
After eliciting their views on quitting strategies and experiences, the same participants were 
questioned more deeply about their understandings of addiction; in particular, their views about 
the idea that their smoking is due to physiological changes in the brain from smoking that 
represent nicotine addiction. The remainder of this thesis explores smokers’ ideas about the 
role of their brain in their addiction to smoking, and the potential implications for cessation 
strategies, particularly the use of medications for cessation. 
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Chapter 7. A qualitative study of smokers’ views of brain-based 
explanations of tobacco dependence. 
 
Chapter 2 described a recent development in the biomedicalisation of smoking cessation: the 
development and promotion of the brain disease model of addiction (BDMA). Up until 
recently, the BDMA has not been applied to smoking in the same way as it has been to alcohol 
and dependence on illicit drugs. But as was demonstrated in Chapter 3, there is an increasing 
emphasis on the role of the brain in health promotion materials about smoking, pharmaceutical 
company advertisements for cessation pharmacotherapy, and media reporting on smoking. 
Academic and institutional definitions of smoking are beginning to incorporate the idea that it 
is a “chronic disease”, and that the primary feature is the brain’s reliance on nicotine. While 
previous qualitative literature outlined in Chapter 3 has found some evidence that physiological 
explanations of smoking as a nicotine addiction do not dominate lay understandings of 
smoking, more recent evidence is required as scientific understandings of smoking move 
towards a biological conception that focuses on addiction to nicotine, and the neurological 
mechanisms by which this occurs.  
 
While some have been enthusiastic about the potential for brain-based explanations of 
behaviour to alter societal and individual attitudes towards drug use, empirical evidence thus 
far does not support these claims (O’Connor & Joffe, 2013). It is important to assess how lay 
understandings may be influenced by neurobiological ideas in specific fields. This chapter 
explores how the sample of smokers described in Chapter 6 view the role of their brain in their 
smoking, and evaluates the potential for brain-based explanations of addiction to lead to 
increased feelings of fatalism, decreased stigma, and more positive attitudes towards 
medications in smokers, as has been hypothesised in the academic literature outlined in Chapter 
3.  
 
The majority of this chapter is comprised of a paper that was published in The International 
Journal of Drug Policy in 2016, with a conclusion summarising the implications for this thesis.  
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Abstract 
Background: The role the brain plays in the creation and maintenance of tobacco dependence 
has become increasingly prominent in explanations of smoking that are presented to the public. 
The potential for brain-based explanations of smoking to influence smokers’ understandings 
of their addiction, their sense of self-efficacy, and perhaps even their treatment preferences, 
has been raised by some working in the addiction field. However, little empirical evidence 
exists in this area. Methods: This paper reports on semi-structured interviews with 29 daily 
smokers. Participants were shown a brief presentation about the neuroscience of nicotine 
dependence. They were then queried about their awareness of the role of the brain in smoking, 
and the consequences of this knowledge for their understandings of smoking and their 
treatment preferences. Results: Our results indicated that many participants displayed some 
awareness of the link between the brain and addiction. While there was a diversity of ideas 
about the potential impacts of neuroscience knowledge about smoking, there was an overall 
tendency to maintain pre-existing treatment preferences, and to assert individual responsibility 
for smoking. Emergent themes that arose were the brain as a special organ, the discourse of the 
“other” smoker, and the distinction between physical and psychological facets of addiction. 
Conclusion: While brain-based explanations of smoking are unlikely to revolutionise lay 
understandings of smoking, neuroscience information should be presented in a way that does 
not negate people’s sense of agency and self-efficacy in relation to quitting smoking.  
 
 Introduction 
Public portrayals and perceptions of cigarette smoking have changed dramatically in recent 
decades. There has been a shift from the idea that smoking is a habit to the idea that it is an 
addiction, and more recently, an addiction located in the brain. This paper examines the 
attitudes of smokers toward brain-based understanding of addiction to smoking, and the ways 
they interpret its relevance for their everyday practice of smoking.  
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Neuroscience research has provided strong evidence demonstrating the addictive nature of 
tobacco smoking. This research has focused mainly on the role of nicotine, and has revealed 
that nicotine produces behavioural reinforcement by binding to nicotinic acetylcholine 
receptors in the brain, thereby influencing dopamine release in the brain’s mesocorticolimbic 
reward circuit (Benowitz, 2010; De Biasi & Dani, 2011). The brain’s stress system is also 
affected by chronic nicotine administration in ways that may contribute to the withdrawal 
symptoms such as anxiety and irritability that many smokers experience on cessation 
(Bruijnzeel, 2012). At the molecular and cellular levels, plastic changes in the brain, such as 
changes in synaptic connectivity and the regulation of gene expression, occur with repeated 
nicotine use and are associated with the development of the clinical signs of addiction: craving, 
withdrawal, and tolerance (Govind et al., 2009; Govind et al., 2012; Peng et al., 1994).  
 
The general news media regularly report on neuroscientific research, often uncritically, but it 
is difficult to evaluate the extent to which the public have been exposed to or accept these 
findings.  Articles have appeared in the mainstream media with titles such as “Nicotine takes 
control of brain” (Fewster, 2002, June 11) and “Quitting is a brain game” (Author not 
attributed). The public have also been exposed to brain-based explanations of smoking via 
advertisements for smoking cessation medications. An Australian campaign by Pfizer is headed 
with the phrase “Break the hold nicotine has over your brain” (Pfizer, 2015). Additionally, 
influential institutions in the USA have begun to define addiction as a “brain disease” or “brain 
disorder.” For example the National Institute of Drug Abuse (NIDA) describe addiction as a 
“chronic, relapsing brain disorder” (National Institute on Drug Abuse, 2007) and the American 
Association for Addiction Medicine define it as “a primary, chronic disease of brain reward, 
motivation, memory and related circuitry” (American Society for Addiction Medicine, 2015). 
An emphasis on how drugs affect the brain is evident in much of NIDA’s public education 
material, including that on smoking (National Institute on Drug Abuse, 2006).  
 
The veracity of the “brain disease model” has been critiqued at length in the academic literature 
(Courtwright, 2010; Hall, Carter, & Forlini, 2015; Russell & Davies, 2009). Our goal here is 
not to address the “reality” of the claim, but to anticipate its potential social implications, 
specifically its effects on smokers’ understandings of their own smoking behaviour. A number 
of claims have been made about how an emphasis on the role of the brain could influence the 
way addicted individuals understand their addiction and the best ways to quit. Proponents 
believe that it will reduce the stigma associated with addiction, thereby increasing treatment 
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seeking, and also that it will lead to the development of more efficacious and technological 
treatments (Dackis & O'Brien, 2005; Gardner, Tapper, King, DiFranza, & Ziedonis, 2009; 
Leshner, 1997). Others however, express concern that the BDMA could reduce feelings of 
individual responsibility for tobacco smoking or other substance use and undermine addicted 
individuals’ beliefs in their ability to stop using or their willingness to try. In the case of 
smoking, critics are concerned that quitting self-efficacy will be reduced if smokers are told 
that they require medical treatment due to a biological “need” to smoke (Caron et al., 2005) 
and hence that medicalisation of smoking may reduce unassisted quit attempts (Chapman & 
MacKenzie, 2010). Conversely, some believe that new smoking cessation treatments will be 
viewed as “magic bullets”, with smokers becoming overly optimistic about the potential for 
medical treatments to “cure” their addiction to smoking (Dingel et al., 2011).  
 
These can be seen as examples of a wider concern about the influence of “brain talk” on 
subjectivity and identity. Nikolas Rose believes that neuroscientific discourses of human 
behaviour are creating “neurochemical selves” (Rose, 2003). That is, individuals are coming 
to understand their identity and behaviour as mediated by chemical occurrences in their brain. 
Sociological accounts of addiction have problematised such an emphasis on biology. They 
have noted the power relations inherent in reductive biomedical accounts of addiction, and 
prefer to describe drug use as a rational response by social actors (Weinberg, 2011). But as 
Weinberg has noted, in doing so, some sociological work on addiction has downplayed the 
sense of “viscerally felt compulsion” that is evident in the accounts of those who describe 
themselves as addicted to drugs (Weinberg, 2002). Weinberg recommends a post-humanist, 
empirical approach to addiction that acknowledges the “local practice” of addiction as an 
embodied experience (Weinberg, 2002, p. 2013).   
 
There is little empirical research examining the psychological or behavioural impact of 
neurobiological understandings of nicotine addiction on smokers. A survey study by Hughes 
(2009) found that many smokers believed that an inability to quit smoking was due to addiction, 
but only a small proportion believed that biological factors were to blame. Hughes also found 
that smokers’ causal beliefs were not strongly related to treatment preferences. He 
recommended that qualitative research be conducted in order to explore in more depth 
smokers’ understanding of the causal determinants of addiction and their treatment preferences. 
Research from the genetics field has looked at the impact of genetic understandings of tobacco 
addiction on smokers’ sense of control and treatment preferences (Cappella et al., 2005; Park 
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et al., 2011; Wright et al., 2003), however mixed findings and variations in study design mean 
that no clear conclusions can yet be drawn from this data. Moreover, it remains to be seen if 
people will respond to genetic and neuroscience information in similar ways, given important 
differences between the two (Green 2006). 
 
This paper will report on qualitative research examining how smokers interpret and apply 
information about the brain and addiction to their own lived experiences as smokers. The aims 
are to:  
 Explore the extent to which smokers believe their brain is involved in their smoking 
behaviour; 
 Document the ways that smokers incorporate neurobiological explanations of 
addiction into their mental models of smoking; and 
 Assess the ways in which brain-based understandings of addiction might influence 
smokers’ sense of self-efficacy and their treatment preferences.  
 Method 
The data reported here are drawn from the initial qualitative component of a mixed-methods 
study examining neurobiological understandings of smoking and addiction. For this qualitative 
stage of the research, semi-structured interviews were conducted with 29 participants who 
smoked daily. Participants were recruited from a large metropolitan city in Australia. Because 
this was an exploratory study, purposive sampling was used in order to recruit a diverse range 
of participants in relation to age, gender, and education. The technique of maximum variation 
sampling was employed, with periodic reviews of the sample in order to ensure diversity 
(Patton, 1990). Means of recruitment included handing out flyers, advertising on mailing lists, 
and placing flyers at community centres and on noticeboards.  
 
Participants were interviewed at a location that suited them and provided with a gift voucher 
in appreciation of their time. Interviews were conducted individually, except in one case where 
two relatives attended together and were interviewed concurrently. In order to introduce the 
type of research that exists on smoking and the brain, we prepared a short audiovisual 
presentation outlining findings on how tobacco works in the brain and its relationship to 
nicotine dependence. This was shown to participants on a tablet device during the interview. 
As NIDA are a major proponent of the brain disease model of addiction, the information we 
included in the slideshow was adapted from their publication aimed at teenagers titled “Mind 
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Over Matter: The brain’s response to nicotine” (National Institute on Drug Abuse, 2006). This 
is a colourfully illustrated pamphlet which provides information about how tobacco works in 
the brain to produce addiction in easy to understand language. The fact that we provided 
information framed as “scientific” to stimulate discussion about the brain and smoking 
inevitably influenced the responses of participants to the questions that followed. In some cases 
it provoked discussions about the trustworthiness or otherwise of science and scientists. Also, 
we presented a “strong” version of the neurobiology of addiction, where the complexity of the 
interactions of neurobiology with other factors was not discussed. This method of providing 
what might be labelled a “short science explainer” for participants has been used in other 
studies to introduce a potentially unfamiliar topic to participants and to provide a stimulus for 
discussion (Buchman et al., 2013; Choudhury et al., 2012; Horstkötter, Berghmans, Feron, & 
De Wert, 2014). This method of eliciting participant responses to the same information can 
reveal the idiosyncratic ways that such information is interpreted and applied. 
 
After viewing the presentation, participants were asked a series of questions about the role of 
the brain in smoking behaviour. While the interview guide allowed flexibility in questioning 
and sometimes varied according to the trajectory of individual interviews, typically the 
following questions were asked:  
 Were you aware of the ways in which nicotine acts on the brain? If so, where did you 
hear about it?  
 To what extent do you think that smoking affects your brain?  
 How does this information influence your understanding of your smoking?  
 Does it make stopping smoking seem easier or harder? How does it affect your belief 
in your ability to stop smoking?  
 Does it affect your view of your personal responsibility for smoking? How? 
 Does this information affect your view on the best method for quitting?  
These interview questions were based on themes found in the literature on the effect of 
biological explanations on lay understandings of behaviour, as well as data from a previous 
study that looked at how members of the general public responded to information about the 
brain’s role in addiction (Meurk, Hall, et al., 2013). The University of Queensland Human 
Research Ethics Committee granted ethics approval for this study.  
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The framework of thematic analysis was used to analyse the interview data (Braun & Clarke, 
2006). Patterns observed in the data were labelled as codes using the NVivo 10 software (QSR 
International Pty Ltd., 2010) by the first author (KM). Another author (AC) independently 
developed codes after reading a selection of transcripts. A consensus approach was utilised, 
where differences in codes and themes were discussed and negotiated until a consensus was 
reached about the final coding scheme. KM then conducted a critical analysis of the coding 
scheme in order to collate the codes into the major themes that are presented here.  
 
 Results 
Participants 
We recruited 29 participants who were evenly distributed in relation to gender (M=15, F=14). 
Most participants were in the middle age ranges, with fifteen participants aged 26-54, nine 
younger participants (18-24 years olds) and five participants older than 55. Eleven had 
completed a university degree, ten had completed a trade certificate or diploma, four had 
completed secondary school and four had not finished secondary school. With regard to 
heaviness of smoking: seven participants were heavy smokers, smoking more than 20 
cigarettes a day (CPD); 11 smoked 11-20 CPD; and ten smoked 1-10 CPD (missing n=1). The 
Heaviness of Smoking Index (HSI) was calculated to measure the tobacco dependence of 
participants (Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991). Each participant quoted 
below is categorised as having low, medium or high dependence based on the following cut-
offs: 0-1: low dependence, 2-3: medium dependence, 4-6: high dependence (Balmford et al., 
2011). Based on these categories, 10 participants were highly dependent on nicotine, nine were 
moderately dependent, and 9 had low dependence. We were unable to calculate the HSI for 
one participant due to missing data.  
 
Awareness of neurobiological aspects of nicotine addiction 
Much of the speculation about the psychological impact of brain-based explanations of 
addiction assumes that people are currently unaware that their brain is involved in their 
addiction. They posit that neurobiological understandings of addiction will constitute an 
important change in the way that addiction is understood. Contrary to this claim, most 
participants reported that they were already aware that smoking influenced their brain. For 
them, the information presented about the neurobiological basis of addiction to smoking was 
not surprising, shocking or revolutionary.  
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“I knew it goes to the brain and it activates something, but I just wasn’t aware 
of the terminology and things like that.” [Male, aged 26-40, low dependence]  
Only a small minority of participants reported having no knowledge that smoking affected the 
brain.  
“I did not realise that – I thought it was sort of more your lungs that it was 
related to, not your brain, if that makes sense.” (female, 26-40, medium 
dependence) 
Similarly, another young woman stated that: “because I always assume drugs messes your 
head, whereas smoking was purely like physical, you know like lungs and heart and throat and 
stuff” (female, 18-25, low dependence). This participant separates nicotine from other drugs by 
emphasising the physicality of smoking and the involvement of other (non-brain) parts of the 
body, in contrast to the mind-altering nature of illicit drugs. Because the psychoactive effects 
of nicotine are mild, and regular smokers do not experience any obvious intoxication, the brain 
does not become central in accounts of smoking.   
 
For the majority of participants their knowledge of this link between nicotine addiction and the 
brain was often “fuzzy” or “vague” and most could not cite a specific source from which they 
had acquired this information. Their discussions about the role of the brain in smoking were 
characterised by qualifiers and filler words such “something” and “things like that”. Terms 
such as “chemicals” and “receptors” were used in imprecise ways. The role of nicotine was not 
well understood. Some smokers thought that nicotine was a depressant because they felt 
relaxed after smoking. Others thought that nicotine was responsible for the negative health 
effects that have been attributed to tobacco smoke. Only a handful of participants, mainly those 
who had studied biological science at university level, demonstrated a more sophisticated 
knowledge about how nicotine works in the brain. So while many participants knew the brain 
was somehow involved in addiction, few understood how it was involved.  
Like say with caffeine you get a headache and whatever so you sort of know all 
that. I wouldn't go into the technical bit with the receptors and all that lot but 
pretty much you've got to keep your levels. (male, 26-40, medium dependence) 
It was common for participants to state that the details about the way nicotine worked in the 
brain to produce dependence were “interesting”, or that this information offered an “insight” 
into their smoking.  
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I guess it clarifies exactly what processes are going on inside your body in terms 
of why it gets a hold of you.  Why it has that addictive properties.  Why the 
withdrawal then happens and it's similar to things that I've heard of before.  It's 
just massive over-stimulation of receptors then leads to them being so deadened 
that nothing affects them anymore.  So you need to just keep going and keep 
going and keep going.  It's basically understanding that physiological process 
makes it a bit clearer, but I still think that it is a choice to start and then once 
one is aware that they're addicted, it's not really something you can turn around 
and say well it's not my fault my brain told me to do it. (female, 26-40, high 
dependence) 
As the above quote shows, insight into the biological basis of nicotine addiction does not 
necessarily influence ideas about the fundamental nature of smoking. In this participant’s case, 
and that of many others, smoking is framed in terms of personal choice and autonomy. Also, 
not all participants found the link between smoking and the brain interesting or noteworthy. 
One questioned the significance of the brain’s role by pointing out that “anything - absolutely 
anything that you do and you do repetitively and for a long duration of time affects your brain, 
anything.” (male, 26-40, medium dependence) 
 
 The focus of the remainder of this paper is on whether neuroscience findings about addiction 
might result in anything other than curiosity value amongst smokers.  
 
The brain and quitting methods 
The claim that biological explanations of addiction will increase the use of, and adherence to, 
medication assumes that people’s explanatory models of addiction correspond in predictable 
ways to the treatments they choose: it is assumed that people who have biological 
understandings of their addiction will be more likely to seek assistance from health 
professionals and use medications, Conversely, those who believe their addiction is a social or 
psychological problem may see less value in using medications and therefore be more likely to 
quit unassisted or to favour psychological or behavioural approaches. 
 
Smokers interviewed for this study often stated that neuroscientific accounts of nicotine 
addiction might inform the cessation strategies that they, or other smokers, would employ. 
120 
 
However, the ways in which they thought it would inform quitting tactics varied widely, as 
illustrated by the contrasting quotes below: 
“It’s just - like, the neurotransmitter - it’s like playing sport. When you smoke 
a lot you get really good at it, and then so what you’re trying to do, what I’m 
trying to do when I quit is to get bad at it, try and reverse it.  So I’m just trying 
to maybe go cold turkey, slow it down, try and push myself.” (male, 18-25, low 
dependence) 
 
“I suppose if it's so entrenched within your system and sometimes we do need a 
helping hand.  Yes we want to go cold turkey but maybe there's a point where 
we can't and it pretty much consumes us.  So we may need to go to a doctor and 
get prescribed medication to kick the habit.” (female, 55+, high dependence) 
These two individuals come to very different conclusions about the implications of addiction 
neuroscience for quitting methods. The first participant acknowledges that smoking causes 
changes to the brain, but believes the brain can also be returned to its original form without 
medical assistance. All that is needed is to “get bad” at smoking by weaning off or stopping 
smoking. This is consistent with the idea of brain plasticity, where individuals can “work on” 
or “improve” their brain by way of brain exercises or other behavioural alterations. The concept 
of brain plasticity has become a culturally salient concept that is widely reported in the media 
and popular science (Pickersgill, Martin, & Cunningham-Burley, 2015; Pitts-Taylor, 2010), so 
it is not surprising to find it used by smokers to understanding quitting. However, for the second 
participant, the role of the brain implies an “entrenchment” of addiction that can only be 
overcome using medical intervention.  
  
Attitudes toward the use of the cessation medication varenicline reveal the diversity in lay 
representations of neuroscience knowledge. Participants were provided with a brief description 
of how varenicline (trademarked as Champix in Australia) works in the brain. More than one 
third of participants were unaware of the existence of prescription medications for smoking 
cessation prior to the interview, however even the few participants who had used varenicline 
seemed unaware of how it worked in the brain. Most of those who discussed varenicline 
reported that knowing how it worked in the brain increased their positive perceptions of it: 
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“I think the information about Champix filling the receptors, like that's good 
information. I think it's just the side effects I don’t like about Champix.” (female, 
18-25, medium dependence) 
However, having positive perceptions of cessation medications, or believing that they “could” 
be a good idea, did not mean that they were a preferred quitting method. A fear of side effects 
was common. Also, many participants, particularly those from younger age groups, expressed 
a preference for unassisted quitting.  
“Well yeah, I still think the best method is habit change but if they perfected 
Champix to not do everything else that it does side effect wise and was just 
filling receptors to help with withdrawal then I think that would be great.” 
(female, 18-25, medium dependence) 
For a smaller number of smokers the idea that Champix worked in the brain made it less likely 
they would use it. They were concerned that Champix would interfere with the normal function 
of their brain and described this possibility as “scary”. For example, one participants stated that 
“I knew Champix did something scary, chemical stuff going into your brain, don't like it” 
(female, 26-40, low dependence). Another thought that if Champix reduced feelings of pleasure 
for smoking, then it may do the same for other pleasurable experiences: 
“I didn’t realise actually what Champix did either.  It actually stops the receptor 
- I don’t like that.  I don’t like that at all…it’s playing around with your brain, 
if that makes sense and I don’t know, I know this might sound silly but if you – 
I don’t know, because sometimes you eat something and it feels good. Is that 
going to stop also that pleasure as well?” (female, 26-40, medium dependence)
  
The association between cessation medications and the brain was not the only reason for 
disliking medication for cessation. Negative attitudes towards pharmacological cessation aids 
reflected a general aversion to taking medication. There was a belief, again expressed mainly 
by younger adults, that medication should be taken only when absolutely necessary, and that 
quitting smoking was not serious enough to warrant it.  
“I'm always against medical treatment. Even if I have a small headache, I never 
go and take the medicine. If I have a bit of cold, I never take any tablet or 
anything. I just try and let it go with the time.” (male, 26-40, low dependence) 
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The contradiction inherent in being frightened by the effects of pharmaceutical medications 
whilst consuming a harmful product (tobacco) that contains a psychoactive drugs (nicotine) 
was not lost on all participants. The participant quoted below noted it, but it remained 
unresolved:  
“I knew Champix did something scary, chemical stuff going into your brain, 
don't like it.  I mean I'm fully aware that nicotine's going into your brain but I 
don't know, scary stuff.” (female, 26-40, low dependence) 
 
Even among those positively disposed to using pharmacological treatment for smoking 
cessation, the importance of psychological factors was often emphasised. The use of terms such 
as willpower, mindset, and “readiness” to quit were very common throughout many interviews. 
For example, smokers who had tried many times to quit, including attempts using 
pharmacological cessation aids, attributed their failure to a lack of willpower, or a belief that 
they weren’t yet “ready” to quit. The smoker quoted below acknowledges the availability of 
medications but does not believe that this negates the need for the individual to exert “effort” 
in their quit attempt.  
“There's medications available.  What do you think personally is going to work 
for you?  We can try a range of things here.  But the effort has to come from the 
individual regardless.” (female, 55+, high dependence) 
 
Autonomy and feelings of fatalism 
Participants in this study were asked whether knowledge about how nicotine worked in the 
brain to produce addiction affected their beliefs about their ability to quit. The most common 
response was that it made quitting smoking seem easier. Some thought that emphasising the 
role of the brain in addiction made smoking seem more serious, thus increasing motivation for 
quitting. One participant, who had not known that smoking affected the brain, stated that:  
 “I guess it hasn’t made it harder for me to stop smoking, I guess it’s made it 
easier in the respect that I guess I’ll think twice before I reach for a cigarette.” 
(female, 26-40, medium dependence) 
A number of participants thought that knowing how varenicline worked made it seem more 
effective, and consequently made quitting seem easier.  
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“I suppose understandings how the, you know Champix and things like that are 
supposed to work, makes it seem more likely that it would work. Yeah, so I guess 
easier.” (female, 41-54, medium dependence) 
A few participants thought that knowing exactly how nicotine worked in the brain was 
empowering. They equated a greater amount of understanding about smoking to a greater sense 
of control over their smoking.  
“The more understanding I have of it the more I have control of it. That’s how 
I feel. I think I have more control over the smoking now that I know what I’m 
doing.” (male, 18-25, low dependence) 
Not all believed that an awareness of the neural basis of addiction would lead to a greater sense 
of control over smoking. More than a third said that emphasising the role of the brain in tobacco 
dependence made it seem more difficult to quit smoking. Some commented that it made their 
addiction to tobacco seem more “real.” This coincided with a belief, expressed by several 
participants, that nicotine addiction was less serious and easier to cure than addiction to other 
drugs. They expressed shock at comparisons between the similar effects of nicotine and illicit 
drugs on the brain.  
“You know it shocks me to watch it and I'm like oh gosh, you'd think that would 
make you want to stop, but it almost makes me think, no I am addicted. You 
know whereas before I just feel like, no I could stop.” (female, 18-25, low 
dependence) 
As can be seen above, emphasising the role of the brain in nicotine addiction did lead to 
fatalistic responses in some participants.  
“So it's something that I can't control, it's something that the brain's just 
automatically doing.  So that's going to make it even harder, not am I just 
fighting this, I'm actually fighting something that's chemically happening.” 
(female, 26-40, high dependence) 
This individual speaks of “the brain” as if it is separate from her, and believes that it operates 
“automatically”, independently of her own desires and motivation. For this smoker, an 
awareness that “chemicals” are involved implies that there is more to smoking than just 
individual choice.  
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It is important to note that there were also smokers who were dismissive of the idea that 
neuroscience information on addiction would have any effect on the way they perceived their 
smoking. These people often stated that knowing how nicotine worked in the brain provided 
some level of insight into their smoking, but it was mainly a “matter of interest” that would not 
affect their smoking behaviour or attitudes.  
“I'm very sort of intellectual in my thinking, so it's sort of oh that's nice to know. 
I'm glad I know it.  It's not so much that that's going to affect my smoking.” 
(female, 26-40, high dependence) 
Participants were also asked whether knowing how addiction occurred in the brain affected 
their sense of personal responsibility. Almost all participants in this study strongly rejected the 
idea that an awareness of the neurobiological basis of tobacco dependence would influence 
their sense of personal responsibility for their smoking.  
 “No, because I'm not going to say that - for want of a better term - I'm fucked 
in the head now, so I'm not responsible for my actions.” (male, 26-40, high 
dependence) 
Only a single participant thought that knowing about the brain’s role in addiction would reduce 
self-blame, and even here, it was framed around this discourse being useful for other smokers, 
rather than for herself.  
It's not necessarily your fault that you're finding it difficult to quit smoking when 
you have changed your physiology through what you've done. (female, 26-40, 
high dependence) 
 
Predicting the effects of raising awareness in smokers of the neural mechanisms of nicotine 
addiction will be difficult, and there may be unintended consequence such as increasing 
feelings of fatalism. One participant discerned the contradictory effects that may arise from 
brain-based understandings of smoking, saying that it make quitting seem: 
 “A little bit harder.  It makes it seem more technical.  Then at the same time 
you're just like okay well, if that's what this does, then you can do this and that 
and formulate something to replace it, which is like nicotine or Nicorette.  Both 
ways, I guess.” (female, 18-25, low dependence)  
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Emergent themes 
Three emergent themes recurred throughout the interviews. These were 1) the brain as a special 
organ and 2) the construction of the “other” smoker, and 3) nicotine addiction versus smoking 
as a habit. 
  
The brain as a special organ. Many participants were concerned at the idea that drugs would 
interfere with the “normal” functioning of the brain. This concern applied to both recreational 
drugs such as nicotine in the form of cigarettes, and to pharmacological cessation aids that 
influenced the neurochemistry of the brain to reduce cravings and relapse. Outside influences 
on the brain were perceived as being harmful, with several participants describing drugs as 
“messing with” or “screwing with” the brain. This was of particular concern for the participant 
quoted below, who explicitly linked their brain with their identity. The brain is described as a 
special organ, because unlike other organs, it contains the “essence” of an individual. 
“It's a lot more terrifying than having lung cancer and I know that sounds 
terrible but it just is. It's my brain and we all sort of associate it with it's our 
essence, it's us, you know, yeah.” (female, 26-40, low dependence) 
Others thought the brain was special because it is so vital to the functions of everyday living. 
These participants were not concerned with addiction, but were concerned that brain 
“impairment” that would lead to a loss of function.  
“Well I guess from an intellectual point of view I don't want my brain any 
further impaired than it already is.  I'm fairly reliant on it.  Not a good 
scenario.”(female, 55+, high dependence) 
Physical illnesses were contrasted with illnesses of the brain, because the latter afflicted the 
mind – “I don't know, and it shouldn't be because physical illnesses are bad as well, but you 
always worry about your brain don't you?” (female, 18-25, low dependence).  
 
The construction of the “other” smoker. Participants very frequently contrasted their own 
smoking with that of other smokers by distinguishing themselves from other smokers on a 
number of dimensions. For example, smokers were described as differing by personality traits. 
Many commented that the impact of brain-based understandings of smokers would vary 
depending on factors such as a smokers’ sense of personal responsibility, or the amount of 
willpower and motivation they had:  
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 “But it does very much depend on personality type.  There's defeatist people 
out there that just accept and don't say well okay that's critical information.  
That just means that whatever I choose in order to give up once I'm committed 
to it then these things have to be more strongly in place because it's going to be 
a tough battle.” (female, 55+, high dependence)   
There was a tendency for some participants to position themselves as better educated and more 
knowledgeable smokers, who would interpret neuroscience information in the “correct” way. 
Other uneducated, or “unintelligent” smokers would misinterpret material emphasising the role 
of the brain. 
“If you're not intelligent enough to understand it for what it is, then you might 
go, oh, well, then my brain is rewired now. I can't. I can't quit. There's a lot of 
people out there that are not thinking on the same level that we are, so too much 
information in their hands - when they don't understand that information 
properly - is useless to them.” (male, 26-40, low dependence)  
Several smokers made the distinction between those who were physically addicted to nicotine 
and those who were psychologically addicted to smoking. When asked whether educating 
smokers about the neural basis of addiction would be helpful, one responded:  
“…there are different kinds of smokers and each one has a different kind of 
addiction, you know so I mean this would be really helpful to those who are 
addicted to cigarettes just because of the nicotine, but you wouldn’t help the 
vast majority.” (male, 18-25, medium dependence) 
For those smokers who did not believe themselves to have a physical addiction to nicotine, 
information about the neurobiological mechanisms of addiction was not seen as personally 
relevant.  
Yeah, I mean I don't think I've gotten stupider or anything but, and that's the 
other thing I don't, I smoke really light milligram cigarettes and I don't smoke 
a lot of them so yes I am addicted to the habit and I'm fully aware that I am, I'm 
not in any kind of denial there, I don't know how much nicotine, you know, like 
they're talking about unpleasant withdrawal symptoms and that stuff.  I don't 
really get any withdrawal symptoms if I don't smoke. (female, 26-40, low 
dependence) 
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It was seen as interesting information, but more applicable to heavier, or more physiologically 
addicted smokers.  
 
 Discussion 
The primary aim of this research was to explore how smokers engaged with ideas about the 
neural basis of nicotine addiction. Many of our participants had some awareness that smoking 
tobacco affected their brain. However, few were aware of the detailed neurobiological 
mechanisms associated with addiction to smoking, and some were misinformed.  This is 
consistent with other literature on NRT that has found that smokers do not have a good 
understanding of how nicotine works in the body, and often hold erroneous views about its 
safety due to misunderstandings about the mechanisms of its actions (Ferguson et al., 2011; 
Mooney et al., 2006). This inexactness of smokers’ knowledge about smoking, nicotine and 
the brain is not surprising. We live in a time with a rapidly expanding corpus of scientific 
findings relevant to health, and laypeople cannot be expected to keep up to date with all 
scientific developments, even those that are personally relevant to their health. It is likely that 
exposure to ideas about the neuroscience of nicotine addiction will add detail to smokers’ 
existing understanding of smoking, rather than revolutionise the way that people conceptualise 
their smoking.  
 
Research in other fields indicates people are more likely to incorporate neuroscience 
information into their existing models of human behaviour, than to radically alter their mental 
models to account for biological research findings (Choudhury et al., 2012; O’Connor & Joffe, 
2013; Pickersgill, 2013). Our findings are consistent with this, in that most participants did not 
think that an emphasis on the neurobiological basis of nicotine dependence would change their 
own treatment preferences or their smoking behaviour. Also, the claim that educating smokers 
about the biological basis of addiction will reduce their feelings of self-blame and lead to them 
absolving themselves of responsibility for their smoking by blaming their brain is strongly 
disputed based on the findings from this study. The participants were adamant that they 
remained personally responsible for their smoking. They believed that knowing the role the 
brain plays in creating and maintaining addiction should not negate the need for smokers to 
expend effort in their quit attempts and take responsibility for their actions. Many thought that 
an awareness of the neurobiological basis of addiction increased an individual’s responsibility 
to stop smoking. Partly this was due to the perceived “special” nature of the brain. The brain 
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was seen as a vital organ, and just knowing that it was being affected by smoking should 
motivate people to quit. This may somewhat be explained by the fact that the discourse of 
neuroplasticity infiltrated the accounts of some participant around smoking and the brain. The 
idea of brain plasticity was used by these participants to counter messages about the long-term 
“chronic” changes in the brain that lead to addiction being labelled a “relapsing disease.”  
 
A common concern regarding the BDMA is that if addicted individuals believe that their 
addiction is “hard-wired” into their brain, they may develop a sense of fatalism. Whilst some 
smokers mentioned this possibility in our interviews, they mostly thought that this would occur 
in other smokers, rather than themselves. Smokers in this study maintained their sense of 
autonomy in the face of brain-based understandings of addiction by setting themselves apart 
from “other” smokers. They imagined that other smokers were more heavily addicted or had a 
physiological addiction to smoking. Also, they sometimes positioned themselves as more 
educated and informed about smoking than others. It was a common theme that 
pharmacological treatments for nicotine addiction were suitable for “other” smokers, those who 
had a strong physiological addiction. A number of the smokers in this study, particularly those 
who were younger, stated that they did not have a physiological addiction to cigarette smoking, 
or that their addiction was mild compared to others. Therefore they did not see their own 
smoking as serious enough to warrant the use of medications. While they identified as being 
addicted, they conceptualised addiction differently, seeing it as a “behavioural” addiction or a 
“habit.” This supports the finding of Hughes (2009), who found that it was common for 
smokers to agree that an inability to quit was due to both addiction and to habit, but not to 
biology. Others have found that young people in particular believe themselves to be less 
addicted than other smokers (Weinstein et al., 2004).  
 
The BDMA highlights the addictiveness of smoking, which is portrayed as a “chronic” 
condition that requires treatment, much like alcoholism (Wolff et al., 2013). There is very 
limited evidence that explores whether belief that one is addicted to smoking impacts in any 
way on quit attempts or treatment choices (West, 2011). Our research demonstrates that 
explaining how prescription medications worked in the dependent brain increased positive 
perceptions of cessation aids for some smokers, but there were suggestions that this would not 
necessarily equate to increased uptake of pharmacological cessation aids. This is a very 
complex area to negotiate because it is possible that this emphasis on addiction will conflict 
with public health campaigns that aim to increase quitting self-efficacy in smokers, and also 
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with lay understandings of smoking and cessation. For some of our participants, highlighting 
the role of the brain did make tobacco addiction seem more real and serious, so this possibility 
cannot be entirely discounted. Overall though, our research suggests that emphasising the 
biological basis of addiction will not lead to radical changes in smokers’ confidence in their 
ability to quit smoking.  
 
Because this is qualitative research, the results are not generalisable to the entire smoking 
population. Large quantitative studies are needed to assess the generalisability of our findings 
and to look at differences in relation to age, gender, level of education and heaviness of 
smoking. Also, it should not be assumed that users of illicit drugs or alcohol would respond in 
the same way as smokers because tobacco is a drug with a unique history (Berridge, 1997) and 
users of other drugs may have very different ideas about the role of the brain in their drug-
taking. 
 
A potential limitation of this study is that participants were presented with a specific 
interpretation of neuroscience research on smoking. While the goal was to stimulate discussion, 
there is the potential for such information to constrain the expression of ideas about smoking 
and the brain if participants simply agree with the view of nicotine addiction presented to them. 
This might occur due to a deference to scientific authority, or because participants feel they do 
not have time to process and interpret the information.  Moreover, participants may feel an 
expectation to respond to these ideas as if they were novel and new. Martyn Pickersgill (2013) 
has noted a tendency amongst social scientists to overplay the novelty or significance of 
neuroscience while members of the public are more likely to treat it as an object of “mundane 
significance.” That is, they may ignore it, acknowledge it, or find it “entertaining, rather than 
profound” (Pickersgill, 2013, p. 330). While our results were generally consistent with 
participants treating this information as having “mundane significance”, a minority of smokers 
expressed shock at the “new” information about their smoking that had been presented to them, 
and believed that it might influence their ongoing behaviour.  
 
It is important to anticipate the way in which those who experience addiction as an everyday 
reality will interpret neuroscience knowledge about addiction (Fry & Buchman, 2012). Our 
analysis reveals that providing smokers with information about the neurobiology of nicotine 
addiction can lead to complex and contradictory reactions. For many of our participants, the 
provision of information about the role of the brain in tobacco dependence provided insight 
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and interest, but they did not think it would affect their pre-existing beliefs or intentions. Our 
data suggest that neuroscience information is more likely to influence people’s beliefs about 
other smokers than it is to modify explanations of their own behaviour. However, the results 
also pointed to the possibility that such information may make quitting smoking appear more 
difficult for a minority of smokers.  
 
Because of the wide variety of ways that neuroscience knowledge about nicotine addiction is 
interpreted by smokers, it may be better to present this information in a clinical setting rather 
than in widely disseminated health promotion materials. Health professionals in clinical 
settings can gauge the attitudes of the individual smoker in response to more “medicalised” 
explanations of smoking and correct any misperceptions they may have. Where it is included 
in educative material for smokers, neuroscience information should be presented in a way that 
does not negate people’s sense of agency and self-efficacy in relation to quitting smoking.  
 
 
 Concluding remarks on Chapter 7 
When presented with information about how smoking influences the brain in ways that make 
it difficult to quit, smokers respond in a variety of ways. Firstly, some negate the significance 
of this neuroscientific information. They report already being aware of it, or observe that 
“everything affects the brain”, so why should smoking be any different? Some believe this 
information is relevant to other smokers, but not to themselves as they were not addicted to 
nicotine; or were less addicted than other, heavier smokers. Separating oneself from the “heavy 
smoker” identity was frequent, particularly amongst young people in the sample.  
 
As with Chapters 5 and 6, individual responsibility, willpower and motivation were again 
prominent themes and describing the neuroscientific basis of nicotine addiction did not negate 
their importance. It is clear that smokers are very averse to the idea of absolving themselves 
(or others) of personal responsibility for smoking by taking up a neuroscientific discourse about 
smoking. Steenburgh and colleagues (2012) reported similar findings in drug addicted 
individuals and recommended that neuroscientists acknowledge that a sense of personal 
responsibility is an important factor in ceasing drug use. As has been noted by others, drug 
addiction may lessen self-control, but does not eliminate it (Carter & Hall, 2007; Hyman, 
2007).  
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The impact that neurochemical explanations of smoking and cessation will have on attitudes 
towards cessation medications remains unclear. These findings reveal a tendency for 
information about the neuroscientific mechanisms by which medications work to increase 
positive attitudes towards them. Whether this will influence the actual use of medications is 
unknown. Even where positive attitudes towards medications seemed to increase when the 
mechanisms of their action in the brain were explained, the participants mainly maintained a 
preference for unassisted quitting methods. Moreover, a small number of participants rejected 
the use of varenicline precisely because it worked on the brain. The brain is often described as 
the location of one’s identity, and the idea that something may be “messing” with it was 
disturbing for some participants.  
 
The general disinclination to take medications expressed by numerous participants is relevant 
to sociological discussions around pharmaceuticalisation. Pharmaceuticalisation has been 
defined as “the process by which social, behavioral, or bodily conditions are treated, or deemed 
to be in needs of treatment/intervention, with pharmaceuticals by doctors, patients, or both” 
(Abraham, 2010a, p.290). There is some debate about whether pharmaceuticalisation is one 
aspect of medicalisation or a separate but linked process. Abraham posits that 
pharmaceuticalisation is a separate process but that increasing medicalisation is “a significant 
factor in explaining increased pharmaceuticalization” (2010b, p.608). He argues that increased 
use of pharmaceuticals is not simply a result of improving access to effective medications, but 
has been facilitated by pharmaceutical industry interests influencing the development of 
diagnostic criteria and treatment guidelines, as well as exaggerating the benefits of various 
drugs.  
 
Pharmaceuticalisation is strongly linked to medicalisation in relation to smoking cessation 
pharmacotherapies. Most smokers who are eligible to use cessation pharmacotherapies are at 
risk of diseases from smoking, rather than suffering from such diseases. This means they may 
dismiss the need for medications, which are seen as too serious for their smoking “habit.” (See 
Chapter 6). This is particularly the case where the potential for negative and serious side effects 
have been publicised, as they have been for varenicline. While “tobacco use disorder” is listed 
in the DSM as a diagnosable condition, the uptake of this term and the use of diagnostic criteria 
for smoking has been limited in clinical practice. This may have influenced the shift amongst 
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some organisations to begin to describe nicotine addiction as a health condition in its own right 
by emphasising its biological basis in the brain. This explanation of addiction justifies the use 
of medications that work in the brain to alter the neurochemical pathways related to drug 
dependence. Whether this strategy is successful remains to be seen. The research presented 
here suggests that understanding the biological basis of prescription medications for smoking 
cessation could improve attitudes towards varenicline. But there is also the potential for this 
strategy to backfire amongst those who do not want medications “messing” with their brain. 
Moreover, the strength of alternative explanations of smoking centred around willpower and 
motivation are likely to attenuate the effects of describing nicotine addiction as a brain-based 
disorder.   
 
As described in Chapter 3, much work on lay knowledge of medicine or illness, as well as 
findings from the field of public understanding of science, show that scientific findings are not 
uncritically accepted, but are subjected to various forms of critical appraisal. One means of 
appraisal is to compare the information provided by experts to everyday experiences, or what 
is dismissively referred to by some as “anecdotal data.” This is what Davison, Smith & Frankel 
(1991) described as “lay epidemiology”, and this process has been demonstrated in this study 
and in others in relation to lay understandings of smoking and cessation (Smith et al, 2015).  
 
Another way that such information is judged is according to the credibility of the sender. In 
PUS literature this has centred around the topic of trust. How do laypeople judge the credibility 
of those who are attempting to influence the ideas and opinions of various public stakeholder 
groups? And how does scientific information and its presentation influence lay attitudes 
towards certain scientific claims? Based on qualitative research with Cumbrian sheep farmers 
and their engagement with scientists following the fallout from Chernobyl, Wynne (1992) 
outlined a number of “lay criteria” which people used to judge the credibility of scientific 
claims. These include whether the scientific knowledge works in practice, whether scientists 
have taken account of all available knowledge, the extent of engagement with “lay experts”, 
the affiliations of the scientists, and whether the format of the information is accessible and 
recognisable to laypeople.  
 
Because the information provided to participants in this study about nicotine dependence and 
the brain was presented as “scientific fact,” it is likely participants were making judgements 
about the credibility of the information and the motives behind its presentation. However, the 
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information in the Powerpoint was portrayed as disembodied knowledge, rather than being 
attributed to a particular scientists or interest group. (E.g., “When you smoke tobacco, nicotine 
enters your bloodstream” , “Research shows…”). This may have made it difficult for 
participants to critique the validity or trustworthiness of the information. Most participants did 
not question the accuracy of the information presented, although some thought it did not 
portray the “whole picture” of smoking. However, in the next chapter the role of scientists are 
brought to the foreground, resulting in explicit discussion about their credibility and motives.  
 
Overall, these findings reveal the complex way that information about the neuroscientific 
mechanisms of addiction is negotiated in relation to smokers’ views on smoking and quitting. 
Assumptions that it will induce fatalism, increase treatment seeking, and reduce a smoker's 
sense of personal responsibility, are not supported by these findings. This is consistent with 
research by O’Connor (2013) who found that while the brain was often associated with a 
person’s essence or soul, this did not negate the importance that people attached to free will in 
explaining human behaviour. The evidence presented here begins to outline the complex and 
contradictory ways that neuroscientific information is incorporated into everyday 
understandings of addiction and smoking.  
 
 Original contribution of Chapter 7 
Speculation about the impact that neuroscientific research findings might have on lay 
understandings of various disorders and behaviours is rife. However, as has been noted by 
others, much of this work is “over theorized” (Pickersgill et al., 2011, p. 362) and not based on 
empirical evidence. In relation to addiction studies, Steenburgh (2012) has written that “[a]s 
addiction studies benefit from what can be learned from neuroscience, the neuroscientific study 
of addictions might also benefit from considering what can be learned from the practical 
experience of addiction counsellors and individuals struggling with addiction.” (Steenbergh et 
al., 2012, p. 427).  
 
This is the first research project to examine how Australian smokers understand the role of 
their brain in their smoking. It is important to document how smokers understand their smoking 
in light of new treatment options and advances in scientific knowledge. For most participants 
in this study the idea that smoking influences the brain was not controversial, novel, or 
influential. Perhaps more controversial and more novel is the description of tobacco 
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dependence as a “chronic disease” (Fiore et al., 2008) or a “chronic brain disorder” (Prochaska 
& Benowitz, 2016). The next chapter examines the reactions of the same participants to the 
statement that smoking is a “brain disease”.  
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Chapter 8. “I’m already bad enough” – A qualitative exploration of 
smokers reactions to labelling nicotine addiction as a brain disease. 
 
As described in Chapter 2, the controversial definition of addiction as a “chronic, relapsing 
brain disease” is beginning to be applied to smoking. In the interviews reported in Chapter 7, 
smokers' knowledge and attitudes regarding the role of the brain in smoking behavior was 
explored prior to introducing the term "brain disease". This allowed elicitation of their views 
about the role of the brain in smoking, rather than their views on the label of “brain disease”. 
The results described in Chapter 7 revealed that most participants accepted that smoking 
affected their brain but this did not typically have a large impact on the way that they 
understood their smoking or thought about stopping smoking. Subsequently, participants were 
questioned on the extent to which they agreed that smoking is a brain disease. The reasons they 
agreed or disagreed were analysed, and are reported in this chapter.  
 
 Introduction 
The main tenets of the BDMA have been described in Section 2.6. Proponents of the BDMA 
argue that it will reduce feelings of self-blame in addicted individuals, reduce the stigma 
associated with drug dependence, lead to the development of more efficacious treatments, and 
promote more sympathetic policy responses to drug addiction (Dackis & O'Brien, 2005; 
Gardner et al., 2009; Leshner, 1997). The BDMA portrays addiction as more than simply a 
poor choice or a moral failing (Leshner, 1997) but as a loss of control over behaviour that is 
driven by persistent neurobiological changes produced by chronic drug use that drives 
continued drug use despite the harm that it causes. 
 
The BDMA has been criticised as being overly essentialist, downplaying the complex interplay 
between biology, psychology, social environment (e.g., drug availability), and individual 
upbringing (Caan, 2012; Kalant, 2010; Midanik, 2006). In the case of smoking, for example, 
the tobacco industry has promoted the idea that smokers are genetically predisposed to be 
harmed by smoking as a way of deflecting blame from their unsafe product (Gundle et al., 
2010). Other critics argue that the BDMA undermines free will and agency (Heyman, 2009; 
Lewis, 2015) in ways that may make stopping smoking seem more difficult than it is. This may 
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discourage smokers from attempting to quit without using smoking cessation medicines (Caron 
et al., 2005; Chapman & MacKenzie, 2010; Pierce et al., 2012).  
 
The claim that the BDMA will reduce stigma has been questioned (Buchman, Illes, & Reiner, 
2011; Trujols). Some research suggests that labelling those who experience mental illness as 
having different and problematic types of brains, can lead to an increase in stigma 
(Angermeyer, Holzinger, Carta, & Schomerus, 2011; Kvaale et al., 2013). In the case of 
smoking, the issue of stigma is complex. The stigma associated with alcohol and illicit drug 
addiction is generally seen as negatively impacting upon treatment-seeking, drug use and self-
esteem. In contrast, the stigmatisation of smoking is often viewed positively, under the banner 
of “denormalisation,” which encourages smokers to quit and reduces uptake by young people. 
An explicit example is the use of shame messages in anti-smoking advertising (Amonini et al., 
2015).   
 
Scholarly debates about the accuracy and value of the BDMA have rarely been informed by 
the voices of the individuals who are most directly affected by this framing: those who are 
substance dependent. Commentators from various fields have postulated that advances in 
knowledge about the neural correlates of behaviour will change the way that laypeople 
understand their own actions. This chapter explores how smokers respond to the claim that 
smoking is a brain disease and how useful they find the brain disease label in understanding 
their own smoking. Is this definition of addiction acceptable to them, and how applicable is it 
to their own smoking? Do they believe that this way of defining addiction will reduce stigma, 
or change the way that smoking is understood in helpful ways? We also look at how smokers 
make judgements about the credibility of this neuroscientific claim.  
 Method 
The data presented in this paper are drawn from the same interviews described in Chapter 6 
and 7 and their demographic data can be found in Section 6.3. As described in Chapter 7, during 
the interview, participants were presented with a short slideshow outlining the ways that 
nicotine acts in the brain to produce dependence. Participants’ general understanding of the 
role of the brain in their smoking and its relevance to treatment choices were reported in 
Chapter 7. The interviewer then made the following statement: “Based on the information 
presented earlier, some scientists have claimed that addiction is a brain disease.” Respondents 
were asked what they thought about the idea that smoking was a brain disease, and whether 
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such a label would increase or decrease the stigma associated with smoking, whether it was 
good or bad way to describe smoking, and whether they had heard this definition of addiction 
before. It is important to note that this research was not designed to examine existing attitudes 
towards the idea that smoking is a brain disease. Because application of this term to smoking 
has only begun recently, it was assumed that most participants would not have been exposed 
to it and therefore they would not have pre-existing attitudes that could be prompted. Rather, 
our aim was to elicit smokers’ initial reactions when presented with this view of the scientific 
evidence.  
 
Again, thematic analysis was performed to analyse the results (2006). After close reading, 
initial codes which represented patterns observed within and across interviews were generated 
by the author. These codes were then combined into themes when they were deemed to 
represent a broader topic. The approach taken combined inductive and deductive processes. 
Some themes were included in the interview schedule as they were pre-identified from an 
exploration of the literature, other themes were identified as the data was being analysed. 
Adrian Carter conducted independent coding and labelling of themes from a subset of 
transcripts in order to ensure the validity of the themes. Any discrepancies were discussed until 
a consensus was reached about the final themes. All data was stored and managed using NVivo 
10 software (QSR International Pty Ltd., 2010).  
 Results 
Our analysis revealed three primary considerations that participants referred to when reflecting 
on the claim that smoking is brain disease: 1) the accuracy of the “brain disease” terminology; 
2) the potential social consequences of labelling smokers with a brain disease, and 3) the likely 
social utility of the description. While some participants focused primarily on one of these, it 
was more common to use a mixture of these considerations in forming an overall judgement 
on the acceptability of using the BDMA to understand tobacco smoking.  
 
The idea that smoking is a brain disease was new to most participants. Some had heard this 
terminology in relation to other drugs, but had not heard it applied to nicotine addiction. 
Because this was a question they had not previously considered, participants’ initial responses 
were often uncertain and questioning:  
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A brain disease?  A brain disease?  Interesting.  People seeing addiction as a 
brain disease.  I don’t know what to say to that.  I mean, define disease, you 
know what I mean? (male, 18-25, low dependence) 
Most were, nonetheless, able to reflect on the claim and make some judgements about its value. 
Their views often evolved in the course of the interview as they talked through the implications 
of this terminology. Some people who initially agreed that smoking could be a brain disease 
later disendorsed the idea and vice versa.  
 
Evaluating the accuracy of the “brain disease” explanation of smoking 
Many participants disagreed with the suggestion that cigarette smoking was a brain disease. 
Participants had diverse views of what they thought the term “disease” meant. One referred to 
a disease as something that is “degenerative and harmful.” (male, 26-40, moderate 
dependence). He did not think that nicotine addiction would fit this description unless it was 
“destroying” brain cells. Another thought that diseases were “viral” (male, 18-25, low 
dependence). A disease was also seen as “something that changes in your blood cells and 
deforms something.” (female, 26-40, high dependence).  Others associated the term brain 
disease with physical damage to the brain. Some participants rejected the idea that their brains 
were damaged, citing as evidence that they were fully functioning members of society.  
 
Some did not like the term but struggled to articulate why. They said that it didn’t “sound 
right”, or that it was a “weird” label to apply to smokers. These participants reacted most 
strongly against the word “disease”. The fact that nicotine may change the brain of smokers, 
however, was not disputed by most participants.  
Yeah, I agree that okay I’m addicted to nicotine and yeah, it affects my brain, I 
agree with all that but no, I don’t think, not as a disease, no.  It’s just something 
I guess you’ve got to work on every day. (female, 26-40, moderate dependence) 
A number of those interviewed suggested using different language to describe nicotine 
addiction. One thought that “disorder” was a more appropriate term because “disease” referred 
to something “viral”, whereas smoking was more like a mental disorder such as bipolar 
disorder, “but a very minor grade of the same league.” (male, 18-25, low dependence). 
Significantly, another suggested the term “illness” as an alternative, because an illness is 
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something that you can recover from, whereas a disease suggests chronicity and the need for 
long-term management, which was not consistent with his understanding of his smoking.   
 
There were a number of common beliefs that affected participants’ preparedness to accept or 
reject the idea that smoking was a brain disease. The most common was that a disease was 
something that an individual had no control over – it was perceived as something that 
“happened” to people. As one participant put it, it is “something that’s caused by an outside 
influence.” (female, 26-40, high dependence). This was seen as being inconsistent with 
smoking, which was conceptualised as the result of a choice. The brain disease explanation of 
smoking was rejected because it was perceived as downplaying or ignoring the central role of 
choice in smokers’ understandings of their smoking.  
See, the thing is I could stop smoking right now. I could throw my ciggies in the 
bin and decide, no, never ever ever having one again. I mean, yeah, it's going 
to be a hard decision to make, but I can make it. I can do it. It's just I'm choosing 
not to. Anyone who disagrees is either an idiot or they're irresponsible (male, 
26-40, low dependence) 
 
A number of people thought that the term “disease” was too serious to apply to cigarette 
smoking. One participant thought that it would “make it look probably worse than what it is” 
(female, 18-25, low dependence). The role of nicotine addiction in sustaining smoking was 
downplayed by comparing smoking to other “habits”:  
I think disease is a little harsh, I would think.  I would say it's a - what was that 
word?  It's not disease, it's - I lost the word.  But I wouldn't say it's a disease.  
It's something that your brain is accustomed to, just like how you're feeling - 
you know, like when you're driving how you check the mirrors, when you wake 
up how you do your hair, you brush your teeth.  It's something that your brain 
picks up and learns.  So what you can learn, you can unlearn.  But I wouldn't 
go so far as to call it a disease.  It's just harsh. (male, 18-25, low dependence) 
This quote emphasises that smoking is something that you can “unlearn” or overcome. Diseases 
are perceived as afflictions that individuals have no control over – you cannot stop having a 
disease, but you can decide not to smoke your next cigarette. This view was supported by the 
observation that people could quit smoking without assistance.  
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But then again, how is it then that some people can still stop if it’s affecting - 
the heavy smokers - there have been heavy smokers that have stopped, so how 
is it that they’ve been able to do that if their brain - or is it like a lot of diseases, 
some people smoke, smoke, smoke and never get lung cancer, other people 
never smoke and get it. Yeah, it’s probably a too general a hypothesis. (female, 
55+, high dependence) 
A minority of those interviewed agreed that smoking was a brain disease. One reason for 
accepting this view was the invocation of a predisposition toward addiction in some 
individuals. For these participants, the fact that addiction ran in families, and individuals 
differed in their ability to quit, suggested that smoking was “more than a habit”. Rather, it was 
more a behaviour with a physiological and possibly genetic basis. These considerations made 
the brain disease concept more believable to them.  
I've been in a few rehabs, psych hospitals.  The people that have problems, the 
people that don't, that people that keep coming back over and over again, the 
people that get treatment and go on to be okay and then the people that just 
never have an interest in using drugs at all to start with.  It really seems to vary 
from person to person.  For someone like me I cannot comprehend how someone 
can be a social smoker and just on the weekend I have a couple of puffs - you 
what?  I don't understand how that's possible. I don't have that kind of 
physiology.  I don't have that make-up. (female, 26-40, high dependence) 
Some participants thought that nicotine addiction might partially be understood as a brain 
disease, but it was not seen as capturing the complexity of smoking in people’s everyday lives:  
Maybe partially, but I don't think fully.  I don't think it's fully your brain.  I think 
it's your daily life, your routine, your social group, it's everything else, I think, 
and then maybe partially a brain disease or whatever.  It sounds really terrible 
saying it's a brain disease, but maybe partially. (female, 18-25, low dependence) 
A handful of participants thought that the brain disease explanation may apply to some, but not 
all, smokers. For example, one participant stated that “normal” smoking would not be 
accurately classified as a brain disease, but once people were addicted enough to experience 
withdrawal symptoms, then this label might apply (female, 18-25, moderate dependence). 
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Agreement with the BDMA was often not enthusiastic or wholehearted even among those who 
accepted it. It was more common for participants to offer qualified agreement. Some who 
thought that the brain disease label was accurate did not think it was a good idea to describe it 
that way. 
I don't think it's helpful if scientists are putting that view forward even though 
it may have a hell of a lot of merits. (female, 55+, high dependence) 
They listed potentially negative social consequences of doing so, the topic to which we next 
turn.  
 
Concern about the consequences of the “brain disease” explanation of smoking 
Participants were questioned about the effect they thought the brain disease terminology would 
have on the stigma associated with smoking. Many reported feeling the stigma of smoking 
acutely, and reacted strongly to anything that they thought might increase this. 
I mean, personally for me I do feel that as a smoker I’m already bad enough, 
and then I mean if you just keep pushing a person further you reach a point then 
when the person thinks that okay I’m screwed up I might as well not bother and 
continue being screwed up. (male, 18-25, moderate dependence) 
Most thought that the brain disease label would increase stigma because the word “disease” 
had negative connotations. Examples of words that participants associated with the concept of 
disease were: “dirty”, “disability”, “mental disorder”, “leper”, and “unstable.” Associations 
with the concept of “brain damage” were seen as especially negative. One participant was 
concerned that he would become seen as the “local simpleton” if this terminology was 
introduced (male, 26-40, high dependence). Some participants were aware of the stigma and 
discrimination associated with mental illness, and were concerned that the brain disease label 
would equate smoking with a mental illness. 
…to what extent is brain condition conflated to mental illness and the 
assumptions are therefore maybe not being able to do their jobs or behave 
appropriately which mightn't actually be consciously examined assumptions but 
I think nevertheless we know they exist. (female, 55+, moderate dependence) 
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Fewer participants thought that the brain disease explanation of addiction would reduce stigma. 
A minority thought that describing nicotine addiction as a brain disease might reduce negative 
judgements of smokers because it implied they did not have full control over their behaviour.  
People might be less likely to judge people.  Sort of, oh well, poor things can't 
help it, sort of anymore that you can help having asthma or something. (female, 
41-54, moderate dependence) 
Not all saw increased sympathy from non-smokers as a positive though. Some thought it might 
come in the form of pity.   
Yeah, there's always going to be a certain section of the community that goes, 
oh, those poor people, they've got a disease. I mean, yeah, but with education, 
we could reduce that. (male, 26-40, low dependence) 
 
Another frequent concern participants expressed was that other smokers would use the brain 
disease label to avoid personal responsibility for their smoking. It was often described as an 
“excuse” and a “cop out” that would discourage people from using their willpower to quit 
smoking.  
You don't want people going around making excuses, I've got a brain disease, I 
smoke.  They're never ever going to get out of the rut of maybe I want quit. 
(female, 55+, high dependence) 
No, I see it more as an excuse.  They're going to go to their doctor and say I 
have a medical thing that I can't probably function anymore and I can't change 
it.  Because a lot of people will say no, it's deep in my brain, that's a serious 
problem as well, that's something that you might - I think it just opens a door to 
people who can't do the mind over matter or whatever. (male, 26-40, high 
dependence) 
Participants thought that other smokers would readily accept the implied reduction in personal 
responsibility but rarely saw their own smoking in this way. In contrast to the dominant view, 
one participant reported that a biological understanding of smoking reduced her feelings of 
self-blame. She described the BDMA as “comforting” because it provided a medical 
explanation for her struggle to control her cigarette intake.  
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It's kind of comforting. It does take away that sense of - well I guess it's - yeah, 
the sense of not being able to control the smoking is also a self-esteem issue. It's 
like oh, here I am, I should know better and I smoke. (female, 55+, moderate 
dependence) 
Participants who discussed the implications of labelling smoking as a “brain disease” for 
quitting and treatment-seeking differed in their views. One thought that it could increase 
treatment-seeking by helping smokers to recognise that they have a “real problem” (female, 
26-40, high dependence). A few thought that this language might encourage quit attempts 
because brains are “precious” organs associated with one’s identity and spirituality. Others 
thought the word “disease” was problematic because it made stopping smoking seem more 
difficult.  
It would make it look probably worse than what it is, and like I said before it 
might overwhelm a lot of people and they might think that there's nothing to do 
because they've got a disease, and I think disease is a big word.  Probably for 
the medicine world it would be fine, but for the public, it's a big word to put in 
their minds. (female, 18-25, low dependence)  
A number of male smokers had quite emotional responses to the claim that smoking was a 
brain disease. They expressed anger or became irritated that someone might apply this label to 
them. A handful stated that they would engage in retaliatory smoking if someone labelled them 
as having a brain disease.  
I would be like - you think it's a disease, I'll show you disease, man.  I'll smoke 
even more or something. (male, 18-25, low dependence)  
Some participants said that they would be deterred from seeking treatment if health 
practitioners labelled nicotine addiction as a brain disease.   
I just think it would scare smokers away from treatment programs.  They're just 
saying - well my reaction would be look, just leave me alone please, stop talking, 
we've all got problems and throwing the word disease around is very dangerous, 
I think. (male, 18-25, low dependence) 
These participants expressed suspicion about public health practitioners and scientists. Anti-
smoking education campaigns were described as “scaremongering.” One participant described 
them as “hippies”, and another thought the brain disease label was a “nanny state” campaign 
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to tell people that “we are not allowed to do what we want to do.” (male, 41-54, high 
dependence). These participants thought that the information presented to them was 
exaggerated or not entirely truthful, and asked to be presented with just “the facts.”  
 
While explicit distrust of science in general was only expressed by a few participants, many 
disputed the “scientific claim” that was presented to them. Some gave a brief “apology” for 
disagreeing, or a disclaimer that they were not scientists and were simply expressing their 
personal opinion.  
I wouldn't say it's a brain disease. I don't want to prove the scientists wrong, 
but it's just my opinion. I don't think it's a disease. (male, 26-40, low 
dependence) 
 
Utility of the “brain disease” model of addiction 
It was common for participants to question the feasibility of introducing the brain disease label 
into public discourse about smoking.  This was partly because they thought that it would not 
be accepted by most smokers, regardless of its scientific accuracy. One participant phrased this 
as “buy in”. He did not “buy into” the medical explanation of smoking as a brain disease and 
he thought that this would be true for most smokers. Others thought smokers would find it quite 
amusing to think of smoking in this way because it was inconsistent with their conceptions of 
smoking.  
Smokers would probably laugh at it for trying to make it even worse…people 
would see right through it. (male, 26-40, moderate dependence) 
Other participants thought that the language of smoking as a brain disease may have different 
consequences for different groups in the community. For example, it was common to 
distinguish between the effects of this discourse on smokers and non-smokers. Some believed 
that thinking of smoking in terms of a brain disease might “scare” smokers into making a quit 
attempt so that they could regain a “healthy brain.” However, they were also concerned that 
the brain disease label would increase the judgemental attitudes of non-smokers. 
A good thing for some people, a bad thing for others.  You know what I mean?  Like, if 
you’re a smoker now it may shock you into stop smoking for a - so that’s a good thing.  
The bad thing would be a non-smoker prejudicing towards a smoker and saying that 
they’re a - they have a disability. (male, 18-25, low dependence) 
145 
 
Some distinguished the utility of the brain disease concept for young people and for older, 
established smokers. They thought it might deter young people from starting to smoke while 
discouraging older and more established smokers from attempting to quit.  
…If I wasn’t a smoker and someone said that people who smoke have brain 
disease, it would probably deter me from starting. If I was a smoker and people 
were calling me someone with a brain disorder, I would probably smoke more 
just in spite of them. (female, 18-25, low dependence) 
Others thought it unnecessary to introduce the label because current models of smoking were 
adequate. Introducing this term would only confuse discourses about smoking in society.  
I just think it’s a waste of time. I think it’s something that doesn’t need to be - 
it’s like don’t re-invent the wheel. We know it’s a drug, we know it’s addictive. 
Leave it at that. (male, 26-40, moderate dependence) 
 Discussion 
While most smokers accepted that nicotine acts on the brain to influence their smoking, the 
majority rejected the label of smoking as a brain disease. The main reasons for this were: doubts 
about the scientific accuracy of the claim; concerns that such terminology would increase 
stigma and prejudice against smokers; and a belief that it would lead smokers to absolve 
themselves of personal responsibility for their smoking. Participants also believed that most 
smokers would not endorse such a label, even if it was scientifically accurate.  
 
While a few participants were prepared to defer to the authority of science and accept that 
nicotine addiction was a brain disease, most pointed to what they perceived as inaccuracies and 
deficiencies in the term. This is consistent with the broader empirical literature on public 
understanding of science (PUS) which shows that publics are not passive in their reception of 
scientific information; they more often resist or re-work scientific ideas based on their own 
values or experiences (Choudhury et al., 2012; G. Munro, 2010; O’Connor & Joffe, 2013; 
Pickersgill et al., 2015; Wynne, 1992).   
 
While some in this study made apologies about disagreeing with scientists, a minority 
questioned the motives of the public health approach to smoking. The latter group believed that 
they were being provided with biased information in an attempt to manipulate their behaviour, 
and felt irritated at being told what to do by a “nanny state.” This response highlights the 
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importance of public trust in judgements about science and technology, which has long been 
recognised as an important influence on lay acceptance of science in PUS (Wynne, 1992). The 
tobacco industry has fostered a distrust of public health by criticising tobacco control strategies 
as forms of “nanny state” interference in personal choice and “freedom” (Daube, Stafford, & 
Bond, 2008). The tobacco industry has always attempted to position smoking as a free choice 
that is made by responsible adults who can control their smoking through the use of their 
willpower (White et al., 2013). The gendered nature of beliefs about the role of willpower and 
individual responsibility have been noted by White, Oliffe and Bottorff (2013). They argue that 
the “masculine ideal” of an autonomous and self-contained individual, with internal resources 
of self-control and willpower, reduced the responsibility attributed to the tobacco industry. 
These views about the value of individual responsibility and inner strength persist in societal 
discourses, and in this study, it was largely men who engaged in “nanny state” discourse.  
 
This individualisation of illness has been identified as a feature of contemporary public health 
and of biomedicalisation (Clarke et al, 2003; Lupton, 1993; Pearce, 1996). This entails a moral 
responsibility for individuals to identify the disease risk factors relevant to them and to work 
towards addressing them. If they do not, then they may be subjected to stigma or public 
shaming (Amonini et al, 2015; Lupton, 2014). The findings reported in this chapter show that 
“the individual” is the central locus in lay understandings of smoking amongst smokers. 
Participants emphasised that they took full responsibility for their own smoking, and were 
concerned that other smokers would use a brain disease explanation of smoking to absolve 
themselves of personal responsibility. This also echoes findings from Chapter 5, where the 
general public thought that the best method would “depend on the individual” and their 
willpower and motivation. Thus, both the BDMA, and lay understandings focused on 
willpower, embrace the emphasis on the individual smoker. However, as described in Chapter 
5, smokers have a moral responsibility to try to stop smoking, not to stop smoking in a 
particular way. Taking responsibility for your smoking does not entail a medical approach to 
cessation.  
 
Suspicion of science and public health was not the most common reasons for rejecting the brain 
disease label. Personal experience seemed more influential. Smoking is a topic about which 
smokers have considerable experience and they drew on their own smoking careers, which 
often involved decades of smoking and many failed quit attempts, as well as observations of 
the smoking trajectories of their friends and family. These personal experiences were used to 
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construct a schema of smoking and for many of our participants, the brain disease label did not 
fit with their understandings of smoking. Many described smoking as a habit, or a matter of 
willpower. The idea of smoking as a choice, while co-opted by the tobacco industry, was also 
a part of public understandings of smoking because many people have simply quit smoking 
and apparently succeeded without difficulty (Chapman & MacKenzie, 2010; West & Sohal, 
2006). The denial of this element of choice, as implied by the BDMA, was a common reason 
participants gave for rejecting it.  
 
The fact that participants did not generally reject the scientific information presented in the 
Powerpoint about nicotine addiction (Chapter 7), but often rejected scientists labelling smoking 
as a “brain disease” hints at the role that laypeople believe scientists should have in 
disseminating ideas about addiction. Specifically, speaking factually about the biological 
aspects of addiction was acceptable, but moving beyond this by labelling smokers as a certain 
type of person was not. This was especially so, because of the negative connotations that many 
associated with being labelled as having a “brain disease.” These included a refutation of 
personal autonomy and will, the application of a “sick” role, and an association with “brain 
damage” and the associated loss of full personhood. It was only when scientists were deemed 
to be going “too far” that questions about their credibility began to emerge in the discussions.  
 
Much of the sociological critique of medicalisation describes the adverse social consequences 
of using medical labels for human behaviour. Our research showed that smokers were also 
aware of these potential consequences of particular understandings of smoking. Conrad (1992) 
criticised medicalisation because it can lead to a “dislocation of responsibility”, creating a 
group of people deemed to be in control, and another group of people who are deemed not to 
be in control of their behaviour. Many of the participants interviewed for this study recognised 
this possibility and thought that other smokers would use the brain disease label to diminish 
their personal responsibility.  
 
Conrad has also argued that labelling a behaviour as a disease is “to deem it undesirable.” 
(Conrad, 1992, p. 249). Smoking is already undesirable in many countries, and those 
interviewed reported experiencing significant smoking-related stigma in their everyday lives. 
They recognised that the disease label was value-laden and had negative connotations that 
could increase stigma. Most smokers in this study showed no interest in taking on a “sick role” 
in regards to their smoking. The potential for stigma may partly explain this, but also it may be 
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because, as Keane (2002) has described, cigarettes have a “unique cultural location” in Western 
society. Nicotine is acknowledged as an addiction, however it is an addiction that does not 
often interfere with the activities of everyday life. Also, the harms of smoking are “abstract 
possibilities” (Keane, 2002), when compared to the more immediate harms associated with 
alcohol dependence and addiction to most illicit drugs. This makes more intensive interventions 
such as drug rehabilitation or prescription medications for smoking cessation seem “too 
serious” for many smokers.  
 
The word “disease” was also problematic because smokers attached many and varied meanings 
to it. This is not surprising because the term lacks definitional clarity even among academics 
(DeVito, 2000; Hofmann, 2010; Räikkä, 1996; Scully, 2004). This makes it easy to use narrow 
definitions of the term to dismiss it. Using the term “brain disease” may be counterproductive 
if potentially useful (and more acceptable) messages about the role of the brain in smoking are 
disregarded. Because the term brain disease creates confusion, distrust and disbelief among 
smokers, it is not likely to be helpful in health promotion material or clinical interactions with 
smokers. However, rejection of the brain disease model does not rule out a more nuanced view 
of the role of the brain in smoking. This could play a useful role in providing smokers with 
insight into their own smoking. In fact, many participants who rejected the brain disease label 
found the information about the role of the brain in their smoking interesting and thought it 
provided insights into their smoking, as described in Chapter 7. 
 
Some may argue that smoking is not often described as a brain disease in the tobacco control 
or smoking cessation literatures. However, the use of this type of language is implicit in the 
rationale offered for medical approaches to smoking cessation, e.g., drug treatments such as 
Champix that are claimed to act on neurotransmitters, and experimental treatments such as 
transcranial magnetic stimulation that acts directly on brain function (Li et al., 2013). This 
conceptualisation of addiction is also promoted in health education materials disseminated by 
NIDA that are designed for use by the general public and schools (National Institute on Drug 
Abuse, 2006). Moreover, the results reported here demonstrate that it is the label of smoking 
as a chronic disease that many people rejected, rather than the emphasis on the brain. The 
chronic disease label is increasingly being applied to tobacco dependence. The US Public 
Service Guidelines on treating tobacco dependence define it as “a chronic disease that often 
requires repeated intervention and multiple attempts to quit” (Fiore et al., 2008, p. vi). A 
number of authors have called for tobacco dependence to be treated as a chronic disease, similar 
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to diabetes or hypertension (Aveyard & Raw, 2012; Leone & Evers-Casey, 2012; Prochaska & 
Benowitz, 2016; Wolff et al., 2013). The results of this research suggest that this definition is 
at odds with the way that many smokers understand their own smoking.  
 
Original contribution of Chapter 8 
In the USA, addictions are increasingly being labelled as “brain diseases”. The implications of 
this terminology for the tobacco control field have not been widely examined, despite nicotine 
addiction being the most prevalent form of drug addiction globally. This research is the first to 
look at how smokers respond to being labelled as having a “brain disease”. Our findings 
suggest the need for caution in applying the NIDA “brain disease” label of addiction to nicotine 
addiction. The concerns of the smokers interviewed for this research echoed academic critiques 
of the BDMA. They felt that it did not capture the complexity of their smoking, that it could 
increase (rather than decrease) stigma, and that it may diminish the role of autonomy and choice 
in smoking cessation, something that was believed to be key to a successful quit attempt. 
Disseminating the idea that smoking is a brain disease may increase some smokers’ distrust of 
health professionals, deterring them from seeking assistance or using cessation aids. The fact 
that the description of nicotine addiction as a brain disease is discordant with the lived 
experience of smokers should be thoughtfully considered in debates about the social benefits 
of this approach to addiction. The next chapter will outline the results of a quantitative survey 
that sought to elicit smokers’ views on the role of their brain in their smoking, and the potential 
impact of these views on quitting self-efficacy and treatment intentions.  
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Chapter 9. Do neurobiological understandings of smoking influence 
quitting self-efficacy or treatment intentions?   
 
 Introduction 
The qualitative findings reported in Chapters 5, 6, 7, and 8 suggested that medicalised 
explanations of nicotine addiction do not predominate in lay discourse on smoking. When 
asked about the role of the brain, the smokers that were interviewed acknowledged that tobacco 
use affected their brain, but they did not believe this played the primary role in their continued 
smoking. They attached greater importance to willpower, motivation and personal 
responsibility. The new language of smoking as a brain disease that has begun to infiltrate 
scientific and public explanatory models of addiction was rejected by most participants, who 
questioned its accuracy and believed that it could have negative social consequences for 
smokers.  
 
These findings from the qualitative component of this research inform our understandings of 
how people interpret information about the neurobiology of nicotine addiction however it is 
unclear whether these results will apply in a larger and more representative sample of 
Australian smokers. Qualitative research is by its nature local and situated. The qualitative 
stage of this research project reported in preceding chapters provided unique insights into 
smokers’ understanding of their smoking that informed the development of questions included 
in a large quantitative survey. The aims of the quantitative survey were to: (1) determine the 
prevalence of smokers’ attitudes identified in the qualitative stage in a large sample of 
Australian smokers; and (2) explore relationships between demographic and smoking-related 
variables and smokers’ beliefs about the role of the brain in smoking.  
 
The quantitative study described in this chapter examines the extent to which smokers endorse 
neurobiological explanations of smoking, and assesses whether their endorsement of brain-
based explanations of smoking influences quitting self-efficacy or their preferences for using 
particular smoking cessation methods. The specific research questions addressed were:  
 What proportion of Australian smokers endorse neurobiological explanations of 
tobacco dependence?  
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 What sociodemographic variables predict the endorsement of neurobiological 
explanations of smoking?  
 Is there a relationship between endorsement of neurobiological explanations of 
tobacco dependence and intentions to use pharmacotherapy for future smoking 
cessation attempts?  
 What is the relationship between endorsement of neurobiological explanations of 
smoking and feelings of quitting self-efficacy amongst Australian smokers?  
 Method 
Design and Sampling 
The data reported in this chapter come from an online survey of 1,538 smokers in Australia. 
All participants were smokers recruited from a commercial online research panel accredited to 
quality assurance standards ISO20252 and ISO26363. Participants on this panel were recruited 
from both online and offline sources and those who completed the survey received points for 
participation that could be converted to gift vouchers. The median length of time it took to 
complete the survey was 18 minutes.  
 
Invites were sent to panel members who had previously reported that they were a smoker and 
the invitation strategy was adjusted daily with quotas to obtain a sample representative of the 
demographic profile of the population of Australian smokers in terms of age and gender 
(Australian Institute of Health and Welfare, 2014). To be eligible, participants were required 
to be aged 18 years old or older, an Australian citizen or resident, smoked daily, and had 
smoked more than 100 cigarettes in their lifetime. The recruitment process is outlined in Figure 
9-1. Of the 6,520 invited participants who clicked on the link to the survey, 4,273 did not smoke 
daily, 49 had not smoked at least 100 cigarettes and 16 exited the survey prior to completing 
the eligibility questions, and were therefore excluded. Of those who met the eligibility criteria 
(N=2,182), 625 dropped out prior to completion. Seven were identified as duplicate cases 
caused by a computer error, and were removed from the dataset. Despite reporting daily 
smoking on the screening questions to assess eligibility, 12 participants stated that they smoked 
zero cigarettes per day on a subsequent question and were excluded from the dataset.  
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Figure 9-1 - Recruitment process for survey 
 
 Survey development 
The survey was informed by an extensive literature review (Chapters 2 and 3) and the results 
of the qualitative component of the project (Chapters 5, 6, 7, 8). Given the paucity of research 
in this area, the survey design was also informed by research in related areas, such as studies 
Recipients who clicked on link 
to start survey 
n=6520 
Ineligible recipients: 
 4273 did not smoke 
daily 
 49 had not smoked 100 
cigarettes 
 16 left survey prior to 
completing all 
eligibility criteria 
  
 Total: 4302 
 
Eligible recipients who 
commenced survey 
n=2182 
Eligible participants who 
completed survey 
n= 1538 
Excluded 
 625 did not complete 
survey n=625 
 7 identified as duplicates 
 12 removed as recorded 0 
for cigarettes smoked per 
day 
Total: 644 
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of the attitudes of persons experiencing other drug addictions towards the role of the brain in 
their addictions (Meurk et al., 2014; Netherland, 2011; Pescosolido et al., 2010) as well as on 
public perceptions and knowledge of genetics (Docherty et al., 2011; Houfek et al., 2008; Park 
et al., 2011; Phelan, Cruz-rojas, & Reiff, 2002; Sanderson, O'Neill, Bastian, Bepler, & 
McBride, 2010; Smerecnik, Grispen, & Quaak, 2012; Wright et al., 2007). 
 
A number of important themes that emerged from the qualitative component of the research 
described in earlier chapters were incorporated into the survey instrument. For example, during 
the interviews, it became clear that participants often described themselves as being different 
from other smokers. When responding to questions about the nature of smoking, participants 
often referred to “other smokers”, rather than themselves as smokers. Therefore, we decided to 
include questions examining participants’ views on their own smoking and their views on other 
smokers  
 
 Measures 
Demographic and smoking related variables 
 
Sociodemographic variables included: age, gender, education (less than year 12, completed 
secondary school, post school qualifications, bachelor degree or higher), whether the 
participant was born in Australia, employment status (employed or self-employed, 
unemployed, a student, home duties or carer, volunteer or charity work, retired or on a pension, 
unable to work, other) and postcode.  
 
Smoking-related variables included: age of smoking initiation, how many times they had tried 
to quit in the last year, future quitting intentions, and their enjoyment of smoking. Level of 
nicotine dependence was measured using the HSI, which contains two items: time to first 
cigarette of the day, and number of cigarettes smoked per day (Heatherton et al., 1989).  
 
Quitting self-efficacy was measured using a single item asking “If you decided to give up 
smoking completely in the next six months, how sure are you that you would succeed?” This 
item has been used extensively in the International Tobacco Control Policy Evaluation Project 
(ITC) (Borland et al., 2010; Hyland et al., 2006; Siahpush, Yong, Borland, Reid, & Hammond, 
2009) and in other national surveys (Bonevski et al., 2015). Response options were: not at all 
sure, slightly sure, moderately sure, very sure, or extremely sure.  
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The Reasons for Smoking Scale used in the UK Smoking Toolkit Study (Fidler & West, 2009) 
was adapted for the purposes of this survey. Those items not prominent in the qualitative results 
reported in earlier chapters were replaced with those that featured frequently in qualitative data 
from this project. For example, smoking for pain relief was not mentioned by any participants 
in the interviews, so was replaced with “psychological addiction”, which was frequently given 
as a reason for smoking.  
 
Beliefs about the neurobiology of smoking 
Four items were developed to assess strength of endorsement of beliefs about the role of 
neurobiology in smoking. Participants were asked to rate the extent to which they agreed with 
the following statements on a four-point scale (strongly disagree, disagree, agree, strongly 
agree) and the option of “don’t know” as a response:  
“Smoking is a brain disease”;  
“Smoking changes the chemistry of the brain”;  
“Smoking damages the brain”  
“Smoking is a brain disorder”; and  
“Don’t know.” 
To investigate the extent to which they believed that the brain was implicated in smoking, they 
were given the statement “Smoking causes...” and were asked to complete the sentence with 
one of the following options: “Long lasting changes to the way the brain works”; “Temporary 
but substantial changes to the way the brain works”; “Minor changes to the way the brain 
works”; “No changes to the way the brain works”; or “I have no idea what effect smoking has 
on the brain.”  
 
Based on the interview data, we expected participants to have limited knowledge of how the 
brain was involved in nicotine dependence. Therefore, later in the survey, participants were 
shown an excerpt from a book written for the general public by Professor Robert West, a 
leading UK tobacco researcher. The book aims to present scientific evidence about quitting to 
smokers to help them develop evidence-based strategies for quitting. The excerpt (quoted 
below) gives more detail about how the brain is implicated in tobacco dependence, to allow 
participants to respond to a more detailed, nuanced description of the role of the brain than that 
presented in previous items. Professor West describes the neurobiological basis of smoking as 
follows:  
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“You smoke because the nicotine you have been inhaling all those years has changed 
your brain chemistry to create powerful urges to smoke. The urges come about because 
every puff on a cigarette sends a rapid nicotine “hit” to the part of your brain that 
makes you do things…These urges are triggered because nicotine has trained the part 
of your brain that gets you to do things to light up a cigarette whenever you find yourself 
in a situation where you would normally smoke.” (West, 2013, p. 34)  
Participants were asked how well this description explained their own smoking, and how well 
it explained the smoking of others. Response options were: not a lot, a little, a lot, completely, 
or don’t know. They were then asked again if they believed that smoking was a brain disease, 
in order to assess whether providing details about the neurobiological basis of tobacco 
dependence from an authoritative source influenced their responses to this question.  
 
A set of questions also explored participants’ views on possible social consequences of the 
BDMA. They were asked whether they thought that accepting a brain-based explanation for 
smoking would influence: smokers’ desire to stop smoking, smokers’ confidence in their ability 
to quit; negative social attitudes towards smokers; personal responsibility for smoking; 
sympathy for smokers; treatment-seeking for smoking cessation; and smokers’ feelings of 
guilt. Options were: decrease, have no effect, increase or don’t know. The full survey is 
included as Appendix D. 
 
Use of pharmacotherapy for smoking cessation 
Participants were provided with a list of smoking cessation strategies and asked to check all of 
those that they had previously used. Those who reported having used nicotine replacement 
therapy (NRT) or prescription medications (Champix or Zyban) were coded as having used a 
medication for smoking cessation. In addition, intention to use pharmacotherapy in future quit 
attempts was assessed with the question “If you decided to make a quit attempt, how likely is 
it that would use the following method.” Response options were: definitely wouldn’t use, 
probably wouldn’t use, probably would use, definitely would use, and don’t know. Those who 
selected probably or definitely would use for NRT or prescription medications were 
categorised as intending to use medications. All other responses were classed as not intending 
to use medication. 
 
Further questions explored general attitudes toward various quitting strategies. These are not 
reported here. A first round of pilot testing of the survey with a convenience sample of smokers 
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from the research team’s networks (n=5) was conducted to assess the comprehensibility of the 
questions and the length of time it took to complete the survey. In order to improve 
comprehensibility, minor changes to wording were made based on suggestions from those who 
piloted the survey. A second round of pilot testing with 50 participants recruited by the market 
research company ensured that there were no problems with the online administration. As no 
problems arose in this second round of pilot testing, data from these 50 pilot surveys are 
included in the final dataset.  
 
 Statistical data analysis 
After descriptive analyses (counts and percentages) were conducted, two key items measuring 
the strength of endorsement of brain-based explanations of smoking were selected for further 
analysis: 1)“Smoking changes the chemistry of the brain”; and 2) “Smoking is a brain 
disease.” The latter item was chosen to represent NIDA’s BDMA. The former measures a 
weaker representation of the role of the brain in smoking and does not include the controversial 
term “disease.” For each of these items, the five point Likert scale was converted into a three 
level categorical variable that comprised of: (1) disagree (disagree combined with strongly 
disagree), (2) agree (agree combined with strongly agree), and (3) don’t know. While similar 
analyses in the literature have excluded “don’t know” responses, this was not appropriate in 
this study because a high proportion of respondents selected “don’t know” for these items.  
 
For each of these two key items, contingency tables and the Pearson’s chi-squared statistic 
were used to examine which variables were associated with scores on these two items. 
Categorical independent variables were gender, education, level of nicotine addiction 
(measured by the HSI), self-efficacy, and intention to use medication. Age was analysed as a 
continuous variable using ANOVA. 
 
A binary logistic regression analysis then explored the relationship between endorsement of 
each of the two key neurobiological explanations of smoking and intention to use medication 
in a quit attempt. In the first binary logistic regression, intention to use medication was entered 
as the outcome variable (0=no intention and don’t know, 1=intend to use). Predictor variables 
were entered in two blocks using the Enter method in SPSS v22. The first block contained 
demographic variables and smoking characteristics: gender (male=0/female=1), age 
(continuous), level of education, HSI score (low=0-1, moderate=2-3, high=4-6), self-efficacy 
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(low=not all sure and slightly sure, moderate = moderately sure, high = very sure and extremely 
sure), past use of cessation medications (0 = no, 1= yes). In the second block endorsement of 
brain-based explanations were added, specifically “Smoking is a brain disease” and “Smoking 
changes the chemistry of the brain”. A correlation analysis including the last two items showed 
that all items were sufficiently distinct from each other to treat them as separate variables (see 
Appendix F). 
 
Another binary logistic regression analysis investigated the relationship between endorsements 
of neurobiological explanations of smoking and self-efficacy. The outcome variable was a 
dichotomised version of self-efficacy (0 = low, 1 = moderate/high). Again, predictor variables 
were entered in two blocks using the Enter method in SPSS v22. The first block contained 
demographic variables and smoking characteristics: gender (male=0/female=1), age 
(continuous), level of education, HSI score (low=0-1, moderate=2-3, high=4-6), past use of 
medications (0 = no, 1 = yes). In the second block endorsement of brain-based explanations 
“Smoking is a brain disease” and “Smoking changes the chemistry of the brain” were added.  
 
 Results 
Participant demographics 
The age of participants ranged from 18-88 years old with a mean age of 43 years (SD 16.1). 
Soft quotas were set for recruitment so that the sample would align with the proportion of the 
Australian population who smoked by gender and age, based on data from the National Drug 
Strategy Household Survey (2014). All quotas were met except for a very slight under-
representation of males in the 18-24 and 25-29 age groups.  
 
The proportion of the sample born in Australia aligned closely with the population data [72.8% 
born in Australia] (ABS, 2013). In relation to education, 26.4% had no post-secondary 
qualification, 32.2% had completed some post-secondary education at less than bachelor 
degree level, and 31.3% had completed a bachelor degree or higher. See Table 9.1. 
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Table 9.1 - Participant demographics for survey 
Age, mean (SD) 43.0 (16.1) 
Gender % 
     Male  
     Female 
 
54 
46 
Educational attainment % 
     Did not complete high school 
     High School 
     Post-secondary qualifications (e.g., trade training) 
    Bachelor Degree or higher 
 
18.6 
17.8 
32.2 
31.3 
Born in Australia % 72.3 
Employment status 
Employed or self-employed 
Unemployed 
Student 
Home duties/carer 
Retired/Pension 
Other 
 
54.9 
6.3 
6.6 
9.1 
16.7 
6.4 
Employment status – other = volunteer work, unable to work, something else.  
 
Smoking related variables 
Table 9.2 reports on the variables relating to participants’ smoking. The mean number of 
cigarettes smoked per day was 15 (SD 9.6). In line with previous studies, a score of 0-1 on the 
HSI was categorised as low dependence, 2-4 as moderate dependence, and 5-6 as high 
dependence (Borland et al., 2010; Cooper et al., 2010). Approximately 75% of participants 
reported moderate or high nicotine dependence. 
 
Most participants (80%) had tried to quit in the past, and a similar proportion intended to quit 
in the future. Almost half reported low levels of self-efficacy in relation to quitting, and 
approximately half had used cessation medication for a past quit attempt (either NRT or 
prescription medication). Approximately two thirds of participants said that they would use 
NRT or prescription medications if they were to make a quit attempt. This is consistent with 
data showing that around 60% of smokers in Australia had used help to quit (Cooper et al., 
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2011), but discordant with qualitative findings reported in preceding chapters, which showed 
negative attitudes towards cessation aids.  
 
Table 9.2 - Smoking-related variables 
Cigarettes per day, mean (SD) 15.11 (9.6) 
Nicotine dependence % 
        Low 
        Moderate 
        High 
 
25.8 
45.8 
28.4 
Ever tried to quit  (% Yes) 79.9 
Intend to quit % 
Yes, within 30 days 
Yes, after 30 days, but within 3 months  
Yes, but not within the next 3 months 
No, not planning on giving up 
 
14.4 
31.4 
34.9 
19.2 
Self-efficacy % 
       Low 
       Moderate 
       High 
 
47.0 
32.4 
20.5 
Ever tried medication % 
Nicotine replacement therapy     
Prescription medication     
Total used medication 
 
41.7 
24.0 
49.6 
Intend to use medication % 
    Nicotine replacement therapy 
    Prescription medication 
    Total intend to use medication 
 
54.1 
45.4 
67.2 
Nicotine dependence measure HSI: 0-1 = low dependence, 2-3 = moderate dependence, 4-6 = high dependence.  
 
Reasons for smoking 
There was a tendency to endorse most of the reasons for smoking that were listed (see Table 
3). Almost 80% of participants agreed or strongly agreed that they smoked because they were 
addicted to smoking. Most also agreed or strongly agreed that they were addicted to nicotine 
(72%), and that they smoked because they experienced cravings (78% agree or strongly agree). 
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The idea that smoking was a habit was strongly endorsed, with 87.4% of participants agreeing 
or strongly agreeing that they smoked because their smoking had become a habit. 
Approximately 80% agreed or strongly agreed that they smoked because it helped them to deal 
with stressful situations. More than half agreed or strongly agreed that they smoked because of 
a psychological (61%) or physical addiction to smoking (64.1%). Less commonly endorsed 
reasons for smoking were that they had an addictive personality and that smoking helping them 
to socialise.  
 
Table 9.3 - Reported reasons for smoking 
 Strongly 
disagree 
Disagree Agree Strongly 
agree 
Undecided 
I am addicted to cigarettes 3.1% 10.5% 50.1% 28.5% 7.7% 
I have a psychological addiction 
to smoking 
5.5% 15.3% 42.5% 18.5% 18.1% 
I experience cravings for 
cigarettes 
2.7% 11.8% 50.7% 27.3% 7.5% 
Smoking is an important part of 
my everyday routine 
4.9% 17.8% 51.4% 16.7% 9.2% 
It helps me to socialise 16.5% 33.2% 32.1% 7.5% 10.7% 
I want to avoid withdrawal 
symptoms 
6.8% 19.8% 43.2% 18.8% 11.3% 
I am addicted to nicotine 3.8% 12.8% 45.5% 26.5% 11.3% 
I have an addictive personality 10.9% 26.8% 34.3% 12.9% 15.0% 
It helps me deal with stressful 
situations 
2.9% 10.3% 53.2% 26.3% 7.3% 
It has become a habit 1.9% 6.0% 47.1% 40.3% 4.7% 
I have a physical addiction to 
smoking 
5.4% 15.5% 44.8% 19.3% 14.9% 
 
 
Endorsement of brain-based explanations of smoking 
Table 9.4 shows the percentage of participants who agreed or disagreed with a number of 
specific statements about the role of the brain in smoking. The majority (57.9%) agreed or 
strongly agreed that smoking changed brain chemistry. The findings were similar for the 
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statement that smoking damages the brain (63.9% agree or strongly agree). Fewer participants 
agreed that smoking was a brain disease or a brain disorder. Nevertheless, around one third 
agreed or strongly agreed that smoking was a brain disease. There were high proportions of 
“don’t know” responses for each item, suggesting that many were unfamiliar with the role of 
the brain in smoking, or did not feel confident enough to make a judgement. Because a neutral 
option was not included in the scale, it is also possible that those who have a neutral position 
selected the Don’t Know option.  
 
Table 9.4 - Endorsement of brain-based explanations of smoking 
 Strongly 
disagree 
Disagree Agree Strongly 
agree 
Don't 
know 
Smoking is a brain disease 13.1% 25.2% 24.8% 9.6% 27.2% 
Smoking changes the chemistry of 
the brain 
3.6% 9.3% 42.2% 15.7% 29.3% 
Smoking damages the brain 4.0% 12.3% 38.8% 15.8% 29.2% 
Smoking is a brain disorder 14.5% 26.1% 24.1% 8.5% 26.7% 
Some smokers have an increased 
chance of becoming addicted to 
cigarettes because of their genes 
7.7% 17.8% 35.4% 12.9% 26.1% 
 
An additional item examining the extent to which participants thought that their brain was 
affected by smoking revealed that 27.4% thought that smoking caused long-lasted changes in 
brain function, 18.7% thought it caused temporary but substantial changes, 15.1% thought 
smoking caused only minor changes to the way the brain works, and 8.6% thought smoking 
did not change the brain. Again, a high proportion of smokers expressed uncertainty about the 
relationship between smoking and the brain, with 30.2% selecting the response “I have no idea 
what effect smoking has on the brain.” Correlations between these items were moderate, 
ranging from 0.50 to 0.68, meaning that the items were distinct enough to be treated separately 
in analyses. The correlation table can be found in Appendix F.  
 
After being presented with the quote from Robert West, participants were asked to what extent 
this description described their own and others’ smoking. Responses are shown in Table 9.5.  
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Table 9.5 - Acceptance of Robert West’s explanation of smoking 
 Not at all A little A lot Completely Don't know 
Accept explanation - self 5.2% 34.2% 35.3% 15.5% 9.8% 
Accept explanation others 2.0% 26.7% 40.9% 13.7% 16.8% 
 
Most participants thought that this description of smoking explained their own smoking to 
some extent. Only a very small proportion believed it did not explain their smoking at all. There 
were some small differences between whether participants accepted this explanation in regards 
to their own smoking versus that of others. Participants were more likely to express uncertainty 
about whether this description applied to other smokers than themselves.  
 
Participants were again asked if they thought smoking was a brain disease, to assess whether 
providing a description of how nicotine worked in the brain would increase their acceptance of 
their explanation. A cross-tabulation showing movement between categories is provided in 
Table 9.6. Table 9.6 shows that there was some movement between categories, but the majority 
of participants who agreed or strongly agreed remained in one of these categories after being 
presented with Robert West’s explanation of the role of the brain in smoking. Similarly, the 
majority who disagreed or strongly disagreed selected one of these options on the second 
occasion they were asked. There were few who initially selected “strongly agree” or “strongly 
disagree” who later switched to an opposing category. Notably, almost half of the participants 
who initially selected the “don’t know” option changed their response after reading the Robert 
West quote. Of the 45.1% who changed from “don’t know”, 25.1% selected “agree” or 
“strongly agree”, while 20% switched to “disagree” or “strongly agree”. This suggests that 
providing more detail about the neurobiological basis of tobacco dependence may reduce 
uncertainty about the claim that smoking is a brain disease, but does not sway people to change 
their opinions in one direction over the other. 
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Table 9.6 - Change in agreement that smoking is a brain disease after being presented with Robert West explanation  
 
 Smoking is a brain disease (Time 2) Total 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
Don't 
know 
Smoking is a brain 
disease (Time 1) 
Strongly agree 45 
30.4% 
70 
47.3% 
6 
4.1% 
6 
4.1% 
21 
14.2% 
148 
100.0% 
Agree 31 
8.2% 
230 
60.5% 
54 
14.2% 
15 
3.9% 
50 
13.2% 
380 
100.0% 
Disagree 11 
2.8% 
85 
21.9% 
179 
46.1% 
42 
10.8% 
71 
18.3% 
388 
100.0% 
Strongly disagree 8 
4.0% 
21 
10.4% 
67 
33.2% 
81 
40.1% 
25 
12.4% 
202 
100.0% 
Don't know 7 
1.7% 
98 
23.4% 
70 
16.7% 
14 
3.3% 
230 
54.9% 
419 
100.0% 
Total 102 
6.6% 
504 
32.8% 
376 
24.5% 
158 
10.3% 
397 
25.8% 
1537 
100.0% 
Missing data n = 1 
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Participants were also questioned about the potential consequences of emphasising the role of 
the brain in smoking dependence (see Table 9.7). The most common response for most items 
was that describing smoking in the way outlined by Robert West would have no effect but the 
“don’t know” response was again very common. Forty per cent of participants thought that 
emphasising the role of the brain would increase their desire to quit smoking, with only 5.1% 
reporting that they thought it would decrease their desire to quit. Almost half of those surveyed 
thought that the number of people willing to seek medical treatment would increase if smoking 
was explained in neurobiological terms. Most did not think it would increase negative attitudes 
towards people who smoke (stigma), or decrease smokers’ confidence in their ability to quit.  
  
Table 9.7 - Expectations of consequences of brain-based explanations of smoking 
 Decrease No effect Increase Don't 
know 
The desire to stop smoking 5.1% 34.0% 40.1% 20.8% 
Smokers  confidence in their ability to quit 11.6% 32.6% 32.4% 23.4% 
Negative attitudes towards people who smoke 11.1% 44.6% 23.0% 21.3% 
The sense of personal responsibility that people 
feel for their smoking 
9.3% 34.7% 31.0% 25.0% 
Sympathy towards people who smoke 5.6% 45.7% 27.4% 21.3% 
The number of people willing to seek medical 
treatment for their smoking 
2.9% 26.5% 46.2% 24.4% 
Feelings of guilt in those who smoke 10.9% 40.4% 25.9% 22.8% 
 
 
Who endorses brain-based explanations of smoking? 
The results of the bivariate analyses are presented in Table 9.8. Endorsement of the belief that 
“smoking changed brain chemistry” was not significantly associated with gender or level of 
nicotine dependence but it was strongly associated with age. The mean age of those who agreed 
that smoking changed the chemistry of the brain was ten years lower (39.55, SD = 14.55) than 
those who did not know (49.27, SD = 16.64), and approximately 4 years lower than those who 
disagreed (44.12, SD = 17.64).  
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It was also associated with education. Those who had a lower level of education were more 
likely to say that they did not know whether smoking changed the chemistry of the brain 
(37.4%) compared to those with a bachelor degree (19.7%). Those with a bachelor degree or 
higher qualification were more likely to agree that smoking changed brain chemistry (68.5%) 
than those who had not completed high school (47.6%).  
 
Those with low self-efficacy were less likely to agree that smoking changed the chemistry of 
the brain than those with high self-efficacy (50.5% versus 67.4%). Those who agreed that 
smoking changed brain chemistry were more likely than those who disagreed to intend to use 
medication on their next quit attempt.  
 
The findings were similar for endorsement of the statement that “smoking is a brain 
disease”. Again, level of nicotine dependence was not related to endorsement while age was 
strongly related. Younger participants were more likely to agree that smoking was a brain 
disease, and less likely to say that they did not know. Females were more likely to disagree that 
smoking was a brain disease than males (41.3% versus 35.9%). Again, those with a university 
degree were more likely to agree that smoking was a brain disease (45.6%) than those with the 
lowest level of education (26.2%) and less likely to say that they didn’t know. Those who 
agreed that smoking was a brain disease had higher self-efficacy and were more likely to 
express an intention to use medication.  
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Table 9.8 - Proportion of smokers who endorsed brain-based explanations of smoking stratified by demographics and smoking 
characteristics 
Strata Smoking changes the chemistry of 
the brain 
p Smoking is a brain disease p 
Agree Disagree Don’t know Agree Disagree Don’t know 
Gender 
   Male 
   Female 
 
484 (58.2) 
406 (57.4) 
 
107 (12.9) 
91 (12.9) 
 
240 (28.9) 
210 (29.7) 
0.94  
308 (37.1) 
221 (31.3) 
 
298 (35.9) 
292 (41.3) 
 
225 (27.1) 
194 (27.4) 
0.04 
Age (M, SD) 39.55 
(14.55) 
44.12  
(17.64) 
49.27  
(16.64) 
<0.001 38.18  
(14.26) 
43.66 
(16.63) 
48.09 
(16.12) 
<0.001 
Highest education 
   Did not complete high school 
   Completed high school 
   Post-school qualification 
   Bachelor degree or higher 
 
136 (47.6) 
151 (55.1) 
273 (55%) 
330 (68.5) 
 
 
43 (15) 
36 (13.1) 
62 (12.5) 
57 (11.8) 
 
107 (37.4) 
87 (31.8) 
161 (32.5) 
95 (19.7 
<0.001  
75 (26.2) 
83 (30.3) 
151 (30.4) 
220 (45.6) 
 
110 (38.5) 
102 (37.2) 
200 (40.3) 
178 (36.9) 
 
101 (35.3) 
89 (32.5) 
145 (29.2) 
84 (17.4) 
<0.001 
Level of dependence 
   Low 
   Moderate 
   High 
 
232 (58.6) 
414 (58.9) 
242 (55.5) 
 
 
51 (12.9) 
85 (21.1) 
61 (14) 
 
113 (28.5) 
204 (29) 
133 (30.5) 
0.80  
135 (34.1) 
251 (35.7) 
142 (32.6) 
 
160 (40.4) 
364 (37.6) 
164 (37.6) 
 
101 (25.5) 
188 (26.7) 
130 (29.8) 
0.57 
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Self-efficacy 
  Low 
  Moderate 
  High 
 
365 (50.5) 
312 (62.5) 
213 (67.4) 
 
92 (12.7) 
59 (11.8) 
47 (14.9) 
 
266 (36.8) 
128 (25.7) 
56 (17.7) 
<0.001  
186 (25.7) 
188 (37.7) 
155 (49.1) 
 
301 (41.6) 
186 (37.3) 
103 (32.6) 
 
236 (32.6) 
125 (25.1) 
58 (18.4) 
<0.001 
Intention to use medication  
   Intend to use medication 
   No intention to use 
         medication 
 
661 (64) 
229 (45.3) 
 
117 (11.3) 
81 (16) 
 
255 (24.7) 
195 (38.6) 
<0.001  
401 (38.8) 
128 (25.3) 
 
377 (36.5) 
213 (42.2) 
 
255 (24.7) 
164 (32.5) 
<0.001 
Total 57.9 12.9 29.3 - 34.4 38.4 27.2 - 
Figure is presented as n (% within strata), except for age (mean, SD). X2 used to test for statistical significance except age where one-way ANOVA conducted 
(Welch). Agree = agree plus strongly agree, disagree = disagree plus strongly disagree. Medication = prescription medication or NRT.  Level of dependence  
(HSI):  0-1 low, 2-3 moderate, 4-6 high.  
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Is intention to use medication influenced by beliefs about the neurobiological basis of 
smoking?  
 
As described in Section 9.5 above, forward stepwise binary logistic regression analysis 
assessed whether brain-based understandings of smoking were related to intention to use 
medication. The regression was conducted in two blocks to assess whether the two key brain-
related items improved on a model including only demographic and relevant smoking related 
variables. The Enter method in SPSS V22 was used for each block. The first block included 
the demographic and smoking-related variables of age, gender and level of education, nicotine 
dependence (HSI), smoking cessation self-efficacy, and past use of medication. This model 
was statistically significant (p<0.001) and together these variables correctly predicted intention 
to use medication in 67.7% of participants. When agreement with the statements that smoking 
changes brain chemistry and smoking is a brain disease was added in Step 2 of the model, the 
model remained statistically significant but the predictive power of the model only increased 
very slightly to 68.6%. Though this increase was statistically significant, the small difference 
is unlikely to have any practical significance. The final model with all variables included is 
presented in Table 9.9.  
 
Intention to use medication for smoking cessation was not related to age (OR 1.00, 95% CI 
0.99-1.00) or gender (OR 0.87, 95% CI 0.69-1.10), once other factors were controlled for. 
Education was significantly related to intention to use cessation medications: those who had a 
university degree were more likely than those with no high school education to intend to use 
medications (OR 1.75, 95% CI 1.23-2.48). Those with a moderate level of nicotine dependence 
(scored 2-3 on the HSI) were less likely to intend to use medications than those categorized as 
having low nicotine dependence (OR 1.34, 95% CI 1.02-1.78). There were no statistically 
significant differences in intention to use medication between those with low and higher levels 
of self-efficacy. Participants who agreed that smoking changed the chemistry of the brain were 
more likely to report an intention to use medication (OR 1.62, 95% CI 1.13-2.31) as were those 
who agreed that smoking was a brain disease (OR 1.5, 95% CI 1.11-2.01). These effect sizes 
were statistically significant but only of moderate size. The biggest predictor of intention to 
use medications was past use: those who had used cessation medications in the past were 
approximately three times more likely to intend to do so in the future (OR 3.14, 95% CI 2.46-
4.02).  
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Table 9.9 - Binary logistic regression model regressing intention to use cessation 
medications (yes versus no) on socio-demographic and smoking characteristics  
Factor Odds 
Ratio 
95% (CI) confidence 
internal around OR 
P-value 
Lower Upper 
Female sex (reference = males) 0.87 0.69 1.10 0.216 
Age 1.00 0.99 1.00 0.266 
Education 
Did not complete high school (ref) 
Completed high school 
Post-school qualification 
Bachelor degree or higher 
 
 
1.07 
1.30 
1.75 
 
 
0.74 
0.94 
1.23 
 
 
1.54 
1.80 
2.48 
 
 
0.727 
0.117 
0.002 
Nicotine dependence (HSI) 
Low dependence (ref) 
Moderate dependence 
High dependence 
 
 
1.34 
1.35 
 
 
1.02 
0.97 
 
 
1.78 
1.87 
 
 
0.038 
0.072 
Self-efficacy 
Low self-efficacy (ref) 
Moderate self-efficacy 
High self-efficacy 
 
 
1.30 
0.85 
 
 
0.99 
0.62 
 
 
1.71 
1.16 
 
 
0.061 
0.301 
Prior use of medication 
No (ref) 
Yes 
 
 
3.14 
 
 
2.46 
 
 
4.02 
 
 
<0.001 
Agreement that smoking changes 
brain chemistry 
Disagree (ref) 
Agree 
Don’t know 
 
 
 
1.62 
0.87 
 
 
 
1.13 
0.59 
 
 
 
2.31 
1.29 
 
 
 
0.008 
0.496 
Agreement that smoking is a brain 
disease 
Disagree (ref) 
Agree 
Don’t know 
 
 
 
1.50 
1.06 
 
 
 
1.11 
0.79 
 
 
 
2.01 
1.44 
 
 
 
0.007 
0.690 
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Missing cases =7. Sex: Male = 0, Female =1. Nicotine dependence (HSI): 0-1 = low, 2-3 = moderate, 4-6 = high. 
Prior use of medication = ever use of NRT or prescription medications for smoking cessation. Agreement that 
smoking changes the chemistry of the brain = agree and strongly agree. Disagree that smoking changes the 
chemistry of the brain = disagree and strongly disagree. Agreement that smoking is a brain disease = agree and 
strongly agree. Disagree that smoking is a brain disease = disagree and strongly disagree.  
 
Is smoking cessation self-efficacy influenced by beliefs about the neurobiological basis of 
smoking?  
Another binary logistic regression analysis tested the relationship between self-efficacy and 
beliefs about the role of the brain in smoking. While some studies have suggested that believing 
that addiction to smoking is based in the brain could decrease self-efficacy, the qualitative 
research reported in Chapters 7 and 8 suggested that it could also increase some smokers’ self-
efficacy. The self-efficacy item was measured on a five point scale, but for the purposes of this 
analysis it was dichotomised so that those with low self-efficacy (those who had responded that 
they were not at all or slightly sure they could quit within the next six months) were compared 
to those who had selected one of the remaining responses (moderately sure, very sure, 
extremely sure). This dichotomisation is consistent with a previous study (Fathelrahman et al., 
2009), and its suitability was assessed by cross-tabulations of self-efficacy responses with other 
important variables. These showed that those who reported being not at all sure or a little sure 
that they could quit had similar responses on other questions. Conversely, those who reported 
moderate-high levels of cessation self-efficacy responded quite differently to those with low 
self-efficacy. These cross-tabulations are presented in Appendix F. The results of the binary 
logistic regression are presented in Table 9.10. 
 
Predictor variables entered in the first block were age (continuous), gender (male=0, 
female=1), level of education, level of nicotine dependence (HSI) (low, moderate/high), and 
past use of medication (No=0, Yes=1). This model was statistically significant (p<0.001) and 
correctly assigned 63.4% of participants on self-efficacy. Block 2, where agreement that 
smoking changed the chemistry of the brain (no, yes and don’t know) and that it was a brain 
disease (no, yes and don’t know) were entered, and was also statistically significant (p<0.001). 
The addition of two brain-endorsement items marginally increased the predictive power of the 
model, correctly assigning 66% of participants. 
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Table 9.10 - Binary logistic regression model regressing level of self-efficacy on socio-
demographic and smoking characteristics 
Factor Odds 
Ratio 
95% (CI) confidence 
internal around OR 
P-value 
Lower Upper 
Female sex (reference = males) 1.03 0.83 1.29 0.78 
Age 0.98 0.98 0.99 <0.001 
Education 
Did not complete high school (ref) 
Completed high school 
Post-school qualification (eg diploma) 
Bachelors degree or higher 
 
 
1.40 
1.43 
1.60 
 
 
0.98 
1.04 
1.16 
 
 
1.99 
1.95 
2.22 
 
 
0.065 
0.026 
0.005 
Nicotine dependence (HSI) 
Low dependence (ref) 
Moderate dependence 
High dependence 
 
 
0.77 
0.40 
 
 
0.59 
0.29 
 
 
1.01 
0.54 
 
 
0.06 
<0.001 
Prior use of medication 
No (ref) 
Yes 
 
 
0.80 
 
 
0.64 
 
 
1.00 
 
 
0.05 
Agreement that smoking changes brain 
chemistry 
Disagree (ref) 
Agree 
Don’t know 
 
 
 
0.92 
0.62 
 
 
 
0.65 
0.42 
 
 
 
1.30 
0.91 
 
 
 
0.62 
0.013 
Agreement that smoking is a brain 
disease 
Disagree (ref) 
Agree 
Don’t know 
 
 
 
1.73 
1.08 
 
 
 
1.32 
0.81 
 
 
 
2.26 
1.45 
 
 
 
<0.001 
0.59 
Missing cases =7. Sex: Male = 0, Female =1. Self-efficacy: low = 0, moderate and high = 1. Nicotine dependence 
(HSI): 0-1 = low, 2-3 = moderate, 4-6 = high. Prior use of medication = ever used NRT or prescription medications 
for smoking cessation. Agreement that smoking changes the chemistry of the brain = agree and strongly agree. 
Disagree that smoking changes the chemistry of the brain = disagree and strongly disagree. Agreement that 
smoking is a brain disease = agree and strongly agree. Disagree that smoking is a brain disease = disagree and 
strongly disagree.  
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Gender and past use of medication did not make a statistically significant contribution to the 
final model (OR gender 1.03, 95% CI 0.83-1.29; OR use of medication = 0.80, 95% CI 0.64-
1.00). Those who were younger were less likely to report low self-efficacy (OR 0.98, 95% CI 
0.98-0.99), although this effect was small. Higher levels of education were significantly 
associated with high cessation self-efficacy. The odds of high self-efficacy were 1.6 times 
higher in those with a university degree than in those who did not complete high school (OR 
1.6, 95% CI 1.16-2.22). As might be expected, participants with high levels of dependence had 
lower levels of self-efficacy than those with low-levels of nicotine dependence (OR = 0.40, 
95% CI 0.29-0.54). Those who agreed and disagreed that smoking changed the chemistry of 
the brain did not differ in terms of their self-efficacy but those who said that they “don’t know” 
were more likely to belong in the low self-efficacy group (OR 0.62, 95% CI 0.42-0.91). For 
the brain disease item however, there was a statistically significant difference between those 
who agreed and disagreed:  those who agreed that smoking was a brain disease were more 
likely to have high self-efficacy than those who disagreed (OR 1.73, 95% CI 1.32-2.26). 
 
 Discussion 
One aim of this quantitative study was to investigate the proportion of Australian smokers who 
endorse brain-based explanations of smoking. Such research has not been conducted in 
Australia, but is worthwhile as it can indicate of the extent of the medicalisation of smoking, 
and the uptake of neuroscientific explanations of addiction. The results demonstrate that around 
one third of our sample of Australian smokers agreed that smoking was a brain disease, and a 
similar proportion did not know whether this explanation of smoking was true. Given the 
generally very negative sentiment toward this terminology in the qualitative interviews, we 
expected higher levels of disagreement with this statement.  As expected, a higher proportion 
of participants (57.9%) agreed with the statement that smoking changes the chemistry of the 
brain, but a substantial proportion of participants were uncertain. Further analyses revealed that 
those who were less educated were more likely to say that they did not know. This is consistent 
with other research on PUS (Bauer, 1996). It was unclear whether this is because they have 
less knowledge around the topic of smoking and the brain, or because they are more generally 
less likely to express opinions on unfamiliar topics. The complexities of the “don’t know” 
response have been outlined by researchers in PUS. In particular they have noted that this 
response does not always signify ignorance, but can be due to “the absence of representation, 
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to a sense that the question is irrelevant to the respondent and/or it may relate to the defensive 
needs of the individual” (Bauer & Joffe, 1996, p. 11). 
 
Another aim was to examine whether socio-demographic variables predicted endorsement of 
brain-based understandings of smoking. Results revealed that endorsements of brain-based 
beliefs about smoking were not uniform across social groups. Those who endorsed the stronger 
form of the “brain disease” explanation of smoking were more likely to be: male, younger, 
have a higher level of self-efficacy, have more education, and intended to use medication on 
their next quit attempt. Those who agreed with the less controversial language that smoking 
changes the chemistry of the brain were similarly younger, more highly educated, more likely 
to intend to use medication, and had higher self-efficacy than those with disagreed. These 
findings are discordant with predictions that the BDMA will reduce self-efficacy in addicted 
individuals but supports speculation that it could increase the use of cessation medications 
(Chapman & MacKenzie, 2010).   
 
A third aim was to assess whether endorsement of brain-based explanations of smoking were 
associated with intention to use medication. A binary logistic regression analysis with intention 
to use medication as the outcome variable showed that when other factors were controlled for, 
endorsement of smoking as a brain disease and agreement that it changed the chemistry of brain 
were both positively associated with intention to use medication. This effect, although 
statistically significant, was only of moderate effect size. A greater effect was seen for past use 
of medication, with those who had used medication in the past having around three times higher 
odds of intending to do so in a future quit attempt. This is consistent with research showing 
that those who have used NRT or prescription medication often report finding them helpful 
(Hung et al., 2011) and that current smokers who had used NRT or bupropion in the past were 
more likely to perceive them as helpful compared to those who had not previously tried them 
(Hammond et al., 2004). 
 
The last aim was to investigate whether believing smoking was a brain disease was associated 
with low self-efficacy. A binary logistic regression with level of self-efficacy as the outcome 
showed that after other factors were controlled for, those who agreed that smoking was a brain 
disease had greater odds of having high self-efficacy. This conflicts with the speculation of 
those such as Chapman and McKenzie (2010), who believe that the biomedical understandings 
of addiction will increase feelings of fatalism in relation to smoking.  
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It must be acknowledged that the size of many of these statistically significant differences were 
small, reflecting the large sample size in this study. Statistical significance does not necessarily 
mean that the predictor variable will have a large (or any) significant impact at a clinical or 
population level. The findings from this study suggest that endorsement of brain-based 
explanations of smoking may have a small effect on treatment preferences and self-efficacy. 
While these effects may be small, the belief that smoking changes brain chemistry or is a brain 
disease in some cases had a larger effect than other factors such as age, gender and level of 
nicotine dependence.  
 
A number of limitations must be acknowledged. Firstly, participants were not recruited via 
random sampling. Participants were existing members of an online market research panel so 
there may be differences between smokers who are members of this panel, and the general 
populations of smokers. While resourcing requirements ruled out the possibility of other 
sampling methods, such as random digit dialling for recruitment, the changing nature of survey 
recruitment means that online panels are increasingly being used as a cost-effective and valid 
means of collecting survey data (American Association for Public Opinion Research, 2010). In 
addition, the validity of older methods of random sampling such as random digit dialling is 
being challenged by the increasing use of mobile phones and reductions in response rates 
(Australian Communications and Media Authority, 2014; Fogliani, 1999). Also, our sample 
closely matched the Australian population of smokers in relation to age, gender, and being born 
overseas. Our cross-sectional data also preclude drawing conclusions about the direction of the 
relationships between the outcome and predictor variables.  
 
The high proportion of “don’t know” responses was of interest, and further research could 
investigate the reasons why respondents selected “don’t know.” It could be due to a low level 
of knowledge among smokers about how smoking affects the brain, or more simply could be 
the result of not including a neutral response category. There is debate in the survey 
development literature about whether to include a neutral option and/or don’t know option in 
attitudinal surveys. However, no consensus has been reached and context must be considered 
when making decisions for each item. For items relating to endorsement of brain-based 
understandings, a “don’t know” option was provided because it was expected that some 
participants would be unfamiliar with the topic. A neutral response was not included, as it has 
been shown that people may select this option to reduce the cognitive load of choosing a 
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positional response. It is possible that some of the people who selected “don’t know” in this 
survey would have selected a “neutral” or “midpoint” option if it were presented.  
 
As described in Chapter 7, it has been claimed that advancements in neuroscience will lead to 
a transformation in the way that “personhood” is understood (O’Connor & Joffe, 2013). More 
specifically, it is thought that emphasising the role of the brain in behaviour across various 
domains will mean that people come to view themselves as biological beings who are 
controlled by their brain, thereby reducing perceptions of free will (Caron et al., 2005; 
O’Connor & Joffe, 2013; Rose, 2003). This quantitative study contributes to the literature on 
neuroscience and society by exploring empirically whether brain-based understandings of 
smoking are associated with attitudes towards medical treatment, or feelings of self-efficacy. 
The findings presented here counter the claim that biological understandings reduce self-
efficacy by showing that the belief that smoking is a brain disease was associated with higher 
quitting self-efficacy. This is consistent with qualitative research that describes the complex 
way that neuroscience information is incorporated into beliefs about human nature and 
behaviour in ways that maintain a sense of autonomy and agency (Pickersgill, 2011; O’Connor 
& Joffe, 2013).  It is also consistent with the qualitative component of this research (Chapters 
7 and 8), in which participants acknowledged the potential for neurobiological beliefs to induce 
fatalism in other smokers, but strongly felt that it would not lead to an exculpation of personal 
responsibility or a reduction in quitting self-efficacy in relation to themselves.  
 
In relation to understanding oneself as a “neurochemical self”, this research shows that 
neurochemical explanations of smoking were accepted by many smokers. The “brain disease” 
label, however, was not endorsed by the majority. This demonstrates that neurobiology, when 
presented as scientific fact, rather than a claim or label applied to an individual or group, was 
acceptable to the majority of smokers. When this scientific information was used to label 
smokers as a certain type of neurologically-determined person, it was often resisted and 
questioned. Thus, the way neurobiological information about addiction is presented is likely to 
have a great impact on the way it is interpreted and incorporated into public understandings. 
This aligns with the qualitative research presented in Chapter 8 that demonstrates that the 
participants in our sample resisted being labelled as a sufferer of a “brain disease”, and that for 
some smokers, this labelling led to questions being raised about the credibility and motives of 
those who described smoking in this way. The label of smoking as a “brain disease” was not 
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accepted as a logical or valid extension of the information about the role of the brain in 
maintaining smoking behaviour.   
 
Those concerned about the biomedicalisation of smoking predict that it will lead to an emphasis 
of medical treatments at the expense of unassisted quitting (Chapman & McKenzie, 2010). The 
research presented here is consistent with other Australian studies (Cooper et al., 2011) in 
showing that around half of smokers had used pharmacotherapy in the past. This was the first 
Australian study to examine the extent to which causal beliefs about smoking were associated 
with intention to use medications for quitting. The findings show that agreement with 
neurobiological explanations of smoking were associated with greater intention to use 
pharmacotherapy for smoking cessation, but it must be remembered that the brain-related 
variables only accounted for a small amount of variance in the intention to use medications. 
The only other study that has examined beliefs about the causes of smoking and their 
relationships towards treatment attitudes similarly found weak relationships (Hughes, 2009). 
There are likely to be many other factors that influence an individual’s decision on whether to 
use pharmacotherapy for smoking cessation. 
 
Overall, these results suggest that a neurobiological view of smoking does not dominate public 
understandings of nicotine addiction among smokers in Australia. Where people do endorse 
brain-based explanations of smoking, this does not have the negative consequence of reducing 
cessation self-efficacy as has been suggested by some. On these results, it is possible that 
emphasising the role of the brain could increase intention to use cessation pharmacotherapies 
but any such effect is likely to be small. Many factors influence a smoker's preference regarding 
cessation methods and their sense of self-efficacy. Combining all these factors into a model 
still accounts for only a small amount of the variance in these outcome variables. This is not 
surprising given the complexity of smokers’ conceptions of addiction, the brain, and agency 
demonstrated in the interview component of this study.  
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Chapter 10.  Discussion 
 
Cigarette smoking remains a major public health problem in Australia and worldwide. As with 
other types of addiction, there is an increasing emphasis on the use of medications to assist 
smokers to quit smoking and a growing interest in the brain mechanisms that underlie nicotine 
addiction. The “biomedicalisation” of smoking cessation is seen by some as a positive 
development that will lead to increased availability of effective medical treatments; a reduction 
in the stigma associated with smoking; and greater uptake of, and adherence, to biomedical 
treatments (Britton, 2009; Finnell, 2000; Wolff et al., 2013). Others think it could reduce 
attempts at unassisted quitting, increase feelings of fatalism in smokers, and exacerbate the 
stigma that smokers already experience (Caron et al., 2005; Chapman & MacKenzie, 2010; 
Elam, 2015a; Gillies & Willig, 1997). There is very little empirical evidence available to test 
these competing predictions about biomedicalisation or to highlight how biomedical 
explanations of smoking have been incorporated into lay understandings of smoking. No work 
of this sort has previously been done in Australia. This research project drew on the literatures 
of lay understandings of health and illness, (bio)medicalisation, and tobacco control in order to 
explore how the changing nature of tobacco treatment is reflected in the public understandings 
of smoking and cessation.  
 
 Original contribution of the current research  
This research project assessed the extent to which smoking has become medicalised in 
Australia by exploring lay discourse in Australia around smoking cessation, as well as 
the attitudes of daily smokers towards assisted and unassisted quitting. Following this more 
general examination, specific attention was given to the impact of the BDMA, and the effects 
that brain-based explanations of addiction may have had on smokers understanding of their 
smoking. Because this is an under-researched area, this study used mixed methods research, 
with an initial exploratory qualitative stage that informed the development of a large 
quantitative survey of Australian smokers. This discussion draws together the findings from 
the three studies reported in this thesis in order to answer the following questions, each of 
which will be elaborated on below:   
 To what extent has a medical discourse of tobacco dependence been incorporated into 
lay understandings of smoking and cessation in Australia?   
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 Do smokers believe tobacco dependence is based in their brain, and what are the 
implications for treatment choices and quitting self-efficacy?   
 
In addition to contributing to the tobacco control literature by exploring the meanings 
associated with addiction to smoking, the research also contributes to the literature on lay 
engagement with neuroscience. Most previous research in this area has looked at the impact of 
neuroscience research on those who have been diagnosed with a disorder where a change in 
neurobiology is implicated (Bröer & Heerings, 2012; Buchman et al., 2013; Pickersgill et al., 
2011), or members of the general public who find neuroscience research mostly “innocuous” 
(O'Connor, 2013, p. 257). The participants in this project were somewhere in between, a non-
clinical sample whose behaviour has begun to be attributed to their neurobiology by experts 
and the popular media.  
 To what extent has a medical discourse of tobacco dependence been incorporated 
into lay understandings of smoking and cessation in Australia?  
As outlined in Chapter 2, the process of biomedicalisation involves the application of medical 
definitions to previously nonmedical problems, the development and promotion of 
biotechnologies, and an increasing emphasis on risk and self-surveillance (Clarke et al., 2003). 
It has been argued that there is an increasing biomedicalisation of smoking in Australia and in 
other high income countries. This is reflected in the increased use of pharmacotherapies for 
smoking cessation (Cooper et al., 2011), the emphasis on smoking cessation interventions by 
health care professionals (Zwar et al., 2014; West, McNeill & Raw, 1998), and the labelling of 
tobacco dependence as a “chronic disease” (Fiore et al., 2008) or “chronic brain disorder” 
(Prochaska & Benowitz, 2016). In Chapter 2, it was argued that certain factors unique to 
tobacco control are likely to limit the reach of biomedical approaches to smoking cessation. 
However, there was little empirical research identified that explored the extent to which a 
biomedical model of smoking and cessation is present in lay understandings of smoking and 
nicotine addiction. 
 
The interviews that were conducted in Study 1 and Study 2 aimed to redress this neglected 
topic, and revealed the limited impact of the biomedical model on lay understandings of 
smoking. While more smokers are using medications in Australia in quit attempts, many are 
not using them for a sufficient periods of time or are using less than the recommended dose 
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(Balmford et al., 2011; Cooper et al., 2011). The research reported in this thesis provides some 
potential explanations for this: 
1) Smoking was often perceived as a matter of willpower and individual choice. It was 
seen as the personal responsibility of the individual to quit smoking and there was a 
common belief that quitting unassisted was the best method. However, this did not 
mean that a medical approach was completely rejected. Rather, it was frequently 
portrayed as suitable for “other” smokers, particularly those who were “heavy”, long-
term or addicted smokers. The difficulty of quitting unassisted was often 
acknowledged, but the convenience, safety, and anticipated sense of achievement if 
successful made this method very appealing to many smokers.  
2) There was a common belief that a smoker must feel “ready” to quit, and reach a 
tipping point where their desires and circumstances are aligned in order to 
successfully quit. Balmford and Borland (2008) note that in those who have an 
addiction, there will always be ambivalence about quitting. If smokers wait for a time 
when they do not feel any ambivalence or uncertainty about their ability to quit, then 
they may never attempt to stop smoking. Our findings show that the belief that 
someone must be “ready” to quit before they can succeed was very common and a 
potential barrier to making quit attempts using medications. This leads to the Catch 22 
that if someone is ready to quit, they are seen as not needing the assistance of 
pharmacotherapy. However, if they are ready to quit, then the use of medications is 
not seen as necessary or sufficient.  
3) There was some ambivalence amongst daily smokers about the nature of their 
addiction to smoking. While most agreed they were addicted to smoking in some 
sense, their conceptualisations of addiction were complex and multidimensional. They 
did not see their addiction to smoking as a purely physiological entity or biologically 
based. That is, they did not equate addiction to smoking with nicotine addiction. 
Rather, they used a broad concept of addiction that incorporated behavioural 
habituation, psychological urges and societal influences. Smokers who see nicotine 
dependence as only explaining a small part of their addiction, or reject nicotine 
addiction completely, see limited value in the use of nicotine replacement therapy. 
  
As we saw in Chapter 2, Conrad has proposed a list of factors that facilitate or impede 
medicalisation, including: “the support of the medical profession, availability of interventions 
or treatments, existence of competing definitions, coverage by medical insurance, and the 
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presence of groups challenging the medical definition.” (Conrad, 1992, p. 220). The interplay 
of these competing factors in Australia has contributed to the incomplete medicalisation of 
smoking cessation observed in the studies included in this thesis, as discussed below.  
 
In Australia, the national approach to reducing tobacco smoking has emphasized population 
level strategies to motivate smokers to attempt to quit (e.g. public smoking bans, mass media 
campaigns, retail display bans, high tobacco taxation, graphic health warnings and plain 
packaging) with only limited investment in interventions to assist smokers to quit (Australian 
Intergovermental Commitee on Drugs, 2012). Other countries, most notably the UK, have 
invested more heavily into treatments for smokers, with a wider range of cessation medications 
available at no cost, and individual face-to-face counselling and group support sessions 
provided at stop smoking clinics (McNeill, Raw, Whybrow, & Bailey, 2005). In Australia, 
NRT in the form of patches and two prescription medications (varenicline and bupropion) are 
subsidised by the government when prescribed by a doctor, which both increases access to 
these treatments by reducing their cost, and also places cessation in a medical context. 
However, while the medical profession supports treating smoking as a medical issue in their 
professional guidelines but there is some resistance amongst clinicians to routinely 
implementing these guidelines in doctor-patient consultations (Zwar & Richmond, 2006). 
 
It should be noted that while NRT and prescription medications have demonstrated efficacy in 
clinical trials, there remains a debate within the tobacco control community about the extent to 
which clinical trial results translate into real world effectiveness (Alpert et al., 2013; Kasza et 
al., 2013). Even the most intensive treatment programs that involve the provision of 
pharmacological cessation aids as well as group or individual counselling lead to quitting in 
only about one quarter of smokers (Hartmann-Boyce et al., 2013). This means that 75% of 
smokers continue to smoke after using these cessation aids when combined with behavioural 
support. Because of this, there are also public health advocates in Australia that publicly oppose 
the promotion of smoking cessation medications and instead promote unassisted cessation as 
the best way for smokers to quit smoking (MacKenzie & Rogers, 2015). While a small increase 
in the success of quit attempts through increased use of cessation medicines may be cost 
effective and worthwhile at a population level, the research reported in this thesis shows that 
at an individual level, smokers are cognisant that use of cessation medications often does not 
result in long-term abstinence.  
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Competing definitions of smoking cessation are evident in public discourse. These include that 
it is a matter of: willpower; individual responsibility; and a personal choice. These have been 
promoted by the tobacco industry to deflect attention from the industry's role in promoting and 
sustaining the market for an addictive product (Daube et al., 2008; White et al., 2013). Quitting 
unassisted has a low success rate, but in this research failures were attributed by participants to 
a lack of willpower, or the belief that unsuccessful quitters had not yet reached the point where 
they “really” want to quit. Also, the findings indicate that personal experience was often the 
foremost consideration when smokers explained the reasons for their preferences for different 
cessation methods. These findings align with the research of Smith et al. (2015) who found that 
those who had quit unassisted prioritised “lay knowledge directly from personal experience 
and indirectly from others over professional or theoretical knowledge” (Smith et al., 2015, p. 
1).  
 
 Do smokers believe tobacco dependence is based in their brain, and what are the 
implications for treatment choices and quitting self-efficacy?   
The growth of addiction neuroscience emerged in the sociopolitical context of moral panic 
about drugs, increased funding for treatment of drug dependence, and the growing prestige of 
neuroscience (Vrecko, 2010). Tobacco was often excluded from discussions around the role of 
the brain in drug addiction because of its widespread use, the influence of the tobacco industry, 
the long delay between initiation of smoking and adverse health outcomes such as lung cancer, 
and the fact that nicotine addiction typically does not impair societal functioning. While there 
is a long history of alcohol and illicit drug dependence being described as biologically-based 
“disease”, this model has been applied far less frequently to nicotine dependence. This provides 
an opportunity to study how the unique nature of tobacco dependence, and its history, influence 
the acceptability of biomedical labels and treatments.  
 
In relation to the neurobiological basis of nicotine addiction, Chapters 7 and 8 revealed that 
most of the smokers that were interviewed for this research reported awareness that smoking 
influenced their brains. Many saw this as common sense information and could not list a 
specific source for this information. The all-encompassing nature of the brain in human 
behaviour and identity meant that everything was seen to affect the brain, including smoking 
tobacco. This suggests that those who speculate about the transformative impact that 
neuroscience information could have on lay understandings of addiction are probably 
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overestimating its likely effect. Neuroscience information is more likely to add detail to 
smokers’ understandings, rather than fundamentally altering the way they perceive the nature 
of their dependence on cigarettes, and is likely to have even less impact on their smoking 
behaviour. This is consistent with research that shows that unless the role of the brain is brought 
to the fore via a brain injury or disorder, it is seen as operating in the background, as an object 
of  “mundane significance” (Pickersgill et al., 2011).  
 
While the neurobiological mechanisms of addiction were seen as interesting by many 
participants, most believed that this information would have a minimal impact on their 
smoking. During the interviews, some smokers stated that knowing how pharmacological 
treatments for smoking cessation worked in the brain made them more appealing. However, 
this rarely translated into a stated intention to use them in future quit attempts. The brain was 
sometimes seen as a “special organ”, and a minority of participants were disturbed by the idea 
that medications worked in the brain. Concerns about side effects, particularly in relation to 
varenicline, seemed to outweigh any potential benefits of quitting using these medications. 
While the quantitative component of this project showed that endorsement of brain-based 
explanations of smoking were associated with increased intention to use medications for 
smoking cessation, this effect was of moderate size, and accounted for only a small proportion 
of the variation in intention to use medications in future quit attempts.  
 
The findings presented here do not support the claim that emphasising the neurobiological basis 
of addiction leads to increased fatalism in smokers. While some participants did see the 
potential for neurobiological explanations of nicotine addiction to reduce feelings of control 
and self-efficacy, this was predicted to occur in “other” smokers, rather than themselves. The 
majority of smokers interviewed in Study 1 and Study 2 maintained that they had control over 
their smoking and would be able to stop when they really wanted to, even where the difficulty 
of this task was acknowledged. As already discussed, this emphasis on self-control and 
responsibility in relation to smoking has been linked to wider societal discourses that value 
autonomy, personal responsibility and inner strength (Gillies & Willig, 1997; Smith et al., 
2015; White et al., 2013). In addition, the quantitative research presented here suggests that 
endorsement of the brain-based explanations of smoking may be associated with higher levels 
of self-efficacy. Together these findings should dispel concerns that educating smokers about 
the role of the brain in tobacco dependence will lead to feelings of fatalism about smoking and 
to a reduction in quitting self-efficacy.   
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Philosophical debates about the relationship between the brain and free will have primarily 
occurred in two areas: legal responsibility and addiction. In relation to legal responsibility, it 
has been argued that neuroscience will have a “transformative effect” on legal institutions by 
“transforming people’s moral intuitions about free will and responsibility.” (Greene & Cohen, 
2004). This research on addiction showed the opposite, that existing beliefs about responsibility 
and choice are strongly maintained by addicted individuals. 
 
The results presented here suggest that one of the key factors limiting the biomedicalisation of 
smoking cessation are strong lay beliefs about the role of willpower in stopping smoking. As 
noted by many others, lay beliefs are often grounded in the everyday experience of individuals, 
as well as the public discourses that they are exposed to. Theories such as lay representations 
theory have outlined how new representations become grounded, or anchored, in core cultural 
beliefs (Moscovici, 1988). In the case of addiction, new beliefs about the neurobiological basis 
of addiction are related back to the core cultural beliefs of free will and individual 
responsibility.  
 
 
 Strengths and limitations of this research 
Representativeness of samples 
Due to time and resource constraints, it was not possible to recruit random samples for the 
studies described here. For Study 1, participants were drawn from a national market research 
database, to which they had already been recruited via random digit dialling. Households 
selected for the study were limited to those who resided in the Brisbane area. Quotas were set 
for age and gender in order to recruit a diversity of participants. However, those who were 
willing to respond to a market research company, and to participate in a one hour face-to-face 
interview, may differ from those who refused to join the panel, or who were on the panel but 
refused to be interviewed.  
For Study 2, participants were again limited to the Greater Brisbane area to allow for face to 
face interviewing. While an effort was made to recruit using a range of methods in order to 
ensure participant diversity, the majority of participants came from a single online classified 
site, which limits their representativeness. Indeed, it was more difficult to recruit older adults 
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for Study 2, which may be the result of reduced internet access in this bracket (Australian 
Bureau of Statistics, 2014). A senior's database was also used to compensate for this limitation. 
For Study 3, an online market research panel was contracted to recruit participants. While every 
effort was made to select a company that was able to provide the most robust sample of 
smokers, and quotas were set in relation to age and gender, the sample recruited may not be 
representative of the whole population of smokers. While the survey was completed by a large, 
national sample, it is unclear how different those who make up the online panel are from the 
general population of Australian smokers on the variables of interest to this study. Despite this 
limitation, the use of market research companies is becoming common in addiction research 
and Section 4.6 lists a number of ways that researchers can ensure they are getting the best 
sample possible using this recruitment method.  
Cross-sectional design 
Because this research was cross-sectional, inferences about directionality and causation cannot 
be drawn. The qualitative research reported here shows that many factors may influence 
smokers’ preferences for different quitting methods. These factors include: one’s own past 
experience with a particular method; the vicarious experiences of family, friends, and 
acquaintances; beliefs about the strength of one’s addiction to smoking; beliefs about the nature 
of addiction to smoking; beliefs about the side effects of the cessation method; the cost and 
convenience of using the method; general attitudes towards taking medications for health 
problems; and trust in those promoting the method. Of these considerations, personal 
experience and concerns about side effects were particularly salient for many of the smokers 
who were interviewed. The role of personal experience in decision-making about smoking 
cessation was reflected in the quantitative survey that found previous use of cessation aids was 
the strongest predictor of intent to use in a future quit attempt. Providing neuroscience 
information about the mechanisms of addiction to smoking is unlikely to have a large impact 
on smoking behaviour or quitting intentions given the complexity with which people develop 
treatment preferences, with differential weightings for each factor, and a comparison of the 
costs and benefits along each of these dimensions.  
 
Qualitative research informed the development of the quantitative survey but it is possible that 
there were other influential variables that were not measured. These might include the views 
of smokers' regular treating general practitioner about smoking and the role of cessation 
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medications, or exposure to pharmaceutical company advertising (although this is less likely 
in Australia, where direct to consumer advertisements of prescription medications are not 
permitted). It would be of interest to conduct similar research in the USA or New Zealand, 
where direct to consumer advertising of prescription medications is legal. Furthermore, 
replicating this study in a country that has adopted a greater emphasis on assisted cessation in 
their national approach to reducing smoking (such as the UK) would allow exploration of the 
impact of emphasising access to professionally assisted smoking cessation at the national level 
on smokers' cessation method preferences and attitudes toward the BDMA. 
 
Eliciting stakeholder attitudes towards novel biotechnology and scientific findings 
Eliciting views about specific scientific developments or novel medical technologies can be 
difficult where prior knowledge is expected to be low, or where people have not yet had the 
time, reason or opportunity to form explicit attitudes. Providing participants with insufficient 
background on the topic may lead to confusion or feelings of inadequacy. The method used 
here, of providing participants with a brief summary of the science in everyday language, is a 
method has been used in other studies on PUS (Buchman et al., 2013; Choudhury et al., 2012; 
Horstkötter et al., 2014). Providing some background gives participants a stimulus to respond 
to and allows researchers to observe differences between participants in the interpretation of 
the same material.  
 
Of course, providing such a stimulus inevitably shapes the responses of participants. Therefore, 
it is important that researchers make it clear when participants are responding to a specific 
stimulus, and provide sufficient detail about it. In some research in this field it is unclear what 
stimulus or interview question participants are responding to. For example, in some empirical 
studies on the BDMA, it is unclear whether participants were asked if they thought that 
addiction was “a disease”, or whether they were asked about the more recently terminology of 
addiction as a  “brain disease” (Morphett & Meurk, 2013). Also, there has been some conflation 
of neuroscience and genetics, with the term “neurogenetics” being used by some social 
scientists (Dingel et al., 2011). While there are important linkages between genetics and 
neuroscience, it is important to develop at least a rudimentary knowledge of how stakeholders 
interpret neuroscience so that similarities and differences between lay conceptualizations of 
genetic information and neuroscience information can be assessed (Green 2006). 
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 Clinical and public policy implications of the findings  
The utility of the brain disease model of smoking 
Existing smoking cessation aids are only moderately effective and there are no signs that this 
situation will change in the near future. While it is unclear to what extent the optimism about 
biomedical treatment for nicotine addiction will be realised in the longer term, Ronald Green 
(2006) has warned scientists against exaggerating the therapeutic potential of neuroscience 
research. He writes that there is a “therapeutic gap” that is associated with translating basic 
science findings into clinical therapeutics, and that giving false hope about cures can have 
detrimental effects.  
"There is a powerful tendency in all biomedical areas to offer enticing therapeutic 
visions as a way to elicit public support or increase governmental funding for research. 
Yet the same public enthusiasm that leads to increased funding can turn into budget 
cuts, resentment, and even research restrictions, when, instead of cures, the actual 
payoff is burdensome knowledge and a host of new ethical quandaries produced by 
poor therapeutic options." (Green 2006, p. 110) 
The research presented in this thesis suggests that labelling smoking as a “brain disease” will 
have limited utility, and it may be that smokers themselves will not be strongly accepting of 
biomedical approaches to smoking until they can see evidence of the benefits of treating 
tobacco dependence in this way.  The strong form of the BDMA was not acceptable to the 
majority of the smokers interviewed or surveyed. It was described by many as a stigmatizing 
and inaccurate description of smoking. Most agreed that smoking did influence their brains; it 
was the label of “disease” that was rejected.  
 
The reasons that smokers rejected the brain disease label echoed critiques that have been made 
by academics, namely: that the BDMA reduces the complexity of smoking; does not account 
for individual choice and personal preferences for unassisted quitting; and could increase the 
stigma associated with smoking. As described in Chapter 2, Farrimond, Joffe and Stenner 
(2010) describe four different smoking identities. Importantly, they note that these identities 
are “produced relationally.” That is, smokers often describe their own smoking in opposition 
to alternative ways of understanding smoking. They write that “appealing to one ‘identity’ 
through health promotion might inadvertently alienate those with a different smoker identity. 
They recommend “highlighting the multiplicity of smoker identities” in interventions 
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(Farrimond et al., 2010). The findings presented here suggest that portraying smoking as a 
purely biomedical issue risks angering and antagonising some smokers. Because the “brain 
disease” description is incompatible with the way that most smokers view their own smoking, 
there seems to be little utility in promoting its use in the public domain.  
 
Given the complex and contradictory ways that neuroscience information about nicotine 
addiction is interpreted by smokers, caution should be applied when including such information 
in health promotion materials. Those developing messages on smoking and the brain should be 
aware that such information is unlikely to have much, if any, impact at a population level. In 
addition, there are risks to emphasising this information, such as the possibility of stigmatizing 
smokers by portraying their brains as different and abnormal; and antagonizing those who 
reject, and are suspicious of, a biomedical approach to smoking.  
Neuroscience information about nicotine addiction could still be presented to smokers in 
clinical interactions or in public health materials to explain how smoking cessation medicines 
work. It is clear that neuroscience information about nicotine and smoking is already in the 
public sphere and it is information that is of interest to many smokers. Based on the data from 
the studies included in this thesis, the following recommendations are provided on how to 
incorporate neuroscience information about addiction into health professional materials for use 
in clinical interactions. 
 
Where information about the neuroscience of nicotine addiction is presented, health promotion 
messages should also acknowledge the other factors that contribute to smoking. The role of 
willpower and autonomy should not be downplayed. Describing pharmacological cessation as 
an additional support to their willpower may better align with most smokers’ views about their 
reasons for smoking, may contribute to a more realistic assessment of the role of medications 
in quit attempts and may help to retain the sense of achievement in quitting smoking that many 
smokers value.  Medication should not be presented to smokers as a magic bullet for smoking 
cessation because for many smokers this is unlikely to align with their previous experience of 
these medications or the testimony of personal contacts. Rather, medications should be 
presented as only one way of assisting a quit attempt and should be recommended as part of a 
wholistic approach to quitting, including behavioural counselling, which has been shown to 
increase the effectiveness of cessation medications.  
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A balance is needed when discussing the difficulty of quitting smoking in health promotion 
materials. Biomedical explanations that describe smoking as a physiological addiction to 
nicotine that is difficult to quit may over-emphasize the difficulty of quitting and deter smokers 
from making a quit attempt. As Chapman and MacKenzie (2010) have argued, most former 
smokers have quit unassisted and many current smokers have achieved some period of 
abstinence. However, disregarding the difficulty that some smokers experience when quitting 
may lower low self-esteem and increase self-blame and fatalism in those who repeatedly fail 
in their quit attempts. In health promotion materials, where it is difficult to present the complex 
nuances of the BDMA, any acknowledgement of the difficulty that some smokers may have in 
quitting because of changes that smoking has made to their brain, should be immediately 
followed by positive information on smokers' ability to quit despite these changes.  
 
A recent paper has suggested a contrary view, namely, that smokers’ belief in their ability to 
quit is an “obstacle to treatment utilization.” They suggest that healthcare practitioners 
“normalize the need for assistance” and “emphasize the difficulty of quitting without 
assistance” (Myers et al., 2015, p. 220). The research presented in this thesis suggests that this 
message is likely to be counter-productive to smoking cessation efforts. Unassisted quitting 
should not be presented as an inferior method for smoking cessation, and the difficulty of 
quitting unassisted for some smokers should be acknowledged, but not over-emphasised. Given 
the diverse accounts of smoking and addiction provided by participants in this project, as well 
as the different smoking identities outlined by Farrimond, Joffe and Stenner (2010), it is 
important for clinicians to elicit patient views about the nature of their smoking, and use these 
to tailor treatment plans and messages about cessation to the smoker. A biomedical approach 
that includes medications may suit some patients, but is likely to be rejected by others.  
 
Lay engagement with neuroscience information 
The increasing emphasis on the state of the brain in accounts of human behaviour has led to 
the development of fields such as Neuroethics (Levy, 2008) and Critical Neuroscience 
(Suparna, Saskia Kathi, & Jan, 2009). Those involved in these endeavours aim to anticipate the 
social consequences of brain-based accounts of behaviour for legal systems, health systems, 
education systems and other arenas. However, these fields have a heavy focus on ethics and 
there is a dearth of empirical evidence on the ways in which neuroscience information is 
interpreted and used by stakeholder groups. The research reported in this thesis shows that one 
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stakeholder group, those who smoke cigarettes, largely rejected reductionist accounts of 
smoking as an addiction to nicotine caused by changes in neurochemistry. While the brain was 
typically acknowledged to play a role in smoking behaviour, this did not negate the role 
ascribed to personal choice, motivation and willpower. While a minority of those interviewed 
for this research acknowledged the potential for neuroscientific understandings of addiction to 
lead to feelings of fatalism, this was not often perceived as personally relevant information, but 
rather as a way that the “other smoker” might interpret neuroscience information.  
 
These findings support other empirical research on public understandings of neuroscience 
which has found that neuroscience information is interpreted through the lens of already-
existing cultural worldviews and explanations of behaviour (Bröer & Heerings, 2012; Meurk, 
Carter, et al., 2013; Meurk et al., 2016; O’Connor & Joffe, 2013; Pickersgill et al., 2011). An 
issue deserving further research attention is the way that people conceptualise the link between 
their brain and behaviour. Work has examined how people understand the brain in relation to 
clinical disorders but there is little empirical research with more general populations. There are 
some exceptions, such as research on adolescents’ understandings of the role that their brains 
play in behaviour said to be typical of teenagers, e.g., risk taking (Choudhury et al., 2012). This 
research found that adolescents considered neurological explanations of adolescent behaviour 
to be inadequate and preferred to discuss psychological and social influences on behaviour. 
Another recent exception is work by O’Connor (2013), who conducted interviews with people 
living in London about their views on neuroscience research and its import. Neuroscience 
research did not have great relevance for most participants, although the brain was often 
equated with a person’s self or essence. This however, did not result in a form of determinism, 
where the brain is perceived as a disembodied actor that is causing the individual to feel or act 
a certain way. Instead, the role of free will was emphasised. This leads to questions about 
whether people think of psychological and neurological states differently, or if they consider 
them to be the same thing? Experimental research shows that describing an action in 
neurological terms does not reduce attributions of personal responsibility when compared to a 
psychological account (De Brigard, Mandelbaum, & Ripley, 2009). It is clear that people’s 
ideas about neuroscience and the role of the brain in behaviour are complex and can shift 
according to context. Therefore it is important that empirical research is conducted with various 
groups in diverse settings before general claims about the transformative impact of 
neuroscience on public understandings are made.  
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 Directions for future research 
This project has focused on lay understandings of smoking, smoking cessation, and the role of 
the brain in tobacco dependence. Research examining the same topics in health professionals 
would complement this research. Such research could examine the extent to which doctors and 
other health professionals see smoking as a medical problem that requires medical treatment 
or as a social problem that should be addressed by public policy. It could also examine their 
attitudes towards unassisted quitting and how health professionals accommodate the 
preferences of smokers when discussing quitting options. It could evaluate clinicians’ 
knowledge of the neurobiological mechanisms of nicotine addiction, and explore how they 
integrate this information into their clinical interactions with smokers.  
 
Despite the increasing use of prescription medications for smoking cessation, very little 
research has been done on smokers’ beliefs and attitudes toward the use of medications for 
smoking cessation and their understanding of how these medications work. An exception is a 
study by Vogt, Hall and Marteau (2008) who found that bupropion was perceived as an 
“unnatural” substance that could cause damage to the body. This aligns with general research 
on medication use, which has found that many patients are reluctant to use medication. 
Medicines are sometimes perceived as foreign, unnatural substances that can produce 
dependence and serious adverse side effects (Horne & Weinman, 1999; Horne et al., 1999). It 
has been suggested that labelling requirements for smoking cessation medications may make 
smokers wary about taking these medications, even when some of these risks are trivially small 
in comparison to the well-known health harms caused by cigarette smoking (Shiffman et al., 
2008). This may be because of the immediacy of medication side effects, compared to the long-
term potential for health harms associated with smoking. It could also be the case that smokers 
are mistaking the symptoms of nicotine withdrawal for medication side effects, although there 
is insufficient evidence from current studies to draw this conclusion. It has been suggested that 
explaining the biophysical mechanisms by which smoking cessations work could be an 
effective intervention to increase use of such aids (Finnell, 2000; Raupach et al., 2010; Vogt et 
al., 2008). The qualitative research reported here suggests the effects of such an intervention 
are likely to be complicated. Some participants stated that knowing the mechanisms by which 
prescription medication varenicline worked increased their positive perceptions of it. But many 
of those still reported no intention to use it. In addition, a minority were very concerned about 
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the fact that varenicline entered, and influenced, their brain. Providing detail about how 
medications work in the brain may dissuade some people from using it, despite the 
contradiction inherent in the fact that they are dependent on a psychoactive substance that 
causes lung cancer, heart disease and has many other negative health effects. While this 
research begins to address the lack of research on smokers’ attitudes towards using medications 
for smoking cessation, more research is required in this area, especially in relation to the use 
of prescription medications other than NRT.  
 
It is clear that public understandings of smoking have altered dramatically in recent decades. 
However, there is very little empirical evidence on the effects that incremental changes in 
public perceptions of smoking may have had on the behaviour of smokers, and especially on 
their interest in attempting to quit and their confidence in their ability to do so. There are 
repeated time-series studies, and longitudinal studies, that map smoking behaviours and 
attitudes in various countries. Examples include the International Tobacco Control 4-Country 
Survey (Kasza et al., 2013), the National Drug Strategy Household Survey in Australia 
(Australian Institute of Health and Welfare, 2014), and the Smoking Toolkit Study in the UK 
(Fidler et al., 2011). Longitudinal studies could map various beliefs about smoking over time 
and evaluate their relationships with the quitting strategies that smokers have used and their 
quit successes. These beliefs could include the belief that medication is required for a 
successful quit attempt, that continued smoking is due to a nicotine addiction, and that 
addiction is based on changes in brain chemistry. Another line of exploration that would 
complement the self-report data presented here are behavioural choice experiments to examine 
the impact of neuroinformation on actual behaviour. Such experiments have been conducted to 
explore the impact of genetic information. For example, one study found that participants told 
they had an increased genetic susceptibility to alcoholism were more likely to enroll in a 
responsible drinking workshop (Dar-Nimrod, Zuckerman, & Duberstein, 2013). Another study 
found that informing light smokers that they had a higher risk of nicotine dependence due to 
their genetics increased quit rates at 30 days (Lipkus, Schwartz-Bloom, Kelley, & Pan, 2015). 
 
Another important area of future research is the link between beliefs about nicotine addiction 
and attitudes towards e-cigarettes. The increasing use of e-cigarettes around the world has 
caused sometimes acrimonious debates in the field of tobacco control (Gartner & Malone, 
2014). The regulatory landscape in relation to e-cigarettes is changing rapidly, and it is 
unknown whether e-cigarettes will be banned; regulated and incorporated into a medical 
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approach (much like NRT was); or whether they will become widely accepted as a recreational 
consumer product. One argument for making e-cigarettes widely available for smokers is that 
it is difficult for many smokers to quit due to a chemical dependence on nicotine. The use of e-
cigarettes has been portrayed as a harm-reduction strategy that radically reduces the risks of 
tobacco-related harm by allowing those who are nicotine dependent to obtain nicotine in a form 
that satisfies smokers' addiction without the harms of smoking tobacco. The research reported 
here shows that smokers do not always equate smoking with nicotine addiction, potentially 
limiting the perceived utility of e-cigarettes for some smokers. However, a substantial minority 
of people who use e-cigarettes use non-nicotine liquid, and the hand-to-mouth action is posited 
to be another factor that may help smokers quit smoking by providing a behavioural 
replacement. Studies exploring smokers’ attitudes towards e-cigarettes should further explore 
smokers’ understandings of the role of nicotine in smoking and tobacco dependence.  
 
In summary, this research demonstrates that biomedical explanations of smoking do not 
encompass the complexity of addiction as an everyday, lived experience. This study points to 
the importance of documenting the ways in which those who experience addiction as an 
everyday reality interpret and respond to changing conceptualisations of addiction.  
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Appendix B – Information sheet and informed consent for Study 2 
 
Project Title: Smokers’ understanding of nicotine addiction 
 
Investigators 
 
Professor Wayne Hall     Dr Coral Gartner 
UQ Centre for Clinical Research   UQ Centre for Clinical Research 
The University of Queensland    The University of Queensland 
 
Associated Professor Jayne Lucke   Dr Brad Partridge   
UQ Centre for Clinical Research   UQ Centre for Clinical Research 
The University of Queensland The University of Queensland 
 
Dr Adrian Carter Kylie Morphett 
UQ Centre for Clinical Research UQ Centre for Clinical Research  
The University of Queensland The University of Queensland 
 
About the project 
 
This project aims to examine the understandings of Australian smokers in relation to smoking 
and nicotine addiction. We would like to know your views about why people smoke and how 
to prevent people starting to smoke. In particular, we are interested in: 
 how you understand your smoking 
 your thoughts about addiction in light of recent biomedical research 
 your ideas on treatments for nicotine addiction. 
Why this is important 
 
Recent biomedical research on smoking could change the way that smoking is understood and 
lead to new technologies for the prevention and treatment of smoking. We want to know what 
smokers think because the impact of this information will depend on how well it is understood 
and accepted by smokers.  This research will help to inform public policies responding to new 
technologies for the treatment and prevention of smoking, and existing policies to manage 
smoking.  
 
Eligibility 
 
You are eligible to participate in the study if you are aged 18 years or over and smoke tobacco 
every day.  
 
What you will be asked to do 
 
If you decide to be involved in this study you will be asked to participate in an interview lasting 
approximately one hour. Interviews will be conducted by researchers at a private location at 
The University of Queensland or another location that is convenient for you. 
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In the interview you will be asked a series of questions about your smoking behaviour, your 
ideas about why people smoke, and your attitudes and opinions about different forms of 
prevention and treatment for smoking.  
 
The interview will be audio recorded, transcribed verbatim, and then analysed and presented 
in a way that does not identify you. 
 
Reimbursement 
 
All participants will be provided with a $20 Coles Myer voucher in recognition of their time. 
 
Your rights 
 
If you consent to participate you are still free to withdraw from the study at any time without 
stating a reason. Upon withdrawal from the study all of your responses will be destroyed if you 
request.  
 
Your confidentiality and privacy will be maintained at all times. Your name or other personal 
information will not be linked to your interview data and will be stored in a safe and secure 
location at the University of Queensland. 
 
Need further information? 
The research staff will be able to discuss any questions you may have and will provide guidance 
on where to get further information or assistance. A copy of the research findings will be made 
available to you by post or email if you wish.  
 
This study has been cleared by the human ethics committees of The University of Queensland 
in accordance with the National Health and Medical Research Council’s guidelines. If you have 
any question about your participation in this study please contact Kylie Morphett at the UQ 
Centre for Clinical Research on (07) 3346 5473 or k.morphett@uq.edu.au. 
 
If you would like to speak to an officer of the University not involved in the study, you may 
contact the Ethics Officer on 3365 3924. 
 
We greatly appreciate your help and cooperation in this important study.  
Thank you very much. 
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Appendix C – Interview schedule and demographic survey for Study 2 
 
1. Thoughts about own smoking 
a. How old were you when you started smoking?  
b. Can you tell me about how you started smoking? What was the main reason 
you started smoking?  
c. What are the main reasons that you smoke now?  
d. How much control do you feel you have over your smoking? Could you give 
up if you wanted to? Why/why not?  
e. How difficult do you think it would be to quit smoking? What would make it 
difficult/not difficult?  
f. How much personal responsibility do you feel for starting to smoke?  
g. How much personal responsibility do you feel for continuing to smoke?  
h. Do you feel others have any responsibility for your smoking? Do you feel 
your peers have any responsibility? Your family? The tobacco industry?  
i. Do you feel that smokers are stigmatised? What makes you feel this way? Can 
you give any examples?  
 
2. Addiction 
a. Do you consider yourself addicted to nicotine? What makes you think you’re 
addicted/not addicted?  
b. How do you know when someone is addicted to nicotine?  
c. Why do you think you became addicted to nicotine? 
d. Why do other people become addicted to nicotine? (prompt if necessary: 
social influences, genetics, personality factors, substance itself). Which factor 
is most important and why?  
e. Why can some people quit smoking more easily than others? 
f. Smoking is frequently described as a habit. What do you think about the idea that 
smoking is a habit?  
 
3.  Treatment and Prevention 
a) What sort of things should be done to prevent cigarette smoking by young people? 
b) What do you think the government should do about smoking?  
c) Should the government pay for stop smoking medications? Why/why not?  
d) Should the government provide free medical treatment to smokers for smoking 
related health problems? Why/why not?  
e) Do you think smokers should pay more than non-smokers for health insurance?  
f) Do you think a smoker should have an equal opportunity for a lung cancer transplant 
as a non-smoker? Why/Why not?  
g) What is your view on the following methods for people trying to quit  
smoking? [prompt if required: are they effective, safe, appropriate, what do you 
know about it?] 
(a) No treatment – cold turkey 
(b) Nicotine replacement therapy 
(c) Prescription medication (eg Champix, Zyban) 
(d) Counselling, including quitline 
(e) Self-help materials e.g., books or information pamphlets 
(f) Any other methods that you have thoughts on. 
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h) Can you tell me a bit about any quit attempts that you have made? (how long did you 
quit for? did you find it easy or difficult? what method/s did you use?) 
i) If you were going to quit now, which method would you use? Why?  
j) Do you think you will quit smoking? When?  
k) What is your understanding of the effects of nicotine?  
Nicotine has been shown to produce long-term changes in the brain of smokers.  
[A short powerpoint presentation will be presented to participants on the neurobiology of 
nicotine addiction at this point in order to give them some background to the remaining 
questions].  
 
4. Impact of information about neurobiology of nicotine addiction 
a. Were you aware of the ways in which nicotine acts on the brain? If so, where 
did you hear about it?  
b. To what extent do you think that smoking affects your brain?  
c. How does this information influence your understanding of your smoking? In 
what ways? How does this information make you feel about your smoking?  
d. Does it make stopping smoking seem easier or harder? How does it affect your 
belief in your ability to stop smoking?  
e. Does it affect your view of your personal responsibility for smoking? How? 
f. Does this information affect your view on the best method for quitting? 
[prompt: those discussed above eg cold turkey, medication, NRT, self-help 
materials]. 
 
5. Brain disease model 
 Based on the information presented earlier, some scientists have claimed that 
“addiction is a brain disease.”  
a. What do you think about the idea that nicotine addiction is a brain disease?  
b. Do you think that describing nicotine addiction as a brain disease will increase 
or decrease the stigma of smoking? Why? 
c. Do you think that describing nicotine addiction as a brain disease is a good or 
bad thing? Why?  
d. How might the view that nicotine addiction is a brain disease influence your 
smoking?  
e. Do you think that medical research will lead to more effective treatment for 
nicotine addiction?  
f. Have you heard nicotine addiction described as a brain disease before today? 
If so, where did you hear it? 
6. Is there anything else that you would like to say about this topic that we did not cover 
that you think is important? 
 
CAN YOU PLEASE FILL OUT THIS SHORT SURVEY?  
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Appendix D - Quantitative survey questions 
 
First, we need to ask you a few questions to determine your eligibility for this study. 
 
Do you smoke cigarettes every day?  
1. Yes  
2. No [If no, not eligible] 
 
Have you smoked at least 100 cigarettes (manufactured or roll-your-own), or the equivalent 
amount of tobacco in your life? [If no, not eligible] 
 
What is your age in years? (text box, 2 digit numeric) [If less than 18 terminate, too young].  
 
Are you … 
 
1. Male 
2. Female 
 
Are you …  
1. An Australian citizen  
2. An Australian resident 
3. A resident in some other country [If yes, not eligible]. 
 
Were you born in Australia?  
1. Yes 
2. No 
 
Introduction [Presented if eligible based on screening questions]. 
The purpose of this study is to explore smokers’ understandings of addiction to cigarettes and 
their attitudes towards different methods of quitting. This study is being undertaken by the 
University of Queensland. Participation will involve completing an online questionnaire that 
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will take approximately 25 minutes. This study has been approved by the Human Research 
Ethics Committee of the University of Queensland (Approval Number 2009001022). 
 
You are free to withdraw from the study at any time by simply exiting the survey webpage. 
The University of Queensland will not receive any personal information about you, including 
your name, address or email. Once your survey has been completed, the University will be 
unable to delete your data, as we will not be able to link your personal details with the survey 
data.  
 
If you have any questions about your participation in this research project, please contact Kylie 
Morphett at the University of Queensland Centre for Clinical Research on 07 3346 5473 or 
k.morphett@uq.edu.au. If you would like to speak to an officer of the University not involved 
in the study, you may contact the Ethics Officer on 07 3365 3924.  
 
Do you consent to participate in this research project? In doing so, you agree to Complete one 
25 minute questionnaire about your smoking, your thoughts about methods of quitting and 
addiction to cigarettes.  
 
1. Yes, I consent to taking part under the stated conditions 
2. No, I prefer to not take part 
 
Section 1. Smoking variables 
 
Q1. On average, how many cigarettes do you smoke each day, including both factory-
made and roll-your-own cigarettes?  
Numeric text field. Allow 3 digits.  
 
Q2. How soon after waking up do you smoke your first cigarette? 
1. Within 5 minutes 
2. 6-30 minutes 
3. 31-60 minutes 
4. After 60 minutes 
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Q3. How old were you when you started to smoke cigarettes regularly? (Please try to 
estimate if you cannot remember exactly).  
Numeric text field. Allow two digits.  
 
Q4. Have you ever tried to quit smoking?  
1. Yes 
2. No (SKIP TO Q7) 
 
Q5. What is the longest time period you have ever quit smoking for?  
1. Less than a day 
2. 1-2 days 
3. 3-7 days 
4. More than 1 week and up to a month 
5. More than 1 month and up to 3 months 
6. More than 3 months and up to 6 months 
7. More than 6 months 
8. Don’t know/can’t remember 
 
Q6. How many quit attempts, that lasted at least 24 hours, have you made in the last year? 
(Please try to estimate if you cannot remember exactly) 
1. None 
2. 1-2 
3. 3-4 
4. 5 or more 
 
Q7. How much do you want to give up smoking?  
1. Not at all 
2. A little bit 
3. Quite a bit 
4. Very much 
 
Q8. How much do you enjoy smoking? 
1. Not at all 
2. Not particularly 
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3. Quite a bit 
4. Very much. 
 
Q9. Are you planning on giving up smoking? 
1. Yes, within 30 days 
2. Yes, after 30 days but within 3 months 
3. Yes, but not within the next 3 months 
4. No, I am not planning on giving up.  
 
Q10. If you decided to give up smoking completely in the next six months, how sure are 
you that you would succeed?  
1. Not at all sure 
2. Slightly sure 
3. Moderately sure 
4. Very sure 
5. Extremely sure 
 
Q10a. Is there any additional information you would like to provide about your smoking 
and/or quit attempts?  
1. Yes [Open text field] 
2. No 
 
Q10b Please select the one statement that comes closest to what you believe. Smoking 
causes :  
1. Long lasting changes to the way the brain works 
2. Temporary but substantial changes to the way the brain works 
3. Minor changes to the way the brain works 
4. No changes to the way the brain works 
5. I have no idea what effect smoking has on the brain 
 
Q10c To what extent do you agree with the following statement? (Strongly agree, agree, 
disagree, strongly disagree, don’t know).  
1. Smoking is a brain disease 
2. Smoking changes the chemistry of the brain 
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3. Smoking damages the brain  
4. Smoking is a brain disorder 
5. Some smokers have an increased chance of becoming addicted to cigarettes because of their 
genes   
 
Section 2 – Attitudes towards quitting methods  
 
Q11. How effective do you think the following method is for quitting smoking? (Not 
effective, somewhat effective, very effective, don’t know).  
1. Cold turkey (quitting completely without professional or medical help, and without nicotine 
replacement therapy) 
2. Cutting down or weaning off cigarettes (without professional or medical help, and without 
nicotine replacement therapy) 
3. Nicotine replacement therapy (e.g., patches, gum, lozenge, inhaler) 
4. Prescription medication from a doctor (e.g., Champix, Zyban)  
5. Counselling from a private counsellor 
6. Calling the Quitline 
7. Reading books or brochures about quitting smoking 
8. Online self-help materials about quitting smoking 
9. Electronic cigarettes (e-cigarettes) 
10. Hypnotherapy 
11. Acupuncture 
 
Q12. Have you ever tried to quit using the following methods? Please select all that apply. 
1. Cold turkey (quitting completely without professional or medical help and without nicotine 
replacement therapy) 
2. Cutting down or weaning off cigarettes (without professional or medical help, and without 
nicotine replacement therapy) 
3. Nicotine replacement therapy (e.g., patches, gum, lozenge, inhaler) 
4. Prescription medication from a doctor (e.g., Champix, Zyban)  
5. Counselling from a private counsellor 
6. Calling the Quitline 
7. Reading books or brochures about quitting smoking 
8. Online self-help materials about quitting smoking 
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9. Electronic cigarettes (e-cigarettes) 
10. Hypnotherapy 
11. Acupuncture 
12. I have used a method not listed above to quit  
13. I have not tried to quit 
 
Q12b. Please describe each other method you have used, one method in each box (10 
additional methods allowed) 
 
Q13. How helpful did you find the following method? [List all methods tried from 12a 
and 12b]. 
1. Not at all helpful 
2. A little bit helpful 
3. Somewhat helpful 
4. Quite helpful 
5. Very helpful 
 
Q14. Have you ever thought about using a “clean” nicotine product (e.g., nicotine gum, 
electronic cigarettes etc) as a long-term substitute for smoking cigarettes?  That is, using 
it every day as an alternative to smoking?  
1. No 
2. Yes, but not seriously 
3. Yes, seriously 
 
Q15. If you decided to make a quit attempt, how likely is it you would use the following 
quitting method? (Definitely wouldn’t use, Probably wouldn’t use, Probably would use, 
Definitely would use, Don’t know).  
 
1. Cold turkey (quitting completely without professional or medical help, and without nicotine 
replacement therapy) 
2. Cutting down or weaning off cigarettes (without professional or medical help, including 
nicotine replacement therapy) 
3. Nicotine replacement therapy (e.g., patches, gum, lozenge) 
4. Prescription medication from a doctor (e.g., Champix, Zyban)  
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5. Counselling from a private counsellor 
6. Call the Quitline 
7. Read books or brochures about quitting smoking 
8. Online self-help materials about quitting smoking 
9. Electronic cigarettes (e-cigarettes) 
10. Hypnotherapy 
11. Acupuncture 
 
Q16. If you were deciding which method to use to quit smoking, how important would 
the following be to your decision ? (Of no importance, A little important, Somewhat 
important, Important, Very important).  
 
1. The convenience of the method 
2. The likelihood of side effects 
3. The seriousness of side effects 
4. How well it works  
5. How much it costs 
6. How addicted you are to cigarettes 
7. Whether you have a physical addiction to cigarettes. (That is, experience unpleasant 
symptoms if you go without a cigarette.)  
8. Your family or friends’ experience of using it 
9. Your own experience with it 
 
Q17. Is there any additional information you would like to provide on your view about 
quitting methods? Please type in your thoughts in the box below. If you have nothing to 
add, just type in No. [Open text box].  
 
Q18. To what extent do you agree or disagree with the following statement?  
Please note that by the term “medication” we mean prescription OR over the counter 
medications for smoking cessation e.g., Champix, Zyban, nicotine patches, nicotine gum, 
nicotine lozenge or nicotine inhaler. (Strongly agree, Agree, Disagree, Strongly disagree, 
Don’t know) 
 
1. Quitting cold turkey (without medications) is the best way to quit 
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2. Quitting cold turkey is very difficult  
3. Medications do not deal with important psychological or behavioural aspects of smoking 
4. Knowing that medications are available makes stopping smoking seem easier 
5. Smokers should try to quit without medication before using quit smoking medications 
6. Medications are only helpful for heavy smokers 
7. Willpower plays the biggest role in quitting success 
8. If you don’t have a strong desire to stop smoking, medications won’t be helpful 
9. Only those who are strong can quit smoking without any medication 
10. Most people will need medications to stop smoking 
11. Medications are only helpful for those who have a physical addiction to smoking. 
12. Medications should be used in combination with counselling 
 
Q19. How much control do you feel you have over your smoking?  
1. No control 
2. A little control 
3. A moderate amount of control 
4. A lot of control 
5. Complete control 
 
Q20. How much help do you think you would need to quit smoking?  
1. No help 
2. Some help 
3. A lot of help 
 
Q21. How much control do you feel most other smokers have over their smoking?  
1. No control 
2. A little control 
3. A moderate amount of control 
4. A lot of control 
5. Complete control 
 
Q22. How much help do you think most other smokers would need to quit smoking?  
1. No help 
2. Some help 
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3. A lot of help 
 
Q23. How likely is it that medical research will improve treatments for addiction to 
cigarettes? 
1. Very unlikely 
2. Unlikely 
3. Likely 
4. Very likely 
5. Don’t know 
 
Q24. How likely is it that medical research will lead to a cure for addiction to cigarettes?  
1. Very unlikely 
2. Unlikely 
3. Likely 
4. Very likely 
5. Don’t know 
 
Section 3: Ideas about smoking 
 
Q25. Below are some statements about reasons for smoking. Please indicate the extent to 
which you agree or disagree with these statements (Strongly agree, Agree, Disagree, 
Strongly disagree, Undecided) 
 
I smoke because:  
1. I am addicted to cigarettes 
2. I have a psychological addiction to smoking  
3. I experience cravings for cigarettes 
4. Smoking is an important part of my everyday routine 
5. It helps me to socialise 
6. I want to avoid withdrawal symptoms 
7. I am addicted to nicotine 
8. I have an addictive personality  
9. It helps me deal with stressful situations 
10. It has become a habit 
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11. I have a physical addiction to smoking 
 
 
Q26 Smoking researcher Robert West has written the following about smoking:  
“You smoke because the nicotine you have been inhaling for all those years has changed your 
brain chemistry to create powerful urges to smoke. The urges come about because every puff 
on a cigarette sends a rapid nicotine "hit" to the part of your brain that makes you do 
things…These urges are triggered because nicotine has trained the part of your brain that gets 
you to do things to light up a cigarette whenever you find yourself in a situation where you 
would normally smoke.”  
 
How much do you think the statement above explains your own smoking?  
1. Not at all 
2. A little 
3. A lot 
4. Completely 
5. Don’t know 
 
Q27. How much do you think the statement above explains why others smoke?  
1. Not at all 
2. A little 
3. A lot 
4. Completely 
5. Don’t know 
 
Q28. If the above explanation for smoking was widely accepted, do you think it would 
increase or decrease the following?   (Decrease, No effect, Increase, Don’t know) 
 
1. The desire to stop smoking 
2. Smokers’ confidence in their ability to quit  
3. Negative attitudes towards people who smoke?  
4. The sense of personal responsibility that people feel for their smoking?  
5. Sympathy towards people who smoke?  
6. The number of people willing to seek medical treatment for their smoking 
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7. Feelings of guilt in those who smoke 
 
Q29. Some researchers in the USA have described addiction as a “brain disease.” To what 
extent do you agree that smoking is a brain disease?   
1. Strongly agree 
2. Agree 
3. Disagree 
4. Strongly disagree 
5. Don’t know 
 
Q30. REASONS FOR RATING 
Please type in the box below your reasons for saying you [DISPLAY RATING FORM 
Q28] that smoking is a brain disease. If you can’t say just type in DK (for Don’t know) 
Open text field.  
 
Q31. Imagine that a new "clean" nicotine product has been developed. This new product 
is as satisfying to use as smoking cigarettes. It is also as addictive as cigarettes, but it is 
far less harmful than cigarettes. It also costs slightly less than cigarettes. How interested 
would you be in using this product ? (Not interested, Somewhat interested, Very interested, 
Don’t know/unsure) 
 
1. As a short-term aid for quitting smoking and nicotine (i.e. use for 6 months or less)? 
2. As a long-term substitute for cigarettes (i.e. use for the foreseeable future)? 
3. As a partial replacement for cigarettes to help you cut down the number of cigarettes you 
smoke? 
 
 
Q32. Please indicate how much you agree/disagree with the following statements. By 
“clean nicotine product”, we mean nicotine gum, nicotine lozenges, e-cigarettes or other 
nicotine vaporisers. (Strongly agree, Agree, Disagree, Strongly disagree, Don’t know) 
1. Heavily addicted smokers should be encouraged to switch to less harmful clean nicotine 
products as long-term substitutes for cigarettes 
2. All smokers should be encouraged to switch to less harmful clean nicotine products as long-
term substitutes for cigarettes 
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3. Long-term use of clean nicotine products should be discouraged 
4. Using clean nicotine products long-term is bad because it maintains addiction 
5. Smokers should just quit smoking rather than switching to other products, like clean nicotine 
products 
7. There is no point switching from smoking cigarettes to using clean nicotine products long-
term because this is just swapping one addiction for another 
 
****Section 4 – Some basic information about you  
To finish we need your answers to a few questions about you that will help us to group 
answers together and make sense of what everyone has told us. Remember we will have 
no way of identifying you as an individual. 
 
Q33. EMPLOYMENT STATUS 
First, which of the following describes your main employment status  (select one only)  
1. Employed or self-employed 
2. Unemployed 
3. A student  
4. Home duties and/or carer 
5. Volunteer or charity work 
6. Retired or on a pension 
7. Unable to work 
8. Something else [SPECIFY] 
 
Q34. HIGHEST EDUCATION 
What is your highest educational qualification?  
4. Bachelor degree or higher 
3. Post school qualifications (e.g., certificate, diploma, apprenticeship)  
2. Completed secondary school (Year 12)  
1. Less than year 12 
 
Q35. POSTCODE 
What is the postcode of your current address? (4 digit numeric box) 
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Appendix E - Taverner Research Privacy Policy 
Taverner Research adheres to the Australian Market and Social Research (AMSRS) Code 
of Professional Behaviour, the Market and Social Research Privacy Principles, and all 
requirements of the Privacy Act. 
In accordance with the AMSRS Code of Professional Behaviour, Taverner Research seeks to 
protect the privacy of individuals through protection of personal information. Market and social 
research is based on the willing co-operation of the public and the business community. Such 
co-operation depends on public and business confidence that market research is carried out 
honestly and objectively using processes that protect the identity and rights of individuals, and 
without any unwelcome intrusion. 
As researchers, our responsibilities towards respondents include (taken from the text of the 
Code of Professional Behaviour for illustration purposes) 
Respondents' identities must not be revealed without their consent to anyone not directly 
involved in the market research project (including the client who commissioned the work) or 
used for any non-research purpose. 
Nobody shall be adversely affected or harmed as a direct result of participating in a market 
research study. Respondents must be able to check without difficulty the identity and bona 
fides of researchers. 
Respondents' co-operation in a market research project is entirely voluntary at all stages; they 
must not be misled when being asked for their co-operation. 
No child under 14 years shall be interviewed without parent's/ guardian's/responsible adult's 
consent. 
All indications of the identity of respondents should be physically separated from the records 
of the information they have provided as soon as possible after the completion of any necessary 
fieldwork quality checks. The researchers must ensure that any information which might 
identify respondents is stored securely and separately from the other information they have 
provided, and that access to such material is restricted to authorised research personnel within 
the researcher's own organisation for specific research purposes (e.g. field administration, DP, 
panel or longitudinal studies or other forms of research involving recall interviews). To 
preserve respondents' anonymity not only their names and addresses but also any other 
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information provided by or about them which could in practice identify them (e.g. their 
company and job title) must be safe-guarded. 
These anonymity requirements may be relaxed only under the following safeguards: 
where the respondent has given explicit permission for this under the conditions of 'informed 
consent' summarised in Rule 4a and 4b 
where disclosure of names to a third party (e.g. a sub-contractor) is essential for any research 
purpose such as data processing or further interview (e.g. an independent fieldwork quality 
check) or for further follow-up research. The original researcher is responsible for ensuring 
that any third party agrees to observe the requirements of this Code - in writing, if the third 
party has not already formally subscribed to the Code. 
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Appendix F – Additional statistical analyses 
 
1. Correlations between items on smoking and the brain (n=1538) 
 
 Smoking is a brain 
disease 
Smoking 
changes the 
chemistry of the 
brain 
Smoking 
damages the 
brain 
Smoking is a 
brain disorder 
Smoking is a brain disease Pearson Correlation 
Sig. (2-tailed) 
1 .497** 
.000 
.513** 
.000 
.683** 
.000 
Smoking changes the 
chemistry of the brain 
Pearson Correlation 
Sig. (2-tailed) 
.497** 
.000 
1 .633** 
.000 
.515** 
.000 
 Smoking damages the brain Pearson Correlation 
Sig. (2-tailed) 
.513** 
.000 
.633** 
.000 
1 .541** 
.000 
Smoking is a brain disorder Pearson Correlation 
Sig. (2-tailed) 
.683** 
.000 
.515** 
.000 
.541** 
.000 
1 
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2. Cross-tabulations for self-efficacy categories 
Cross-tabs were conducted in order to examine differences between self-efficacy categories in relation to level of dependence, highest level of 
education, agreement that smoking changes the chemistry of the brain, and endorsement of the idea that it is a brain disease. Those who reported 
moderate and high self-efficacy were more similar to each other in relation to level of nicotine dependence and the proportion of those who had a 
low level of education than those who reported low self-efficacy. The former categories were combined in order to carry out bivariate analyses.  
 
2.1.Self-efficacy by level of dependence cross-tabulation 
 HSI Categories  Total 
Low 
dependence 
Moderate 
dependence 
High 
dependence 
Self-efficacy Low self-efficacy Count 
% within Self-efficacy  
% of Total 
138 
19.1% 
9.0% 
307 
42.6% 
20.0% 
276 
38.3% 
18.0% 
721 
100.0% 
47.0% 
Moderate self-
efficacy 
Count 
% within Self-efficacy  
% of Total 
152 
30.5% 
9.9% 
243 
48.8% 
15.8% 
103 
20.7% 
6.7% 
498 
100.0% 
32.4% 
High self-efficacy Count 
% within Self-efficacy  
% of Total 
106 
33.5% 
6.9% 
153 
48.4% 
10.0% 
57 
18.0% 
3.7% 
316 
100.0% 
20.6% 
Total Count 
% of Total 
396 
25.8% 
703 
45.8% 
436 
28.4% 
1535 
100.0% 
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2.2.Self-efficacy by highest level of education cross-tabulation 
 Highest education Total 
Less than 
year 12 
Completed 
secondary 
school  
Post school 
qualification
s  
Bachelor 
degree or 
higher 
Self-efficacy  Low self-
efficacy 
Count 
% within Self-
efficacy  
% of Total 
174 
24.1% 
11.3% 
131 
18.1% 
8.5% 
237 
32.8% 
15.4% 
181 
25.0% 
11.8% 
723 
100.0% 
47.0% 
Moderate self-
efficacy 
Count 
% within Self-
efficacy  
% of Total 
77 
15.4% 
5.0% 
91 
18.2% 
5.9% 
177 
35.5% 
11.5% 
154 
30.9% 
10.0% 
499 
100.0% 
32.4% 
High self-
efficacy 
Count 
% within Self-
efficacy  
% of Total 
35 
11.1% 
2.3% 
52 
16.5% 
3.4% 
82 
25.9% 
5.3% 
147 
46.5% 
9.6% 
316 
100.0% 
20.5% 
Total Count 
% of Total 
286 
18.6% 
274 
17.8% 
496 
32.2% 
482 
31.3% 
1538 
100.0% 
 
 
